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Abstract  
Connective tissue initially arises from embryonic mesenchymal stem cells (MSC) that 
originate from the mesoderm during embryogenesis and are capable of differentiating 
into connective tissue lineages such as adipocytes, osteoblasts, chondrocytes and 
fibroblasts. Connective tissue is composed of cells held together by the extracellular 
matrix (ECM). The fibrillins and latent transforming growth factor binding proteins form 
a superfamily of ECM proteins characterised by the presence of a unique domain, the 8-
cysteine transforming growth factor beta binding domain (TGFß). The fibrillin proteins 
(fibrillin-1, fibrillin-2 and fibrillin-3 in most vertebrates, encoded by the FBN1, FBN2 
and FBN3 genes respectively), are major components of the 10nM microfibrils found in 
ECM of many tissue types, for example mesenchyme-derived connective tissues. 
Fibrillin-1 and fibrillin-2 are also thought to be required for stabilization and storage of 
latent TGFβ complexes. Mutations in FBN1 cause Marfan syndrome, a connective tissue 
disorder characterised by abnormalities in the microfibrils resulting in musculoskeletal, 
ocular, cardiovascular and other complications. FBN2 mutations lead to congenital 
contractural arachnodactyly, which has a musculoskeletal phenotype similar to Marfan 
syndrome. There are currently no known diseases associated with FBN3 mutations.  
In this project, the expression of fibrillins was investigated using human cell lines during 
early development, mesenchymal stem cell differentiation and in further differentiated 
mesenchymal cell lines, for example in osteocytes (osteosarcomas), chondrocytes and 
fibroblast lineage. Immunocytochemistry was used to examine protein expression, real-
time PCR and expression microarrays to determine mRNA synthesis and RNAi 
suppression of gene expression to determine possible functions of fibrillins and 
associated ECM proteins. In addition, a genome wide bioinformatics evaluation was 
performed of transcription start sites for the fibrillin gene family utilising the information 
obtained from the FANTOM5 consortium.  
The three fibrillin genes showed differing expression patterns in cell lines depending on 
the stage of development/differentiation. During embryogenesis, expression of FBN3, 
FBN2 and FBN1 increased sequentially in that order. Expression of FBN3 followed the 
same pattern as expression of known pluripotency markers, while expression of FBN2 
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correlated with expression of markers for later stages of mesoderm differentiation. FBN1 
expression was associated with mesenchymal markers, and this was supported by a study 
of mesenchymal stem cells differentiation to the adipose lineage. Fibrillin-1 microfibrils 
and RNA expression were present early in primary adult human MSC differentiating to 
adipocytes, suggesting that a fibrillin matrix is required for initial MSC attachment. As 
differentiation proceeded, fibrillin -1 expression decreased, with rapid degradation of the 
microfibrils. Fibrillin-2 expression increased following differentiation and fibrillin-3 was 
not expressed. These results suggest that fibrillin-1 plays an important structural and 
regulatory role in the early stages of connective tissue development but is not required to 
maintain the differentiated state.  
Many genes showed the same expression pattern as FBN1. To better understand the 
importance of fibrillin-1 and its interaction with these coexpressing genes, fibrillin-1 was 
knocked down using siRNA in fibroblast, chondrocyte and osteosarcoma cell lines. There 
were little to no effects identified in chondrocyte and osteosarcoma cell lines, and only a 
few genes were altered following the reduction of fibrillin-1 mRNA in fibroblasts, 
suggesting that fibrillin-1 is not a central regulator but an endpoint. This was surprising 
given its potential role in controlling bioavailability of TGFβ, a key regulator of 
mesenchymal cells.  
In addition, the evolution of the fibrillin gene family was studied and it was found that 
the gene structure, amino acid sequence and genomic positions of each gene are widely 
conserved across vertebrates, suggesting an important role in vertebrate body structure. 
However, the differences in gene structure and sequence between the three fibrillin genes 
suggest divergent function. Fibrillin-1 mutations with the most severe phenotypes are 
located in regions that are highly conserved. This study shows that there is a clear 
developmental and evolutionary distinction between the three fibrillins. Fibrillin-3 was 
associated with pluripotency and its presence in differentiating foetal liver and brain may 
suggest that there are residual pluripotent cells in these developing tissues. Fibrillin-2 
appeared to be a marker for the mesodermal stage and its role in adult cells is currently 
not clear. Fibrillin-1 was present in cells already predetermined to go to mesenchymal 
lineages, but it was minimal in the advanced stages of differentiation suggesting that it 
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may be a marker for relatively plastic mesenchymal cells prior to commitment to a 
specific lineage.  
These results will assist in the understanding of disorders resulting from fibrillin gene 
mutations and have identified coexpressed proteins, potential modifiers that could be the 
targets of gene therapy and candidates for similar connective tissue  
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Chapter 1. Introduction 
Connective tissue forms the support for the organs and tissues of the animal body. 
Adipose, cartilage and bone are all forms of connective tissue. Connective tissue is 
comprised of specific cells that arise from the mesoderm in early development and a 
dynamic extracellular matrix (ECM). The ECM is composed of many fibrous and non-
fibrous constituents including proteins of the fibrillin family, key components of 10nM 
microfibrils within the ECM (Sakai et al., 1986, Zhang et al., 1994, Corson et al., 2004). 
Mutations in the genes encoding fibrillin-1 and fibrillin-2 have been implicated in a 
variety of phenotypes, affecting multiple connective tissues within the body (Sections 
1.3.4 and 1.3.5), indicating their importance within the ECM. The role of the third 
fibrillin, fibrillin-3 has yet to be completely understood. This thesis presents a detailed 
study of expression of the fibrillin gene family and defines co-regulated genes in cells of 
mesenchyme origin, the basis of connective tissue. The overall aim is to better understand 
the role that the fibrillin gene family plays in the ECM of connective tissues.  
1.1 Mesenchymal Connective Tissue  
Connective tissue supports various structures in the body of vertebrates by providing 
strength, elasticity and cushioning. It arises from embryonic mesenchymal stem cells 
(MSCs) (Choo and Lim, 2011), which originate in the mesoderm layer during 
embryogenesis and are capable of differentiating into multiple connective tissue cell 
types (Caplan, 1991). During mammalian development the mesoderm layer becomes 
segmented, sequentially producing the paraxial, intermediate and lateral plate mesoderm 
(Gilbert, 2000). Progenitor connective tissue cells (produced from the various mesoderm 
layers) can be further differentiated into specialised cell types of multiple lineage 
pathways leading to, for example, adipocytes, chondrocytes, myocytes, osteoblasts and 
fibroblasts (summarized in Figure 1.1) (Bruder et al., 1994, Prockop, 1997, Pittenger et 
al., 1999). Cells of these lineages are also involved in connective tissue repair and are the 
major cellular component in scarring and fibrosis (Olivieri et al., 2010, Ferrari et al., 
1998).   
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Figure 1.1. A schematic diagram of ES (embryonic stem) cells differentiating to connective tissue. 
This figure demonstrates the potential of ES cells to differentiate to EB (embryoid bodies) and 
continue to form three layers, including the mesoderm. The mesoderm layer gives rise to 
mesenchymal stem cells (MSC) and which then differentiate into multiple lineages. Image adapted 
from (Bodas and Vij, 2010). 
The mesenchyme derived stem cells continue to form various connective tissues within 
the body, for example bone, cartilage, adipose (fat) and fibroblasts  (Figure 1.1). This 
thesis will examine the role of the fibrillin gene family in early differentiation, 
adipogenesis, fibroblasts, bone and cartilage model systems. The mechanism of 
maturation of these tissue types is described below.   
 
1.1.1 Dermal fibroblast formation  
Fibroblasts are the most undifferentiated and primitive cells created from MSCs. Figure 
1.1 depicts the cells’ ability to differentiate to skin and tendons (Driskell et al., 2013), 
though fibroblasts are also capable of differentiating into adipocytes (Tontonoz et al., 
1994) and smooth muscle cells (Karamariti et al., 2013). They are dispersed in multiple 
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connective tissue types, for example myocardium (Camelliti et al., 2005, Ieda et al., 
2009, Goldsmith et al., 2004) and cartilage (Alberts, 2002b). Fibroblasts are responsible 
for ECM secretion during connective tissue formation for wound repair and are the most 
widely spread connective tissue cell type (Driskell et al., 2013). Their primary function is 
to maintain the structural integrity of connective tissues (Ross and Greenlee, 1966) and 
synthesise collagen (Goldberg and Green, 1964). The studies reported in this thesis used 
neonatal dermal fibroblasts.   
The dermis is located between the epidermis and the subcutaneous tissue of the skin and 
consists of two distinct layers, the papillary and reticular layers (Driskell et al., 2013, 
Janson et al., 2012, Janson et al., 2013). The papillary layer has a thinner ECM and a 
dense cell population while the reticular layer has a dense ECM and lower cell density 
(Driskell et al., 2013). These layers act together to provide a matrix of diverse 
constituents. The layers have distinct cell morphology in that reticular fibroblasts in 
culture are square and stretched in appearance while papillary fibroblasts in culture are 
lean, spindle shaped cells. The precise role of the layers remains unknown, though recent 
microarray analysis demonstrated significant differential expression of 116 genes (Janson 
et al., 2012). For example CNN1 (calponin 1)(OMIM:600806), CALD1 (caldesmon 1) 
(OMIM: 114213), GALNT10 (N-Acetylgalactosaminyltransferase 10 (OMIM: 608043) 
and NEXN (nexilin)(OMIM: 613121) were upregulated in the reticular layer while DCN 
(decorin)(OMIM: 125255) was upregulated in the papillary layer. In addition, the authors 
proposed MGP (matrix gamma carboxyglutamate protein) to be a candidate genetic 
marker for the reticular layer, though the precise role is unknown. The ECM components 
of dermal fibroblasts will be discussed further in Section 1.2.  
 
1.1.2 Adipose formation 
As shown in Figure 1.1, MSCs are also capable of differentiating into adipocytes that 
mature to form adipose connective tissue or fat (Rosen and MacDougald, 2006). Adipose 
tissue stores energy, provides cushioning for the skeletal and organ systems within the 
body, provides thermal insulation (Li et al., 2014), and maintains communication with 
the endocrine system through a nutrient gradient regulating hormone levels such as 
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insulin and cortisol (Galic et al., 2009, Greenwood et al., 1966) and communication with 
the thyroid gland (Santini et al., 2014). There are three types of fat found within the 
human body: white adipose tissue (WAT), brown adipose tissue (BAT) and beige adipose 
(Giralt and Villarroya, 2013, Xue et al., 2007, Wu et al., 2012). WAT is widely localised 
throughout the body, and has a major role in lipogenesis and the glucose-lipid 
equilibrium and inhibition of lipolysis (Vazquez-Vela et al., 2008).  BAT and beige fat 
are heavily involved in thermogenesis (reviewed in (Harms and Seale, 2013). One 
distinguishing genetic marker for BAT and beige adipose is the upregulation of UCP1 
(uncoupling protein 1) (Wu et al., 2012, Okamatsu-Ogura et al., 2014, Matthias et al., 
2000). They also have more abundant mitochondria (Shabalina et al., 2013).   
The process of adipogenesis will be discussed in greater detail in Chapter 3. Briefly, 
mature adipocytes are formed from MSCs, by progression to preadipocytes, early 
adipocytes and ultimately mature adipocytes. There are several key factors involved in 
lineage determination, including IGF1 (insulin-like growth factor 1)(OMIM: 
147440)(Kloting et al., 2008), CSF1 (macrophage colony-stimulating factor)(OMIM: 
120420)(Tanny et al., 2007, Umezawa et al., 1991), glucocorticoids  (Chapman et al., 
1985, Zubiria et al., 2014), and fatty acids (Das, 2006, Bochicchio et al., 2014).  
The precursors for adipocyte formation (preadipocytes) are derived from MSCs that 
exhibit high expression of key adipose transcription factor markers, CEBP (CCAAT 
enhancer binding protein) (OMIM: 116897) and PPARG (peroxisome proliferator 
activated receptor-gamma)(OMIM: 601487). WAT and BAT adipose express high levels 
of PPARG (Nedergaard et al., 2005, Barak et al., 1999). Similar to osteo- and 
chondrogenesis, adipose differentiation is driven by changes in the extracellular matrix 
(ECM), mainly an upregulation of collagen IV (Pierleoni et al., 1998), leading to thicker 
collagen based fibres within the basal membrane. In addition, proliferation ceases and 
lipid vacuoles form within the intracellular space (Gross and Silver, 2014). Lipid 
vacuoles are the major storage units for lipids in adipose tissue (Hahm et al., 2014, 
Mannik et al., 2014). The precise morphological changes and role of matrix genes will be 
discussed in detail in Chapter 3.  
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1.1.3 Cartilage  
Cartilage is a highly elastic connective tissue mainly found between bones, providing 
cushioning and flexibility within the body. There are three major types of cartilage found 
within mammals, hyaline, elastic and fibro-cartilage. Hyaline cartilage is located in joints 
and the lining of bones, for example costal cartilage, and contains 60-85% water 
(Padalkar et al., 2013, Palukuru et al., 2014). Elastic cartilage is localised to auditory 
tubes and the larynx and is similar to hyaline cartilage, though it contains elastic bundles 
within the matrix, causing a more rigid and supportive structure. In addition, hyaline 
cartilage can be differentiated to elastic cartilage to aid in tissue regeneration (Mizuno et 
al., 2014). Fibro-cartilage is primarily located within the intervertebral disks, and sites 
joining tendons or ligaments to bones (Sunshine, 1999). The three types of cartilage are 
generated in a similar fashion, though the ECM composition is distinct (Zambrano et al., 
1982)(Discussed in Section 1.2). Chondrogenesis is a process in which undifferentiated 
MSCs differentiate to a chondrocyte lineage, proliferate, then either mature to 
hypertrophic chondrocytes (terminal differentiation) producing cartilage or undergo 
chondrocyte apoptosis (intermediate chondrocytes) leading into endochondral 
ossification (Discussed in Section 1.1.5) (Goldring et al., 2006).  
Proliferating chondrocytes begin to create a collagen matrix (mainly collagen II, collagen 
IX and collagen XI), which is also rich in proteoglycans including aggrecan (Goldring et 
al., 2006). Aggrecan consists of three globular domains. It is secreted by chondrocytes 
during development and binds to hyaluronan (a viscous ground substance of the ECM) 
providing a gel that supports cartilage load-bearing properties (Kiani et al., 2002). In 
addition an upregulation of SOX9 (Sry-Box 9) is a highly characteristic marker of 
chondrogenesis (OMIM: 608160). Sox-9 has been shown to directly regulate Col2a1 
(Collagen 2, alpha type 1), a key component in chondrogenesis (Bell et al., 1997), in 
mice. It is regulated by FGFs (fibroblast growth factors) (Murakami et al., 2000) and 
essential in the prevention of hypertrophic chondrocyte formation (Huang et al., 2001, 
Chikuda et al., 2004, Goldring et al., 2006). As upregulation of key chondrocytic markers 
occurs, the chondrocytes begin to condense, the actin fibres of the cytoskeleton change 
and cellular adhesion increases (Benjamin and Ralphs, 1998, Daniels and Solursh, 1991). 
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As the chondrocytes differentiate, they become hypertrophic (enlarged) and express high 
levels of ALPL (alkaline phosphatase)(Richany et al., 1959). Expression of SOX9 is 
decreased and both RUNX2 and RUNX3 (Michigami, 2014) are upregulated, leading to 
either further cartilage production (elastic or fibro-cartilage) or endochondral ossification 
(hyaline cartilage)(Goldring et al., 2006). Hypertrophic chondrocytes and intermediate 
chondrocytes produce varying ECM components throughout the process (Discussed in 
Section 1.1.5 and 1.2). 
 
1.1.4 Bone  
Bone is a dynamic connective tissue, undergoing continuous repair and remodelling 
throughout the organism’s life span. There are three distinct lineages that arise from the 
mesoderm to produce bone tissue (Gilbert, 2000). Somites (located within the paraxial 
mesoderm) form the axial skeleton (Resende et al., 2014, Christ and Wilting, 1992, 
Verbout, 1985), the lateral plate mesoderm creates the limb skeleton (Onimaru et al., 
2011, Johnson and Tabin, 1997, Chevallier et al., 1977, Christ et al., 1977) and the 
paraxial mesoderm layer interacts with the cranial neural crest (within the ectoderm) 
giving rise to craniofacial bones (Yoshida et al., 2008, Evans and Noden, 2006). Typical 
bone formation begins with the clustering of undifferentiated MSC cells that undergo 
osteogenesis to produce osteoblasts, ultimately forming osteocytes (Figure 1.1). There 
are several transcription factors essential for the conversion of MSCs to osteoblasts, for 
example RUNX2 (runt-related transcription factor 2), OSX (osterix, also known as 
transcription factor SP7), IHH (Indian hedgehog), β-catenin, and ATF4 (activating 
transcription factor 4). RUNX2 is considered the master regulator of osteoblast 
differentiation and is required for terminal differentiation (Thomas et al., 2004, Stein et 
al., 2004) and IHH is a key regulator of osteogenesis (OMIM1: 600726)(Yoshida et al., 
2004). ATF4 is involved in regulating osteocyte terminal differentiation (Yang et al., 
2004).  
                                                
1 OMIM: Online Mendelian Inheritance in Man (www.ncbi.nlm.nih.gov/OMIM) 
Chapter 1. Introduction 
 
  7 
A calcifying matrix is essential in the production of bone, and expression of specific 
genes, for example, ENPP1 (ectonucleotide pyrophosphatase /phosphodieserase 1) 
(Thomas et al., 2004), and PHOSPHO1 (a bone specific phosphotase)(Macrae et al., 
2010, Houston et al., 2004), are essential in maintaining a homeostatic mineralised ECM. 
OSX (OMIM: 606633) has been shown to be required for mineralisation of the matrix 
with Osx null mice showing no mineralisation during endochondral ossification 
(Nakashima et al., 2002). Furthermore, OSX mutation in humans has been associated with 
osteogenesis imperfecta type XII (MIM: 613849), a disease associated with decreased 
bone mineral density and high incidence of fractures.  
Bone homeostasis, essential for repair and maintenance, involves an ongoing process of 
synthesis of bone by osteoblasts and bone degradation by osteoclasts, phagocytic cells of 
monocyte lineage. β-catenin activity becomes obvious in later bone development and 
couples with the Wnt signalling pathway to regulate osteoclast /osteoblast turn over 
(Kramer et al., 2010, Kokubu et al., 2004, Glass et al., 2005, Bodine and Komm, 2006). 
In addition, members of the TGFß (transforming growth factor beta) (discussed in 
Section 1.3.1) and BMP (bone morphogenetic protein) families have regulatory functions 
in bone development (Chen et al., 2012). For example Tgfb1 depleted mice had decrease 
bone growth and mineralisation (Geiser et al., 2005) and the loss of Bmp2 and Bmp4 
severely disrupted osteogenesis (Bandyopadhyay et al., 2006). BMP2 is also a regulator 
of OCN (osteocalcin), a leading gene in bone mineralisation (Huang et al., 2010).  
There are two types of bone tissue, depending on the characteristics of the osteoid matrix: 
woven bone and lamellar bone, that are developed during intermembranous or 
endochondral ossification, respectively. Ossification refers to the process of bone 
formation.  Intramembranous ossification is a process that synthesises bone directly from 
connective tissue sheets (Dallas and Bonewald, 2010). The formation of lamellar bone 
and endochondral ossification will be discussed in Section 1.1.5.  
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1.1.5 Endochondral Ossification 
As previously introduced (Section 1.1.4), there are two major mechanisms involved in 
early bone formation: intramembranous ossification and endochondral ossification. 
Intramembranous ossification leads to the formation of cranial, jaw, and clavicle bone in 
the absence of cartilage tissue, ultimately forming flat bones in a developing organism 
(Section 1.1.4). Endochondral ossification is the mechanism that creates and sustains 
long bone formation in the body, via a process of cartilage turn over and osteoblast 
mediated mineralisation (Goldring et al., 2006, Mackie et al., 2008).  
Endochondral ossification (reviewed in (Mackie et al., 2008) is initiated by chondrocyte 
driven production of hyaline cartilage. The hyaline cartilage (composed of condensed 
hypertrophic chondrocytes, producing a primary ossification centre) is encased in a 
perichondrium, a membrane that is then invaded by blood vessels transforming it into 
vascularised periosteum (Figure 1.2A). The newly formed vascularised periosteum 
recruits osteoblasts that then begin to secrete osteoid, forming a collar around the hyaline 
cartilage diaphysis (shaft) to maintain structure during mineralisation. Cartilage within 
the centre of the diaphysis (primary ossification site) begins to calcify and cavitates. This 
occurs due to chondrocyte apoptosis resulting from a lack of nutrients surrounding the 
chondrocytes and leading to the deterioration of the cartilage matrix (Figure 1.2B). 
Osteoblasts then invade the internal cavity (primary ossification site), laying down a 
mineralised matrix forming trabecular bone and the medullary cavity (storage unit for 
bone marrow). In addition, blood vessels invade the primary ossification site, and 
promote bone marrow formation. This requires vasculature formation as well as the 
presence of osteoblasts and osteoclasts. Osteoblasts secrete osteoid around the remaining 
hyaline cartilage to promote mineralisation and bone growth, and osteoclasts break down 
the calcified cartilage matrix during life (Figure 1.2C). Secondary ossification sites 
appear at both ends of the newly formed bone (epiphyses), and the above process is 
repeated (Figure 1.2B-Figure 1.2D). There is continuous bone turnover throughout the 
organism’s lifespan. The bone collar is defined as compact bone later in life.  
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Figure 1.2. Endochondral ossification, producing long bones. (A) Hyaline cartilage becomes encased 
in a perichondrium casing (blue lines) and a primary ossification centre is formed (light purple). (B) 
Osteoid secretion promotes the growth of the bone collar (dark purple lines). The primary 
ossification site begins to calcify and produces pores (cavities) causing the deterioration of the hyaline 
cartilage matrix (noted by white mesh-work within the hyaline cartilage). (C) Osteoblasts and blood 
vessels invade the primary ossification centre promoting calcification and bone marrow production, 
respectively. The calcification leads to the formation of trabecular bone (dark grey stripped in the 
image), and the deterioration of the hyaline cartilage matrix continues on both the distal and 
proximal ends of the trabecular bone. (D) The medullary cavity is formed and bone marrow 
production begins. In addition, secondary ossification centres form at the distal and proximal ends of 
the newly created long bone, and steps (A-C) are repeated.  
1.2 Extracellular Matrix  
The ECM is a key characteristic of multi-cellular organisms and is composed of a 
meshwork of elastic and collagenous fibres, embedded in a hydrophilic ground substance 
consisting primarily of proteoglycans and glycoproteins (Alberts, 2002a). The basal 
lamina consists of two major compartments, an ECM space comprised of threadlike 
fibres and pores as well as a basement membrane consisting of sheet-like scaffolding that 
creates a platform for cells and boundaries between tissue compartments (Eshghi, 2008).  
In addition to providing a structural frame to various mesenchyme-derived tissues, the 
ECM mediates interactions between a range of growth factors and surface receptors 
(Alberts, 2002a). As mentioned above, there are differences in the ECM of connective 
tissue types. The differences are indicated by several factors, for example fibre 
organisation and components (discussed in the following sections of Chapter 1). The 
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major components of the ECM include, but are not limited to, collagens, laminins, 
fibronectin, elastin (reviewed in (Halper and Kjaer, 2014, Frantz et al., 2010), the fibrillin 
family (Sakai et al., 1986, Zhang et al., 1994, Corson et al., 2004, Keene et al., 1991) and 
proteoglycans (such as decorin (Melo and Brandan, 1993) and biglycan (Mercado et al., 
2006)) embedded in a viscous ground substance hyaluronan (Toole, 2000)(Figure 1.3). 
Hyaluronan (HA) is the ground substance of the ECM and is a viscous fluid that 
surrounds the ECM fibres (Laurent et al., 1996) (Figure 1.3). HA is a polymer of the 
disaccharide glucuronic acid alternating with N-acetyl glucosamine and is a member of 
the GAG (glycosaminoglycan) polysaccharide family (Heatley and Scott, 1988). Unlike 
the majority of the GAG family, HA contains no sulphate groups, but like other GAG 
family members, it is a massive carbohydrate polymer of 104-105 kDa, and is synthesised 
in the inner side of the plasma membrane (Sedwick et al., 1979, Kakehi et al., 2003). 
Originally HA was thought to be responsible mainly for maintenance and structural 
integrity of the ECM, though it recently has been shown to be important in formation of 
embryonic heart (Toole, 2000) and cerebellum (Baier et al., 2007). 
 
Figure 1.3. A schematic diagram of the ECM. This image depicts the various components of the ECM 
discussed in detail throughout Section 1.2. Legend from Top to Bottom: The black thick line 
represents the basement membrane (basal lamina). Laminin  (dark blue trimers) extends downward 
into the ECM. Elastin (light blue) and fibrillin (bright green) 10 nM microfibres extend across the 
matrix. Collagen fibres (thick light purple lines) are stretched across the ECM in an organised 
fashion, and proteoglycans (maroon “tree” like structures) are vertically aligned between the 
basement and plasma membranes. Fibronectin (purple fibres) are either within in the ECM or bound 
to integrins (blue cylinders) that are embedded in the plasma membrane. The cytoplasm contains an 
actin (red fibres) network.  Hyaluronan (not pictured) is present within the ECM, surrounding the 
described ECM components.  
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1.2.1 Collagen 
Specific collagens provide tensile strength, maintain connective tissue organisation and 
make up one of the most abundant fibre types in the ECM. Initially, fibroblasts (see 
Section 1.1.1) were thought to be responsible for the secretion and synthesis of collagen 
fibres (Goldberg and Green, 1964), but epithelial cells have now been shown to have the 
capability to synthesise collagen (Hayashi et al., 1988). There are currently 28 identified 
forms of collagen, though 80-90% of the collagen in the mammalian body consists of 
collagen I, II and III (Lodish et al., 2000).  
The structures of fibrous collagen proteins are similar. A description of collagen I, the 
main collagen constituent in bone, is given here. Collagen I consists of three coiled 
subunits, two alpha 1 chains and one alpha 2 chain. Each subunit has 1050 amino acids, 
containing repeating sequences of Gly-Pro-X (X=any amino acid) allowing these three 
subunits to combine to form a distinct three-stranded left-handed helical conformation, 
then binding of the strands continues to form a right handed triple helical structure 
(Ramachandran and Kartha, 1954, Ramachandran and Kartha, 1955, Rich and Crick, 
1955, Bhattacharjee and Bansal, 2005, Shoulders and Raines, 2009)(Figure 1.4). 
COL1A1 and COL1A2 mRNA is translated into procollagens, which are glycosylated, 
and hydroxylated in the endoplasmic reticulum (Yamauchi and Sricholpech, 2012, 
Jurgensen et al., 2011). After posttranslational modification is complete, the triple helical 
monomers are assembled in the ECM and the propeptide sequence is removed, allowing 
the triple helical structure to polymerize with other collagen fibres (Stephens, 
2012)(Figure 1.4). The collagen fibres are then cross-linked side-by-side to form packed 
bundles (Fortunati et al., 2014, van den Bogaerdt et al., 2009) (Figure 1.3). The initial 
triple-helical structure and the packing into fibres assists in providing strength to bone in 
the body (Fortunati et al., 2014).  
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Figure 1.4. A schematic of collagen formation. A single polypeptide collagen chain is synthesised in 
ER. The chain self assembles following posttranslational modifications, to form a three stranded 
helical collagen strand within the ER. The propeptides are secreted into the ECM and cleaved to 
from the triple helical structure and the collagen is self assembled into collagen fibrils. The collagen 
fibrils are bound (Section 1.2.1), and the collagen fibres are incorporated into the ECM as shown in 
Figure 1.3.   
There are many other collagen-packing techniques that have been recognised in 
connective tissues. As previously mentioned in Section 1.1.3, cartilage tissue is mainly 
comprised of collagen II and collagen IX.  Collagen II fibres are smaller in diameter than 
collagen I fibres, and are randomly dispersed throughout the ECM in a proteoglycan rich 
and hyaluronan based viscous ECM (Li et al., 2006). It is this compressible structure that 
allows for shock absorption in vertebrate joints. Collagen IX is a non-fibrous short chain 
collagen protein that contains two alpha subunits, and assists in cross-linking collagen 
molecules (McCormick et al., 1987, Mayne et al., 1985). For example, in cartilage 
collagen IX anchors (through crosslinking) collagen II fibres to the proteoglycans (Diab 
et al., 1996, Eyre et al., 2004). The role of collagen II in cartilage is highlighted by the 
phenotypes associated with mutations within the collagen II gene (COL2A1) which give 
rise to multiple connective tissue diseases (OMIM: 120140) including osteoarthritis with 
mild chondrodysplasia (MIM: 604864). Similarly, the regulatory role of collagen IX in 
cartilage maintenance is also evident from the phenotype of Col9a1 null mice, which 
develop chronic joint disease (Fassler et al., 1994). 
In addition to bone and cartilage, collagen is a major component of skin and adipose 
connective tissue. Collagen IV is synthesised in the ER producing procollagen strands 
(Abreu-Velez and Howard, 2012). However, once the strands emerge from the ER, the C-
terminus propeptide is not removed. The amino acid sequence does not contain the 
glycine residue every three bases (Abreu-Velez and Howard, 2012), allowing this 
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collagen to align in a head to tail fashion within the basement membrane along with 
laminin (Discussed in Section 1.2.3) (Vega et al., 1995). This arrangement allows the 
tissue to be more pliable and form collagen-based sheets, and along with epithelial cells, 
give rise to the structure of the epidermis.  
 
Although collagen IV is the leading collagen fibre produced by dermal fibroblasts, foetal 
bovine fibroblast studies indicated the importance of a collagen VI matrix in the 
development of the ECM in skin (Kielty et al., 1993). Collagen VI can be found in most 
connective tissues of the body although it was characterised in bovine skin samples 
(Kielty et al., 1992, Sato et al., 1979).  mRNA for different collagen VI alpha chains are 
also abundant in adipose and smooth muscle cells (http://biogps.org) and protein 
expression has been characterised in the synovial lining of human and bovine joints 
(Waggett et al., 1993). Collagen VI is the highest expressing collagen in adipose tissue 
and levels of both protein and mRNA are elevated in obese patients (Pasarica et al., 
2009). Collagen VI forms triple-helical trimer structures, which are then disulfide bonded 
in pairs forming anti-parallel dimers (Engel et al., 1985). Two of these dimers are 
crosslinked to form a secreted tetramer that is assembled in a head to tail, beaded fashion 
(Engel et al., 1985, Keene et al., 1991). Collagen VI may be involved in adipose tissue 
inflammation (Pasarica et al., 2009).  
 
1.2.2 Elastin 
Elastin, encoded by ELN (OMIM: 130160) is an important fibrous structure of the ECM. 
It is a component of the elastic fibres and is anchored to the ECM by microfibrillar 
components, such as fibrillin (See Section 1.3) (Figure 1.3). Microfibrils are abundant 
within the ECM of elastic tissues (Kielty et al., 1991). The tropoelastin protein is a 
72kDa soluble polypeptide which consists mainly of glycine, proline and other 
hydrophobic amino acid residues that are translated to produce monomers, that then self 
assemble into fibres due to the hydrophobic domains (Cirulis et al., 2008). The 
monomers are crosslinked to one another through lysine residues by multiple members of 
the lysyl oxidase family, forming desmosine crosslinks (Kagan and Sullivan, 1982, 
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Noblesse et al., 2004). Elastin polymers make up the majority of the elastic fibres. Non-
elastin components include proteins such as the fibrillins (Discussed in Section 1.3) 
(Figure 1.3). A key feature of elastin fibres is their elastic and recoil capabilities. As the 
elastin monomers assemble, they create left-handed helices (similar to collagen) (Section 
1.2.1) that contain no intramolecular hydrogen bonds (Bochicchio and Tamburro, 2002, 
Rauscher et al., 2006). This along with multiple glycine rich domains provides flexibility 
to the protein and thus to the elastic fibres (Jensen et al., 2000). Elastin aligns to fibrillin-
1 or fibrillin-2 microfibrils (Michie et al., 2000, Zhang et al., 1994) and is thought to be 
stabilised by desmosine crosslinks (Akagawa and Suyama, 2000, Ma et al., 2003, 
Bernstein et al., 1994). The elastin based fibres are cross-linked to fibrillin microfibrils to 
form the elastic matrix of the ECM, which has been widely observed in both foetal and 
adult bovine fibroblasts for many years (Jones et al., 1980, Ross and Bornstein, 1969, 
Kewley et al., 1978). The fibrillin proteins will be discussed in detail in Section 1.3.  
 
1.2.3 Laminin 
Laminins are a key structural component of the basement membrane and are secreted into 
the ECM of connective tissues to assist in the maintenance of elasticity and cell adhesion 
(Yurchenco et al., 2004) (Figure 1.3). The basement membrane is comprised of both an 
internal basal lamina and external reticular lamina layer, both with distinct protein 
composition. To date, a total of 16 heterotrimeric laminin proteins, consisting of an alpha, 
beta and gamma subunit, have been identified (Aumailley et al., 2005). The proteins are 
assembled intracellularly starting with the beta and gamma subunits followed by the 
addition of the alpha subunit (Hamill et al., 2009). The heterotrimeric protein is then 
secreted into the ECM where they interact with the integrins of the plasma membrane. 
Integrins are heterodimeric receptors that link the intracellular cytoskeleton to the ECM 
(Figure 1.3), and are responsible for the majority of communication between the intra 
and extracellular regions of the cell through interactions with laminins (Kikkawa et al., 
2000, Delwel et al., 1994, Nishiuchi et al., 2006) and fibronectin (Discussed in Section 
1.2.4) (Engel et al., 1981). Laminins can also be connected with the basement membrane, 
forming a link between the cell and its surrounding environment (Figure 1.3). 
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1.2.4 Fibronectin  
Fibronectin  (encoded by FN1) (OMIM: 135600) is a 440kDa glycoprotein that is 
important in the maintenance of the ECM and cellular adhesion. Mature fibronectin 
consists of two homologous monomers linked by a disulfide bond (Singh et al., 2010). 
Alternate splicing of the FN1 mRNA leads to different isoforms (Ffrench-Constant and 
Hynes, 1989, Barnes et al., 1995, Gutman and Kornblihtt, 1987). Fibronectin exists as a 
plasma soluble form (localised mainly to blood plasma) (Ylatupa et al., 1995, Zardi et al., 
1979, Chauhan et al., 2008) and an insoluble cellular form (To and Midwood, 2011), 
mainly secreted by fibroblast cells (Grinnell and Feld, 1979), that can be present on cell 
surfaces (Xu et al., 2009) and within the basement membrane (Section 1.2.3), throughout 
connective tissues (Mao and Schwarzbauer, 2005)(http://biogps.org). Insoluble fibonectin 
is organised as an elongated, branched fibril network tightly controlled for fast up or 
down regulation (Sevilla et al., 2010) (Figure 1.3). In addition to ECM development it is 
involved in cytoskeleton organisation via interactions with the cell membrane (Baneyx et 
al., 2002, Welch et al., 1990). The fibronectin fibre network is assembled at the cell 
surface after secretion. Soluble compact fibronectin dimers are within the extracellular 
space can then bind to membrane bound integrins (Yonezawa et al., 1996). The dimers of 
fibronectin cluster and stretch or lengthen across the cell surface. Fibronectin contains 
one RGD (Arg-Gly-Asp) ligand-binding site demonstrating integrin mediated binding 
capability. It is also capable of direct binding with membrane bound integrin alpha 9 beta 
1 and alpha 4 beta 1 (Liao et al., 2002). Integrin binding supports cell adhesion 
(Ruoslahti, 1996, Shiokawa et al., 1999) and integrin- RGD binding is essential in 
embryonic development (Takahashi et al., 2007). Fibronectin contains heparan sulphate 
binding sites (Mostafavi-Pour et al., 2001) and dermatopontin binding sites (involved in 
wound repair) (Kato et al., 2014) as well as binding sites for many other molecules. 
Fibronectin protein expression was shown to be essential within multiple organ systems 
when Fn1 null mice were found to be embryonic lethal (Howerton et al., 2008). 
Fibronectin has been implicated as a lead protein in wound repair (discussed in Chapter 
4), through interactions with the acidic ECM protein dermatopontin (Okamoto and 
Fujiwara, 2006, Kato et al., 2014). Fibronectin, in mesenchymal cell types, is also 
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required for 10 nm microfibril deposition (Sabatier et al., 2009, Kinsey et al., 2008), 
anchors the collagen matrix to the plasma membrane (Erat et al., 2013) and assists in the 
organisation of the collagen fibres (Sevilla et al., 2013, Li et al., 2003). 
 
1.2.5 Cytoskeletal actin  
The ECM interacts with the interior of the cell through cytoskeleton proteins, particularly 
cytoskeletal actin. Actin is a major cytoskeletal protein forming approximately 7nM actin 
filaments, known as microfilaments (reviewed by (Dominguez and Holmes, 2011)), 
found within the cytoskeleton (Figure 1.3). Microfilaments are highly ordered structures 
that can be synthesised to form either actin bundles (Splettstoesser et al., 2011) or a three 
dimensional network (Narita et al., 2011, Tang et al., 2001). These structures provide 
mechanical support (Chanet and Martin, 2014), form adherens junctions (Peglion et al., 
2014, de Rooij, 2014), and determine cell shape (Mogilner and Rubinstein, 2010) and 
cellular movement (Mitchison and Cramer, 1996, Kozuka et al., 2007). Actin monomers 
are globular proteins (G-actin) and consist of approximately 375 amino acids 
(Vandekerckhove and Weber, 1979). Three G-actin monomers, containing multiple G-
actin binding sites, then arrange in a head to tail configuration-forming F-actin 
(filamentous actin)(Holmes et al., 1990). The head to tail arrangement creates polarity on 
the ends of the F-actin, one end with a positive charge and the other with a negative 
charge (Cooper, 2000). Filamentous actin bundles are synthesised by two different 
mechanisms depending on the proteins bound to the monomers (Cooper, 2000). For 
example, in microvilli of the intestines, bundling protein, fimbrin, binds actin monomers 
in a tight parallel fashion (Mukherjee and Williams, 1967). In the creation of contractural 
bundles, alpha actinin binds the G-actin loosely in a parallel fashion (Rimm et al., 1995), 
improving interactions with contractile protein, myosin (Burnette et al., 2014). Three-
dimensional networks are formed by crosslinking F-actin by filamin proteins that form a 
V shaped conformation (Holmes et al., 1990). This allows the network to create adherens 
junctions and interact with plasma membrane integrins that directly interact with the 
ECM (Hirata et al., 2014), including fibrillins (Figure 1.3).  
Chapter 1. Introduction 
 
  17 
1.3 Fibrillins  
Although collagens, laminins and fibronectin are the main protein components of the 
ECM (see Section 1.2) the glycoprotein family consisting of fibrillins (fibrillin-1, 
fibrillin-2 and fibrillin-3 in most mammals) are major proteins in the structure and 
function of 10nm elastin associated microfibrils within the ECM (Sakai et al., 1986) 
(Zhang et al., 1994, Corson et al., 2004) (Figure 1.3). In addition to a structural role in 
the microfibrils, fibrillin is thought to aid in the sequestering of TGFβs through 
interactions with latent TGFβ- binding proteins, LTBP1, LTBP3 and LTBP4 (Isogai et 
al., 2003, Massam-Wu et al., 2010, Nistala et al., 2010b, Zilberberg et al., 2012).  
Fibrillins are glycoproteins of approximately 350kD that are located throughout the 
ECM. They are associated with the majority of connective tissue types (Sakai et al., 
1986, Keene et al., 1991). Fibrillin-1 was first isolated from human fibroblast cultures 
and identified as the leading component of 10nm microfibrils in the ECM, through 
immunogold electron microscopy using a monoclonal antibody (Sakai et al., 1986). The 
FBN1 gene is ubiquitously expressed in mesenchymal cell types (Summers et al., 2010). 
Fibrilllin-1 is first synthesised as a proprotein and processing occurs outside the cell by 
members of the furin family (Wallis et al., 2003, Milewicz et al., 1995). The FBN2 gene 
was identified through its homology with FBN1 and fibrillin-2 protein was shown to be a 
microfibril component through immunohistochemistry and localisation techniques in a 
human osteosarcoma cell line, MG-63, and human foetal tissue sections (Lee et al., 1991, 
Zhang et al., 1994). It is particularly prevalent in elastin rich matrices (Zhang et al., 1994, 
Lin et al., 2002). As discussed below, FBN2 mRNA is found in fewer tissues and 
developmental stages than FBN1, although both are expressed at high levels in bone, 
osteoblasts and chondrocytes (Summers et al., 2010). While the localization and 
expression of fibrillin-1 and fibrillin-2 have been well characterised, expression of 
fibrillin-3 is primarily in foetal tissues, particularly the brain, and was reported to be 
absent from the Muridae family (Corson et al., 2004), where only a degenerate Fbn3 
gene could be detected. 
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1.3.1 Fibrillin makes 10nm microfibrils 
Fibrillin-based microfibrils can form one, two and three-dimensional structures. For 
example, the linear fibres (lamina cribrosam) of the ciliary zonule, which anchor the eye 
lens, are composed primarily of fibrillin-1, without elastin (Hernandez, 1992, Wess et al., 
1997, Wess et al., 1998, Hanssen et al., 1998). Intercalating between the smooth muscle 
of the aortic tunica media, they form a two-dimensional network while in skin fibrillin 
microfibrils form a three dimensional meshwork of microfibrils complexed with elastin 
to form elastic fibres (Ramirez et al., 2004, Kielty and Shuttleworth, 1997). 
The exact mechanism for the assembly of these structures is not well understood. Fibrillin 
monomers link in a head to tail manner resulting in a beaded appearance (Kielty et al., 
2002, Reinhardt et al., 1996), which has been hypothesised to mediate the ability of the 
proteins to form multi-dimensional interactions (Sakai et al., 1986, Arnaout, 2004, Lin et 
al., 2002, Kielty and Shuttleworth, 1993a, Mariencheck et al., 1995). In vascular smooth 
muscle formation, fibrillin is known to provide a structured framework for tropoelastin 
deposition that then cross link to form elastic microfibrils (See Section 1.2.2). Elastin 
interacts with fibrillin-1 near the third TB (TGFß-binding protein-like) domain (Section 
1.3.2). The cross linking of elastin to fibrillin microfibrils may be an important aspect of 
elastic fibre assembly (Rock et al., 2004). However, in Fbn1 null mice which lack 
fibrillin-1 protein, the vascular smooth muscle cells (VSMC) produced viable cross 
linked elastic fibres, although there was abnormal medial ECM formation (Carta et al., 
2006). This suggested that fibrillin-1 is not necessary for tropoelastin cross linking in 
elastin fibre formation.  
Fibrillin-2 appears in microfibrils in the early stages of embryogenesis (in contrast to 
fibrillin-1, which was first detected later in development), and is primarily restricted to 
bone and cartilage matrices in adult tissues (Zhang et al., 1994, Nistala et al., 2010b, 
Mariencheck et al., 1995).  It is not understood how fibrillin-3 contributes to microfibril 
structure, but the similarity of its protein structure to fibrillin-1 and fibrillin-2 suggests 
that the same interactions are possible (Section 1.3.2). FBN3 mRNA is mainly present in 
embryonic and foetal tissues, where its expression is low (Corson et al., 2004). 
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Continuing research will be required to better understand the unique mechanism of multi-
dimensional microfibril formation and the role of the three fibrillins at different 
developmental stages.  
1.3.2 Fibrillin and LTBP structure  
The primary protein structure of members of the fibrillin family is shown in Figure 1.5. 
Fibrillins contain 47 epidermal growth factor-like (EGF) domains of which 43 are 
calcium binding EGF type (cbEGF domains) (shown in Figure 1.5). EGF domains are 
found in a range of proteins, including BMP1 (bone morphogenetic protein) 
(NM_001199), TGFα (transforming growth factor alpha, NM_ 001099691) and NOTCH 
1 (a member of the type 1 transmembrane protein family,  NM_017617).  The cbEGF 
domains (along with calcium) have important structural significance in the production of 
beaded fibrillin microfibres (Kielty and Shuttleworth, 1993b, Reinhardt et al., 1997). 
Unique to fibrillins and the closely related latent transforming growth factor beta binding 
proteins (LTBPs) are the 8 cysteine domains (TB domains) of which seven are found in 
fibrillins (Dyer et al., 1995) while three are present in each LTBP protein (Robertson et 
al., 2010). LTBP proteins are smaller than fibrillins but their overall structure is similar 
(Robertson et al., 2010, Davis et al., 2014). A degenerate form of the 8 cysteine domain 
(containing only 6 cysteines) is also found in two members of the follistatin family, FST 
and FSTL3, which do not share any other functional domains (Wilson et al., 2009).  
The structural elements of the fibrillin proteins vary slightly in that fibrillin-1 contains a 
proline-rich internal domain, while in fibrillin-2 this domain is composed of a glycine-
rich region. Fibrillin 3 contains an internal domain rich in both glycine and proline 
(Figure 1.5).  
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 Figure 1.5. The structural components of the fibrillin and LTBP protein family. (Redrawn from 
(Charbonneau et al., 2004, Handford et al., 2000, Isogai et al., 2003). 
Fibrillin-1, fibrillin-2 and fibrillin-3 also contain heparan sulfate binding motifs (Cain et 
al., 2008, Cain et al., 2012, Sabatier et al., 2014, Ritty et al., 2003). Heparan sulfate 
proteoglycans are glycoproteins, which interact with multiple ligands, mediate matrix cell 
migration and wound repair, aid in protecting against proteolysis, can act as receptors for 
proteases and their inhibitors as well as aiding in cell-ECM attachment through integrin 
binding.  Their roles and functions are extensively reviewed in (Sarrazin et al., 2011). 
Fibrillin -1 has over six well-documented heparan sulphate binding sites, and recently 
more have been identified in the C and N terminus regions of the protein (Cain et al., 
2008). The heparan sulphate binding sites in the N terminus and C terminus of fibrillin-1 
mediate different regulatory pathways. For example, heparan binds to the C-terminal 
heparan-binding site of fibrillin-1, inhibiting interactions with tropoelastin, therefore 
causing disruption in elastin deposition (Cain et al., 2008). The N terminus binding sites 
are crucial in fibrillin-1 polymerisation during fibre assembly (Cain et al., 2008). 
Fibrillin-2 has several high affinity heparan binding sites in both the N and C terminus, 
and fibrillin-3 has binding regions within the C terminus (Sabatier et al., 2014). It is 
predicted that the heparan sulfate interactions with the fibrillin family are important in 
microfibril formation and structure.   
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1.3.3 Fibrillin in the sequestering of TGFß 
LTBPs together with fibrillin-1 and fibrillin-2 are involved in the inactivation of TGFβ, 
an important regulator of connective tissue function (Flaumenhaft et al., 1993, Nakajima 
et al., 1997). The proposed mechanism is shown in Figure 1.6. There are three genes 
encoding TGFβ molecules (TGFB1, TGFB2 and TGFB3). All three are initially 
synthesised as larger precursor molecules, which are then cleaved to form two peptides. 
The N-terminal end forms the latency associated peptide (LAP) while the remainder 
contains the active TGFβ molecule, which forms a homodimer, which is complexed with 
the LAP in the cytoplasm to form the small latency complex, or SLC. The SLC binds to 
an LTBP molecule (LTBP1, LTBP3 or LTBP4) through disulphide bonds to the second 
8-cysteine domain, forming the large latency complex (LLC). The LLC is then secreted 
into the ECM where it maintains TGFβ in an inactive state (Figure 1.6A). Release of the 
TGFβ homodimer from the LLC allows it to bind to its receptors (TGFBR1 and 
TGFBR2) on the cell surface and initiate a response, primarily through SMAD signalling, 
which contributes to the regulation of cell division and the epithelial mesenchyme 
transition (EMT) (Chapter 3)(Annes et al., 2003, Derynck et al., 1985, Dubois et al., 
1995, Saharinen et al., 1996) (Figure 1.6B). TGFβ can be activated (released) through 
RGD-mediated integrin binding in the LAP (Yang et al., 2007), conformational changes 
within the SLC (Annes et al., 2004, Wipff and Hinz, 2008), and/or the SLC interacting 
through the actin cytoskeleton (Annes et al., 2004, Munger et al., 1999, Yoshinaga et al., 
2008, Shi et al., 2011). Fibrillin-1 and fibrillin-2 are thought to aid in the inactivation of 
TGFβ in the ECM through interactions with LTBPs (Isogai et al., 2003)(Figure 1.6A). 
The role of fibrillin-3 in modulating levels of active TGFβ has not been clarified.  The 
current understanding of fibrillin, LTBP and TGFβ interaction is depicted in Figure 1.6. 
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Figure 1.6. LTBP and Fibrillin 1 interactions leading to the sequestering of TGFß. (A) Interactions 
between fibrillin and LTBP controlling the bioavailability of TFGß. Both the mature TGFβ 
homodimer and the LAP are contained within the SLC that then forms a disulfide bond to the second 
TB domain of LTBP1 forming the LLC. The LLC is released from the cell and binds to the N 
terminus of fibrillin-1 thereby sequestering TGFβ in an inactive form. (B) TGFß activation and 
SMAD signalling. Active TGFβ is released (See Section 1.3.3) and binds with TGFβ receptors. This 
stimulates a phosphorylation cascade involving SMAD signalling. SMAD 2/SMAD3 are 
phosphorylated, leading to the phosphorylation of SMAD 4. SMAD2/3 and SMAD4 cross the nuclear 
membrane and act as transcription factors to signal further cellular process such as cell growth and 
apoptosis. TGFβ can also signal via a non-canonical ERK pathway (not shown)(Discussed in Chapter 
5). The image was adapted from (Hyytiainen et al., 2004).  
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The LLC is anchored to the ECM by an interaction between the C-terminus of LTBP-1 
and the N terminus region of fibrillin-1 (Isogai et al., 2003) (Figure 1.6A). LTBP-1 has 
been shown to co-localize with fibrillin-1 and fibrillin-2 during microfibril assembly 
(Massam-Wu et al., 2010). LTBP-4 binds with the N terminus of fibrillin-1 with high 
affinity while LTBP-3 does not bind with the same region, suggesting alternative binding 
sites throughout fibrillin-1 (Isogai et al., 2003). LTBP2 appears to compete with LTBP1 
for binding with fibrillin-1 microfibrils, therefore LTBP2 maybe an indirect negative 
regulator for TGFβ storage (Isogai et al., 2003, Hirani et al., 2007). Although the 
fibrillins do not bind TGFβ or the SLC directly, these interactions with the LTBPs 
indicate a contribution of the fibrillins to the regulation of TGFβ (Massam-Wu et al., 
2010). Since TGFβ is a major factor in the differentiation of epithelial cell types to 
mesenchymal cell types (epithelial-mesenchyme transition, EMT) (Zavadil and Bottinger, 
2005)(Described in Chapter 3) and in maintaining ECM formation (Miettinen et al., 
1994), the interactions with LTBPs and hence TGFβ suggest fibrillin proteins may play 
an important regulatory role in the process of differentiation.   
The TGFβs are members of a large gene and protein superfamily, which also includes the 
BMP proteins, myostatin, the activin/inhibin subfamily, and other structurally related 
members. TGFβs and BMPs (but not myostatin) are widely sequestered throughout the 
bone matrix, through interactions with LTBPs and fibrillins (Nistala et al., 2010b, 
Ramirez and Sakai, 2009, Arteaga-Solis et al., 2001, Sengle et al., 2010, Sengle et al., 
2008), as discussed above. In addition, TGFBR2 has a key role in endochondral 
ossification, and studies in mouse models have shown that depletion of Tgfbr2 led to 
incomplete and defective long bone formation (Sueyoshi et al., 2012). Sueyoshi et al., 
(2012) showed that the downregulation of Tgfbr2 had a direct effect on chondrogenesis in 
endochondral ossification, therefore showing that TGFβ signalling is important in 
chondrogenesis. TGFβ also plays a role in regulating fibroblast activity (Clark et al., 
1997), with stimulation of a wound repair matrix following treatment with TGFβ. 
Furthermore, TGFβ signalling has a role in adipose homeostasis. As previously 
described, TGFβ binds to its receptors initiating a SMAD phosphorylation cascade 
(Figure 1.6B). In Smad3 knockout mice, it was shown that blocking TGFβ signalling 
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protected the mice from weight gain, a common phenotype in Smad3 depleted mice 
(Yadav et al., 2011), thereby implicating TGFβ in inducing adipose formation.  
It is thus thought that fibrillins have both a structural role in forming the 10nm 
microfibrils and a regulatory role in the sequestration of TGFβ, which is made more 
obvious in connective tissue disorders arising from mutations in the FBN1 and FBN2 
genes, for example Marfan syndrome. These will be discussed in the following sections.  
1.3.4 Phenotypes associated with Fibrillin-1 Mutations  
As shown above, fibrillins are an integral component of the ECM, and therefore 
mutations in the genes encoding them are likely to cause disruption of the connective 
tissue. Over 2,000 FBN1 mutations have been identified and the majority are associated 
with the autosomal dominant connective tissue disorder, Marfan syndrome (MFS, OMIM 
154700)(Collod-Beroud et al., 2003). The prevalence of MFS is about1 in 5,000 affected 
individuals worldwide (Genetics Home Reference Database, 
http://ghr.nlm.nih.gov/condition /marfan-syndrome). MFS causes multiple signs and 
symptoms primarily affecting the ocular, skeletal and cardiovascular systems (Dietz et 
al., 1991, Loeys et al., 2010, McInerney-Leo et al., 2014). Marfan syndrome is currently 
diagnosed using the revised Ghent criteria (reviewed by (Summers et al., 2012)). The 
MFS phenotype includes chest wall abnormalities, ectopia lentis, aortic aneurysm and 
dissection, overgrowth of long bones and depleted adipose tissue. These manifestations 
of FBN1 mutations are consistent with the structural role of fibrillin-1 in the ECM. In 
addition, studies of mouse models and cultured skin fibroblasts from patients have shown 
that the level of active TGFβ is higher in patients and mutant mice than in controls 
(Neptune et al., 2003, Nataatmadja et al., 2006, Matt et al., 2009)(Table 1.2). In Fbn1 
null mice, TGFß and BMP levels are also very high in osteoblasts (Nistala et al., 2010b). 
These results suggest that the control of TGFß activity is an important physiological 
function of fibrillin-1 in at least the cardiovascular and skeletal systems.  
The phenotype of FBN1 mutations in humans varies from a severe neonatal form of 
MFS, which is lethal in the first few years of life to relatively mild familial ectopia lentis 
or familial scoliosis (Loeys et al., 2010, McInerney-Leo et al., 2014, Faivre et al., 2007). 
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Some families with autosomal dominant familial aortic aneurysm segregate FBN1 
mutations, which are also associated with a number of other dominant conditions (Table 
1.1). 
Disorder/Syndrome/Phenotype OMIM number 
Marfan Syndrome 154700 
Ectopia lentis  129600 
MASS syndrome  604308 
Sphrintzen-Goldberg craniosynostosis 182212 
Stiff skin syndrome 184900 
Weill-Marchesani syndrome 608328 
Acromicric dysplasia  102370 
Geleophysic dysplasia  614185 
Ascending aortic aneurysm and dissection (Francke et al., 1995) 
Lipodystrophy  (Graul-Neumann et al., 2010) 
Table 1.1. Phenotypes associated with mutations in FBN1. Data derived from Online Mendelian 
Inheritance in Man (OMIM, http://www.ncbi.nlm.nih.gov.ezproxy.is.ed.ac.uk/omim/) except where a 
reference is given. 
Most of the mutations in FBN1 are missense, usually adding or removing a cysteine 
residue or involving one of the amino acids of the calcium-binding pocket. The neonatal 
MFS mutations (responsible for the severe disease) appear within the confines of exon 24 
(encoding the fifth TB domain, Figure 1.5) to exon 32 (Faivre et al., 2009).  
Knockout and transgenic mice have been created for fibrillin-1 and fibrillin-2. The 
phenotypes of the mouse models are summarised in Table 1.2. The mouse models do not 
always replicate the human phenotype. For example, mutation or inactivation of mouse 
Fbn1 may not show a heterozygous phenotype, nor the phenotypic variability common in 
human families. However the phenotypes are consistent with connective tissue 
abnormalities similar to those seen in human disease, such as MFS and fibrillin-2 
associated disorders (Chapter 1, Section 1.3.5)(Table 1.2). 
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Gene Mutation Phenotype  Reference  
Fbn1tm1.2Lysa Inversion, Insertion- targeted 
mutation 




Insertion/Deletion/Targeted  MFS Model  Charbonneau et al., 2010 
Fbn1tm3.2Lysa Insertion/Deletion/Targeted  MFS model Sengle et al., 2010 
Fbn1tm1Hcd Single mutation  MFS model, 
including respiratory 
defects  
Judge et al., 2004 
 
Fbn1tm2.1Hcd Insertion Early MFS model 
(embryonic lethal) 
Gerber et al., 2013 
Fbn1tm3.1Hcd Insertion  Skin defects  Gerber et al., 2013 
Fbn1tm1Lper Insertion, deletion MFS model  Lima et al., 2010 
 
Fbn1tm1Rmz Deletion  MFS model, 
including respiratory 
defects 
Pereira et al., 1997 
 
Fbn1tm2Rmz Insertion Cardiovascular, 
respiratory, skeletal 
and muscular 
defects, mortality   
Pereira et al., 1999 
 
Fbn1tm3Rmz Insertion and intragentic 
deletion 
Cardiovascular and 
skeletal defects  
Carta et al., 2006 
 
Fbn1tsk Spontaneous partial 
duplication 
MFS, scleroderma, 
Stiff skin syndrome, 
tight skin 
Blake et al., 2014 
Fbn2fp-2J Spontaneous allele deletion Arachnodactyly Blake et al., 2014 
Fbn2fp Spontaneous allele deletion Fused phalanges  Blake et al., 2014 
Fbn2mz Allele deletion, chemically 
induced 
CCA Miller et al., 2010 
Fbn2fp-4J Spontaneous allele deletion CCA Blake et al., 2014 
Fbn2fp-3J Allele deletion, chemically 
induced  
CCA Munroe et al., 2000 
 
Fbn2tm1Rmz Targeted mutation CCA Arteaga-Solis et al., 2001 
 
Table 1.2.  A list of Fbn1 and Fbn2 knockout and transgenic mouse models.  
There is currently no cure for MFS. However, some drug therapies have been shown to 
be effective in reducing the risk of aortic dissection/aneurysm and osteopenia (a mild 
decrease in bone mineral density).  Due to the progressive nature of aortic dissection and 
aneurysm leading to premature death in patients with severe MFS, one of the first 
therapeutic treatments offered was the use of beta-blockers, propanolol (Shores et al., 
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1994) and atenolol (Vaidyanathan, 2008, Yetman et al., 2005). These drugs belong to the 
class of beta-adrenergic blocking agents that prevent the binding of the hormone 
adrenaline to its receptors on the cell surface, thereby lowering heart rate and blood 
pressure. The reduced blood pressure and heart rate were thought to lower the stress 
applied to the aorta and other cardiovascular components. Early studies of the use of 
beta-blockers in MFS patients showed that it slows the rate of dissection and aneurysm, 
though beta-blockers do not have regenerative properties (Ose and McKusick, 1977, 
Shores et al., 1994). Angiotensin-converting enzyme (ACE) inhibitors have also been 
used to slow aortic dilatation in patients with intolerance to beta blockers (Yetman et al., 
2005). They act to inhibit the conversion of angiotensin I to angiotension II, which is 
catalyzed by ACE. The reduction of angiotensin in the system leads to vasodilatation and 
therefore a decrease in blood pressure and stress on the cardiovascular system (van Vark 
et al., 2012).  For example, ACE inhibitor enalapril was shown to reduce aortic stiffness 
and progression of dissection (Yetman et al., 2005). More recently, treatment with 
losartan, an angiotensin II receptor 1 blocker, was found to lower TGFß activity, improve 
aortic wall recovery and prevent aortic dissection in a mouse model (Nistala et al., 2010a, 
Habashi et al., 2006, Groenink et al., 2013, Trindade, 2013, Pees et al., 2013), and was 
more effective than treatment with enalapril (Habashi et al., 2011). Losartan is currently 
undergoing clinical trials to assess its therapeutic effectiveness on the cardiovascular and 
other affected systems in patients with MFS (Sandor et al., 2014) (Lacro et al., 2014) 
(Yacoub and Radford, 2014) (Groenink et al., 2013 ).  
As previously mentioned, overgrowth of long bones occurs in Marfan syndrome 
associated with the development of osteopenia, resulting from over active osteoclasts. 
Alendronate (Fosamax), a bisphosphonate drug used in the treatment of osteoporosis, was 
effective in treating bone loss through restricting osteoclast activity, in mouse models 
(Nistala et al., 2010a).  
Mutations in some of the closely related LTBP loci are associated with phenotypes 
similar to aspects of MFS. For example, mutations in LTBP2 cause ocular problems 
(OMIM 602091) including glaucoma (MIM: 613086) and ectopia lentis (MIM: 251750). 
Chapter 1. Introduction 
 
  28 
Mutations in other genes involved in TGFß signalling also show some similarities with 
FBN1 mutations. For example, mutations of the TGFß receptor genes (TGFBR1 and 
TGFBR2) can give rise to Loeys Dietz syndrome, which manifests Marfan-like symptoms 
including arachnodactyly (spider fingers), pectus deformities and aortic dissection and 
dilation (OMIM: 610380, 609192, 610168, 608967). Advances in treatment of Loeys 
Dietz syndrome include use of dexamethasone, which facilitates proper microfibril 
processing in human fibroblast cultures showing abnormal matrix assembly (Barnett et 
al., 2011).  
There are currently no known therapeutic agents available for treating other signs and 
symptoms of MFS, including ectopia lentis, adipose depletion and cartilage and bone 
deformities, though some problems, such as pectus deformities and lens dislocation can 
be corrected with surgery.  
 
1.3.5 Phenotypes associated with Fibrillin-2 Mutations 
FBN2 mutations have been associated with congenital contractural arachnodactyly, CCA 
(OMIM 121050) (Putnam et al., 1995). CCA mimics many of the musculoskeletal 
defects of MFS, presenting with long limbs, contractures, spider fingers (arachnodactyly) 
and scoliosis. CCA affects less than 1 in 10,000 individuals 
(http://ghr.nlm.nih.gov/condition /marfan-syndrome), making it less prevalent than MFS. 
According to Universal Mutation Database (http://www.umd.be), there are 113 recorded 
FBN2 mutations resulting in CCA (Frederic et al., 2009).  These FBN2 mutations reside 
primarily between exon 24 and exon 33, a cbEGF domain rich region of fibrillin-2, while 
only two are recorded near the N terminus, in exons 8 and 9. The majority present as 
missense and deletion mutations, thought to prevent proper calcium binding and protein 
folding through impeding disulfide bond formation (Frederic et al., 2009). Interestingly, 
the fibrillin-2 mutations are found in the region corresponding to the region of mutations 
observed in fibrillin-1 in severe neonatal MFS (Frederic et al., 2009). It has been 
proposed that this region (exon 24-32 in FBN1 and FBN2), which displays 71.2% 
homology (Mega Align, Clustal W alignment) (see Chapter 7), is critical to the function 
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of the proteins.  Based on the differing severity of the phenotypes in neonatal MFS and 
CCA, fibrillin-1 has a more universal role than fibrillin-2. A detailed analysis of this 
region in both fibrillin-1 and fibrillin-2 will be presented in Chapter 7. Though CCA 
rarely shows the severe cardiovascular effects seen in MFS patients, some CCA 
mutations result in early lethality due to cardiovascular defects (Gupta et al., 2004).  
1.3.6  Phenotypes associated with Fibrillin 3 Mutations 
There is no specific condition known to be caused by FBN3 mutation, although genetic 
variation at the FBN3 locus was recently linked to polycystic ovary syndrome (PCOS). 
Polymorphism of microsatellite D19S884, located in intron 55 of FBN3, was associated 
with an increase in susceptibility to PCOS (Urbanek et al., 2007). However another study 
failed to replicate the PCOS association (Prodoehl et al., 2009). Since fibrillin-3 is 
degenerate in mice, it has not been possible to create null mice to explore its function 
further. 
1.4 Analysis of fibrillin gene expression  
Expression of a eukaryotic gene begins with the transcription of an RNA copy of the 
gene’s DNA.  Transcription is initiated through promoter site recognition by the RNA 
polymerase enzyme guided by transcription factors that bind to specific DNA motifs in 
the promoter region. The RNA polymerase then transcribes an RNA copy of the DNA 
sequence. In eukaryotes, the nascent RNA must then be processed, including tagging of 
the 5’ end with a modified guanine (the 5’ cap), cleavage and removal of introns 
(splicing) and enzymatic addition of a string of A nucleotides at the 3’ end 
(polyadenylation). The mature mRNA then exits the nucleus into the cytoplasm where it 
binds to the ribosomal subunits to initiate protein synthesis. In the case of ECM proteins 
like the fibrillins, the ribosome is targeted to the endoplasmic reticulum and extensive 
posttranslational processing occurs before and after secretion into the ECM. The final 
manifestation of gene expression requires that each of the stages from initiation of 
transcription to the final activation of the protein is permissive, and regulation can occur 
at any stage.  
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1.4.1  Expression of the fibrillin gene family extracted from 
publically available database, BioGPS   
 
Figure 1.7.  The mRNA expression of the fibrillin gene family. mRNA expression of fibrillin-1 
(probeset: 202765_s_at), fibrillin-2 (probeset: 203184_at) and fibrillin-3 (probeset: gnflh00776_at). 
Images captured from http://biogps.org. Y- axis shows the cells and tissues sampled. The X-axis 
shows the relative expression intensity using Affymetrix U133A human gene expression microarray.  
The publicly available database BioGPS (http://biogps.org), shows gene expression of the 
fibrillin family in humans (GeneAtlas U133A data set) (Figure 1.7). Consistent with their 
role in connective tissue, fibrillins are expressed primarily in cell types and tissues of 
mesenchymal origin. FBN1 and FBN2 were highly expressed in adipocytes, smooth 
muscle cells, cardiac myocytes, and placenta (Figure 1.7). Furthermore, FBN2 showed 
mRNA expression in bronchial endothelial cells and CD33+ myeloid cells (Figure 1.7). 
In humans the expression of FBN3 appears restricted to embryonic/foetal cell types 
(Corson et al., 2004), with some recent data sets showing expression in meiosis phase II 
oocytes (Kocabas et al., 2006). Furthermore, FBN3 mRNA showed high expression in 
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foetal brain and lower expression in foetal lung (Corson et al., 2004) (Figure 1.7). This 
initial survey of gene expression in the fibrillin family demonstrates the broad 
mesenchyme specificity of FBN1, the more restricted expression in FBN2 and the limited 
expression of FBN3 in early development.  
 
1.4.2 Analysis of co-expressed genes  
Genes with similar expression patterns are likely to be co-regulated and interact (Allocco 
et al., 2004). BioLayout Express 3D is a network visualisation tool that employs an 
unstructured approach to cluster genes based gene expression patterns across the sample 
set, which has been used extensively to develop lists of co-expressed (and potentially co-
regulated) genes (Hume et al., 2010, Freeman et al., 2007, Theocharidis et al., 2009, 
http://biolayout.org).  
Gene clustering analysis has been performed on various cell lines and tissue samples in 
mice using published data from Affymetrix microarrays (Summers et al., 2010, Chang et 
al., 2008, Lattin et al., 2008).  Summers et al., (2010) used BioLayout Express 3D to 
analyze microarray data available from GEO (Gene expression omnibus) DataSets 
downloaded from www.ncbi.nlm.gov/gds, the first widescale expression study focusing 
on genes co-expressing with the fibrillin gene family. The BioLayout Express 3D 
clustering results yielded a mesenchyme specific cluster of 205 co-expressed unique 
genes, containing two Fbn1 probes (1425896_a_at and 1460208_at) in the centre of the 
cluster (Figure 1.8A and1.8B). This cluster was referred to as the Fbn1 cluster in 
(Summers et al., 2010), therefore that terminology will be maintained throughout this 
section. The Fbn1 cluster contained 205 genes at r≥0.90 (Figure 1.8) and 31 of these 
genes were present in a cluster with Fbn1 at a higher stringency of r≥0.95. Genes in the 
Fbn1 cluster showed elevated expression in cell lines of mesenchymal origin including 
osteoblasts, both embryonic and adult fibroblasts and myoblasts (Figure 1.8). Expression 
of Fbn1 was very low in hematopoietic samples and moderate in endothelial cell types 
and ES cells (Figure 1.8). 
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Figure 1.8 The Fbn1 cluster. (a) A 3D image of the Fbn1 cluster (nodes in the cluster shown by black 
spheres, edges by grey lines). Other clusters shown by edges only. (b) A 2D image of the Fbn1 cluster 
with the two Fbn1 probes shown as black spheres. (c) Normalised mean expression of genes of the 
Fbn1 cluster across all cell types. The means of two experiments are shown. (d) Expression of the two 
Fbn1 probes, 1460208_at (black) and 1425896_a_at (grey). The means of two experiments performed 
in triplicate are shown for each probe. Raw data available for download at GEO DataSets (accession 
number GSE10246). The above figure was used with permission from Nature Publishing Group 
(Summers et al., 2010). 
GO (Gene Ontology) terminology was used to determine the localisation and functions of 
proteins encoded by genes within the cluster (at r≥0.90) and showed that a total of 33.9% 
were localised to the ECM, 26.0% localised to cellular membranes and 11.3% of genes 
were located in the cytoskeleton. In addition, 25% of the gene products were found to be 
involved in cell proliferation and 10.0% involved in ECM function. Classic mesenchyme 
related genes included in the Fbn1 cluster were Acta2 (smooth muscle actin, alpha 2), 
Bgn (biglycan), a total of 12 collagen genes including Col1a1 (collagen type I alpha 1), 
Col1a2 (collagen type I alpha 2), Col3a1 (collagen type 3 alpha 1), Fn1 (fibronectin 1), 
Lama4 (Laminin alpha 4), Lox (Lysyl oxidase), Sparc (osteonectin), Sox9, Tgfb2 
(transforming growth factor beta 2), Tgfb3 (transforming growth factor beta 3) and 
TgfbIiI (transforming growth factor beta 1 induced 1).  
Clustering which included different data sets showed that this mesenchymal cluster of co-
expressed genes including Fbn1 is relatively robust (Hume et al., 2010, Mabbott et al., 
2011). For example, the original datasets that generated the fibrillin-1 cluster did not 
contain cell types from chondrocyte lineages, therefore further analysis was used which 
included timecourse samples of primary chondrocytes derived from embryonic foot pads 
in mice (James et al., 2005)(Summers et al., 2010). The clustering analysis revealed a 
cluster containing Fbn1 and many other genes that were in the original Fbn1 cluster, 
demonstrated high levels of expression across the whole time course. Since the studies 
presented were specified to cell lines, the researchers performed further BioLayout 
Express 3D analysis on mouse tissues using publicly available microarray data (Su et al., 
2004, Summers et al., 2010). The analysis produced a 119 gene cluster including classic 
ECM genes Fbn1, Fbn2, Eln (elastin), Fbln2 (fibulin 2) and eight collagen genes (for 
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example Col2a1, Col16a1, Col4a1, Col4a2 and Col5a1) at r≥0.75 (Summers et al., 
2010).   
Overall the study by Summers et al., (2010) was able to demonstrate a core set of genes 
that usually co-expressed with Fbn1 as well as indicating possible regulators of fibrillin-1 
in mesenchymal cell lines and tissues. Though fibrillin-2 did not cluster with fibrillin-1 in 
all the analyses, the expression data showed high expression of FBN2 in osteoblasts and 
C3H10T1/2 (differentiating to chondrocyte cells (James et al., 2005)), indicating that 
Fbn2 may be a more bone/cartilage specific gene. However, because mice lack a 
functional Fbn3 transcript, its function and possible gene co-regulators remained 
undefined. Therefore, this thesis will present a wide-scale microarray analysis across 
several human mesenchyme cell lines, as well as early development of human ES cells to 
analyze expression of the entire fibrillin gene family.  
1.4.3 Functional Annotation of the Mammalian Genome, FANTOM 
Throughout my postgraduate studies, I had the privilege of being involved in the 
FANTOM5 consortium, which is a worldwide transcriptome based project sponsored by 
the RIKEN Centre for Life Science Technologies in Yokohama, Japan. The consortium 
has generated five major phases of experiments (FANTOM1-5) from sequenced-based 
gene mapping and annotation to determining specific promoter expression 
(http://fantom.gsc.riken.jp). The data produced by the FANTOM5 projects identified 
transcription start site (TSS) regions and novel alternate promoter usage and provided 
detailed promoter expression levels for both the human and mouse cells and tissues 
(Forrest et al., 2014). Through privileged access to the data from the project (prior to 
publication), extensive information was obtained on expression and regulation of the 
fibrillin gene family (Davis et al., 2014), which will be presented in Chapter 6.  
The FANTOM project originated with the identification of over 20,000 full-length mouse 
cDNAs (Kawai et al., 2001). The cDNA libraries were clustered based on 3’end sequence 
similarity and the clusters were fully sequenced using revolutionary technology, which 
involved inserting biotin onto the cap structure of eukaryotic mRNA (Carninci et al., 
1996). The sequences were then mapped to both the human and mouse genome, 
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contributing to annotation of existing gene families as well as identifying novel genes 
(Kawai et al., 2001). The FANTOM2 project expanded on the existing knowledge of 
FANTOM1 producing an extensive transcriptome of mice and generating a database 
including information on alternate splicing, regulatory elements of UTR regions. 
FANTOM2 identified non-protein coding RNAs as well as antisense RNA (Okazaki et 
al., 2002). FANTOM 1 and 2 developed a large-scale cDNA library for mouse. 
FANTOM3 was a genome-wide analysis of promoter usage, using cap analysis of gene 
expression (CAGE) technology (Carninci et al., 2005, Shiraki et al., 2003, Kodzius et al., 
2006). CAGE technology is a high-throughput method for identification of the 5’ends of 
mRNAs, thus identifying transcription start sites (TSS) and the promoter sequence that 
precedes them (Maeda et al., 2008).  
FANTOM3 showed that most promoters are located in regions rich in cytosine and 
guanine bases (CpG islands) and initiate transcription over a broad sequence of bases. 
This contrasts with the precise initiation on a single base of TATA box promoters, the 
minority of promoters in the mammalian genome (Carninci et al., 2005, Carninci et al., 
2006). Since the number of times a sequence is detected by CAGE is proportional to the 
number of mRNA molecules with that sequence, the data from FANTOM3 and 
subsequent projects also provides quantitative information of expression of the gene from 
a specific promoter. The FANTOM4 project combined CAGE and next generation 
sequencing (deepCAGE) to evaluate promoter usage and regulation in a single cell line 
undergoing a transition in state following activation and showed the regulatory network 
associated with this transition (Suzuki et al., 2009).  
FANTOM5 applied deepCAGE technology to analyze over 900 human and mouse 
tissues, primary cells and cell lines (Forrest et al., 2014). The development of a novel 
browser, ZENBU, allowed for extensive, user-friendly visualization of the CAGE data 
(Severin et al., 2014). FANTOM5 data was used to analyse the fibrillin gene family to 
determine alternate promoter usage and transcript specific expression patterns within the 
family (Chapter 6) (Davis et al., 2014)).  
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1.5 Aims and objectives of the project 
This introduction has provided a survey of available literature, outlined the origin of 
connective tissues and described mature and developing mesenchyme tissue types. 
Furthermore, I have introduced many components of the ECM with an emphasis on the 
fibrillin family. The work described in this thesis is a detailed expression analysis of the 
fibrillin gene family and provides evidence for the role of the fibrillin gene family in cells 
of mesenchyme origin. It leads to a better understanding of the role of the gene family in 
connective tissues. Furthermore, the work assesses the hypothesis that fibrillin-1 is a 
critical regulator of differentiation of mesenchymal cells (Summers et al., 2010). The 
specific aims of the work presented in this thesis were: (1) To analyze the expression of 
the three fibrillin genes at different stages of differentiation and development using in 
vitro cell models, (2) to identify genes that are co-expressed with members of the fibrillin 
gene family, (3) to analyze use of alternate TSS in different tissue and cell types and (4) 
to explore the evolution of the promoter regions and critical protein coding sequences of 
the fibrillin gene family.  
This thesis shows that there is a clear developmental distinction between the three 
fibrillins, and the results presented will assist in the understanding of disorders resulting 
from fibrillin gene mutations and identified co-expressed genes, potential modifiers that 
could be the targets of gene therapy. 
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Chapter 2. General Methods 
Determining expression of the fibrillin genes and identifying genes that are co-expressed 
across mesenchyme cell types was important in understanding the relevance and 
interactions of the genes and gene products in connective tissue cell types. In this study 
connective tissue cell types were represented by cultured human cell lines and expression 
of both mRNA and protein was monitored through a number of approaches, which are 
outlined in this chapter. Detailed materials and methods will also appear in the respective 
chapters.  
2.1 Primary cells and cell lines  
There are three types of human cell culture models presented in this thesis: primary cell 
cultures, transformed cell lines and cancerous cell lines.  Primary cells are extracted from 
tissues and closely mimic the physiological state of cells in vivo. They are adapted to a 
cell culture environment and can be maintained for a finite number of generations. 
Transformed cell lines are populations of extracted cells that have been manipulated to 
become immortal in the laboratory, so that they can undergo cell division indefinitely. 
The final cell types used in this thesis were cancer cell lines. Cancer cell lines derive 
from tumours. They have escaped normal growth controls and are therefore immortal.  
While primary cells are considered the best material for in vitro studies (Forrest et al., 
2014), this study aimed to determine the expression patterns of the fibrillin genes in 
humans and there were ethical and accessibility issues associated with generating primary 
cells for all the relevant tissues. Primary cells were used when available, supplemented 
by cell lines, selected to reflect some of the cell types affected in Marfan syndrome 
(Chapter 1 Section 1.3.4). The use of transformed cell types lead to limitations of the 
work presented in this thesis (Chapter 3, 4 and 5), and if more time were available, 
primary cell types would have been examined. The following subsections will describe 
the cell types used in this thesis.  
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2.1.1 Osteosarcoma cell lines  
In this study two human osteosarcoma cell lines, SAOS2 and MG63 (Pautke et al., 2004), 
were used to analyse the role of fibrillins in bone cells. Osteosarcomas are derived from 
osteoblast progenitors, which have undergone a cancerous transformation (Mutsaers and 
Walkley, 2014). MG63 was isolated in 1977 from an osteosarcoma of a 14 year old 
Caucasian male (Billiau et al., 1977) and SAOS2 was established in 1973 from an 
osteosarcoma removed from an 11 year old female patient (Fogh et al., 1977). The utility 
of MG63 and SAOS2 as model systems for normal bone formation has been debated. 
Though varying cellular morphology and proliferation have been observed (Boskey and 
Roy, 2008), both cell lines demonstrate physiological levels of multiple osteoblastic 
markers including osteocalcin (OC), bone sialoprotein (BSP) and decorin (DCN) (Pautke 
et al., 2004). SAOS2 cells are capable of mineralisation in a calcifying environment, 
while MG63, a less mature cell line, does not mineralise (Houston et al., 2004). In 
addition to these differences in ECM mineralisation, the cell lines demonstrate varying 
levels of FBN1 and FBN2 mRNA (Davis et al., 2014), thereby making these cell lines 
interesting in the study of fibrillin expression. Professor Colin Farquharson (The Roslin 
Institute, University of Edinburgh), kindly supplied cryopreserved SAOS2 and MG63 
cell lines. 
2.1.2 Chondrocyte cell lines 
In addition to osteoblast formation, mesenchymal stem cells can differentiate into 
chondrocytes, producing cartilage (Chapter 1 Section 1.1.3). Human chondrocyte cell 
lines, C20A4 and TC28A2 were immortalised through transfection with the virus SV40 
(Small et al., 1982, Chaney et al., 1986, Arbiser et al., 1991) and were chosen based on 
cartilage specific gene expression, including collagens type II, IX and XI (Goldring et al., 
1994). The line C20A4 was established from costal cartilage of a 5 year old male while 
TC28A2 was derived from the costal cartilage of a 15 year old female. Both patients had 
undergone surgery for pectus excavatum. The line C28I2 is a subclone from TC28A2 
(Goldring et al., 1994). Permission to use the chondrocyte cell lines was granted by Dr. 
Mary Goldring (Goldring et al., 1994) and cryopreserved vials of the cells were supplied 
by Professor Colin Farquharson.  
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2.1.3 Fibroblast cell line 
Fibroblasts are common connective tissue cells that give rise to a collagen and microfibril 
extracellular matrix (Chapter 1, Section 1.2), and have been used as a model system for 
studying fibrillin formation and function (Brenn et al., 1996, Sabatier et al., 2009, Wallis 
et al., 2001, Kielty and Shuttleworth, 1994, Samuel et al., 2003). Primary human 
neonatal fibroblast cells, NHDF, were derived from juvenile foreskin cells, and kindly 
supplied by Dr. Finn Grey (The Roslin Institute, University of Edinburgh).   
2.1.4 Human embryonic kidney cell line  
Human embryonic kidney cell line, HEK293, was derived from human embryonic kidney 
cells transformed with adenovirus type 5 DNA (Graham et al., 1977, Graham and van der 
Eb, 1973, Graham et al., 1974). HEK293 cells have been used to study the gene and 
protein expression levels of fibrillin-1 and fibrillin-2 (Guo et al., 2013, Kirschner et al., 
2011, Wang et al., 2012), though it has been shown that expression levels in this cell line 
are low compared with those of the mesenchymal cell types such as MG63 (Summers et 
al., 2009). The origin of this cell line remains undefined. Though the cells have been 
classically described as epithelial-derived, Shaw et al., (2002) found that the cell line had 
more in common with neurological cells. This cell line was included in the analysis 
because of its relatively low expression of FBN1. The studies could also further clarify 
the origin of the cell line.   
2.1.5 Hemopoietic cell line  
Human leukaemia cell line, THP-1, was derived from the blood of a one year old boy 
diagnosed with acute monocytic leukaemia (Tsuchiya et al., 1980). The monocytic nature 
of the cell line has been verified by the identification of monocytic marker α-naphthyl 
butyrate esterase, and lysozyme production (Tsuchiya et al., 1980). A detailed study of 
THP-1 cells during activation revealed no measurable expression of fibrillin-1 or 
fibrillin-3, but very low expression of fibrillin-2 (Suzuki et al., 2009). This is a mesoderm 
derived hemopoietic cell line that grows in suspension rather than in adherent culture, so 
there is no ECM. Therefore, THP-1 was used as a negative control.  
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2.1.6 Human embryonic stem cells 
Human embryonic stem cells (ES) give rise to the mesoderm layer, which then continues 
to form connective tissue (Chapter 1, Section 1.1)(Chapter 3). Since fibrillin-3 is 
expressed in tissues of foetal origin and in early embryogenesis (Chapter 1, Section 
1.4.1) an expression study of the fibrillin gene family from ES cells differentiating to 
mesoderm was performed. RNA from H1 and RH1 (human ESC cell lines) were kindly 
supplied by Professor Lesley Forrester and Dr. Paul DeSousa (Scottish Centre for 
Regenerative Medicine, The University of Edinburgh), respectively. The methods will be 
discussed Chapter 3. 
2.1.7 Mesenchymal stem cells 
As previously described (Chapter 1 Section 1.1), the mesoderm gives rise to 
mesenchymal stem cells, which continue to form various connective tissue cell types 
within the body.  Fibrillin-1 mutations have been associated with lipodystrophy 
(depletion of adipose tissue) (Graul-Neumann et al., 2010, Goldblatt et al., 2011, 
Takenouchi et al., 2013) (Chapter 1 Section 1.3.4). There is currently very little known 
about the role that fibrillin plays in adipogenesis. Therefore, both primary human adipose 
derived mesenchyme stem cells (ADMSC) and a human embryonic stem cell derived 
mesenchymal stem cell line (hESMP) were differentiated towards the adipose lineage.  
This was to investigate the gene and protein expression of the fibrillin family at various 
timepoints throughout adipogenesis.  
2.1.1.7 Adipose derived MSCs  
Cryopreserved human ADMSC cells were kindly supplied by Dr. Paul De Sousa, Centre 
for Regenerative Medicine, The University of Edinburgh. The cells were originally 
obtained from the Edinburgh Adipose Tissue Bank, Queens Medical Research Institute 
(QMRI), The University of Edinburgh (West et al., 2014). Research was approved by 
South East Scotland Research Ethics Committee 03 (Reference: 1-0/S1103/45). These 
cells and the differentiation protocol are discussed further in Chapter 3.  
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2.1.1.8 hESMP cell line 
hESMP cells were obtained from Cellartis AB (Cellectis Bioresearch, Paris, France) and 
the Materials Transfer Agreement (MTA) was signed by Professor Kim Summers on 
April 25, 2012 in Edinburgh, Scotland, UK (See Chapter 3). 
2.2 Standard Cell Culture 
Cell culture conditions for the ten different cell types examined in this thesis are defined 
in Table 2.1. All cells were incubated in a humidified incubator at 37°C and 5% CO2, and 
treated with Pen Strep (100ug/ml streptomycin and 100U/ml penicillin)(Gibco, Paisley, 
UK), unless otherwise stated. NHDF, ADMSC and hESMP cells required the cell culture 
vessels to be coated with 0.1% gelatin (Sigma-Aldrich, Poole, Dorset, UK) to assist with 
adherence. Cells were all passaged using trypsin (TrypLE TM Express, Gibco). Additional 
cell culture treatments for differentiation and knockdown experiments are highlighted in 
Chapter 3 and 5, respectively.  
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Chondrocyte cell line  C20A4 DMEM 10% non-HI FBS RNABee 
Chondrocyte cell line TC28A2 DMEM 10% non-HI FBS RNABee 
Chondrocyte cell line C28I2 DMEM 10% non-HI FBS RNABee 
Neonatal fibroblast  
cells 
NHDF DMEM 10% HI-FBS 
 
RNAEasy Kit 
Embryonic kidney cell 
line 
HEK293 DMEM 10% non-HI FBS RNABee 
Monocyte cell line THP1 RPMI-1640 10% HI-FBS 
1x GlutaMAX 
RNABee 
Primary adipose derived 
mesenchyme stem cell 




Embryonic stem cell 
derived mesenchyme 
cell line 




Table 2.1. A table of cell culture requirements. GlutaMAX 100x  (Gibco), HI-FBS (heat-inactivated 
foetal bovine serum, GE Healthcare, Little Chalfont, UK), non-HI-FBS (Sigma-Aldrich), DMEM 
(Sigma-Aldrich), modified McCoy’s5A (+25mM HEPES, Gibco), RPMI-1640 (Sigma-Aldrich), and 
bFGF (PeproTech, RockyHills, NJ, USA). 
 
2.3 Analysis of Gene Expression 
2.3.1 RNA purification  
Total RNA extractions were performed using one of two methods throughout this thesis 
(Table 2.1). The first method used RNABee (Amsbio, Abingdon, UK) as per 
manufacturer’s instructions.  Briefly, cells were lysed in RNABee, which is a mixture of 
guanidine isothiocyanate (a protein denaturant) and phenol. Upon addition of chloroform 
two phases were formed with the RNA in the aqueous phase and DNA and protein in the 
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organic phase. RNA was precipitated with isopropanol and washed with ethanol before 
being dissolved in 30-50µl of H2O and stored at -80°C. The second method employed in 
total RNA extraction was the Qiagen RNeasy Mini kit (Qiagen, Crawley, UK), as per 
manufacturer’s instructions. After removal of culture medium, cells were lysed and 
transferred into an RNeasy spin column, which bound the RNA. The column was washed 
and RNA was eluted off the membrane with 30µl of RNase-free H2O and stored at -80°C. 
All RNA samples are listed in Appendix A. 
DNA was removed from all RNA samples using DNase Treatment and Removal 
(Ambico, Invitrogen), as per manufacturer’s instructions. This process uses recombinant 
DNase1 to digest any co-purified DNA in the sample. RNA samples dissolved in H2O 
were thawed prior to treatment.  Following treatment, DNase1 was inactivated and 
samples were stored at -80°C mixed with 2vol of 100% absolute ethanol and 0.1vol of 
3M sodium acetate (ethanol precipitation solution). The samples were stored at -80°C 
until RNA validation.  
2.3.2 cDNA synthesis  
The following protocol for cDNA synthesis was adapted from (Barnett et al., 1998). A 
range of 1ug/ul to 100ng/ul of RNA was added to cDNA synthesis reactions. 3.3µM 
random primers (Invitrogen), 1xPCR buffer (Invitrogen), 3µM MgCl2 (Invitrogen), 
500µM combined deoxynucleotide triphosphates (dNTPs) (Promega, Southampton, UK) 
and 1µM/µl of RNase inhibitor (Promega) was added to the RNA and the mixture was 
incubated at 42°C for 5 minutes. 2 µl of MMLV (Moloney murine leukaemia virus) 
reverse transcriptase (Invitrogen) was then added and cDNA synthesis occurred at 60°C 
for 60 minutes, then 95°C for 5 minutes (Bioer GenePro PCR Machine, Alpha 
Laboratories, Eastleigh, UK). Samples were stored at 4°C. Concentration was determined 
using a spectrophotometer, ND-1000 (Nano-drop, Lab-Tech, East Sussex, UK).  
2.3.3 Primer design and validation 
The Universal Probe Library System - Assay Design Centre (http://www.roch-applied-
science.com) was used in designing the real time PCR primers (Table 2.2). The primers 
were designed to flank an intron to ensure that amplification of genomic DNA (gDNA) 
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was prevented, with annealing temperatures of 60°C. FBN1primers, UQ200 and UQ201, 
were previously designed and validated in (Summers et al., 2009). Primers were 
synthesised by Invitrogen. The primers for human housekeeping gene, GAPDH 
(Hs_GAPDH_2_SG), were purchased from Qiagen (Hilden, Germany).  
Gene Target Primer Primer Sequence 5'-3' 
FBN1 FWD GCTCCCAAACCCTGCAATTT 
 RVS GGCAGTTGTGTTGCTTGGTTG 
FBN2 FWD TGTGCTGAAGGGTTACACGA 
 RVS TCACAGATTCCTGGCTTGGT 
FBN3 FWD ACCTGGACGAATGCACCTC 
 RVS CTGAGCTGACCAGGGTGAAG 
ACTA2 FWD AGCCAAGCACTGTCAGGAAT 
 RVS TTGTCACACACCAAGGCAGT 
BGN FWD CCCAGACCTCAAGCTCCTC 
 RVS TGGGACAGAAGTCGTTGACA 
COL1A1 FWD GCCTGGTCAGAGAGGAGAGA 
 RVS CTCCAGAGGGACCTTGTTTG 
COL1A2 FWD AACACGTCTGGCTAGGAGAAAC 
 RVS TTTCCTTGGAAGTCACTCCTTC 
LTBP1 FWD GCCCTAATGGTGAGTGTTTGA 
 RVS AGATCACAGGGGGATCAGG 
LTBP2 FWD TGCCCTAGTGGAAAAGGCTA 
 RVS TCACACACTCATCCGCATCT 
LTBP3 FWD CACCTGAGGACACAGAGGAAG 
 RVS GAGATCAGCTCGGGGTAGG 
LTBP4 FWD CGTCAGGCCACCTACACAG 
 RVS CAGGGCCTCGAAGTCATCT 
Table 2.2. List of primers used throughout this thesis. Both forward and reverse primers are 
presented in 5’-3’ orientation.  
All primers were initially validated using a standard PCR reaction consisting of the 
following reagents: 10µM each of forward and reverse primer, 10mM combined dNTPs, 
50mM MgCl2 , 10X PCR buffer (Invitrogen), 5U/µl Taq polymerase (Invitrogen), 1µl of 
1 µg/µl cDNA, and DNase / RNase free water to a final volume of 25µl. PCR cycling 
conditions were as follows: 94°C for 10 minutes then 35 cycles of 30 seconds 
denaturation at 94°C, 30 seconds annealing at 60°C and 45 seconds extension at 72°C, 
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followed by one cycle of 10 minutes at 72°C.  Samples were run on 1% agarose 
(Invitrogen) gels in TAE buffer, and primer product was measured against GeneRulerTM 
1KB Plus Ladder (Thermo Scientific, Leicestershire, UK). All amplicons were prepared 
for sequencing by Ailsa Carlisle (The Roslin Institute, The University of Edinburgh) and 
sequenced by Edinburgh Genomics (University of Edinburgh) to ensure that the correct 
sequence was amplified. All primers produced amplicons of the predicted size and all 
gave the correct sequence.  
2.3.4 qPCR 
2.3.4.1 qPCR Conditions 
qPCR was carried out using standard protocols described for SYBR Green 1 Master Mix 
(Roche, West Sussex, UK). 96 well plates were used (Light Cycler 480 multiwell plate 
96, white, Roche). 10µl reactions consisted of 2.5µl of cDNA (1µg/µl) and 7.5µl of 
SYBR Green 1 Master Mix (5µl of SYBR Green 1, 0.5µl each of 10µM forward and 
10µM reverse primers and 1.5µl of H20). The reaction was run on a LightCycler 480 
machine (Roche) using the SYBR Green 1 96-II run template, with the following 
modifications: the annealing time was altered to 15 seconds at 60°C and the single 
extension time to 30 seconds. All qPCR analysis was carried out with the LightCycler480 
software (Roche) provided with the system, using Advanced Quantification which 
involved ∆CT calculations using previously established primer standard curves (Section 
2.3.4.2).  
2.3.4.2 Primer validation and optimisation 
Serial dilutions of cDNA were used to assess the efficiency of quantitative amplification 
for each set of primers. RNA was extracted from cultures of NHDF and MG63 cells after 
seven days of culture and cDNA produced as detailed in Section 2.3.2. The cDNA was 
diluted 1:10, 1:100, 1:1000 and 1:10,000. qPCR was carried out as outlined in Section 
2.3.4.1. Analysis of standard curve output was completed using Absolute Quantification / 
2nd Derivative Maximum, using LightCycler480 software (Roche). The optimal slope for 
the primers was -3.3 though a range of -3.1 to -3.45 was considered acceptable, and with 
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an efficiency of 2 (efficiency = 10 -1/slope). Furthermore, the error of the slope and 
efficiency was acceptable at <0.2.  
 
2.3.5 Microarray analysis 
The RNA in ethanol precipitation solution (Section 2.3.1) was removed from -80°C and 
centrifuged at 12,000g for 20 minutes. The RNA pellet was resuspended in 30-50µl of 
RNase-free water. The total RNA concentration was determined using a Nano-drop 
spectrophotometer (Section 2.3.2). RNA quality was routinely assessed through the 
A260/A280 ratio. For microarray analysis, RNA quality was assessed using Agilent R6K 
Screen Tape System (Agilent, Waldbronn, Germany) as per manufacturer’s instruction. 
Agilent 2200 TapeStation software was used to calculate the RNA integrity number 
(RINE ) values for each RNA sample. RINE values ranged from 1 to 10 and values over 7 
were considered to show appropriate quality RNA for microarray analysis.  
Analysis of RNA using the Affymetrix U219 human microarray platform was performed 
by Edinburgh Genomics, University of Edinburgh. 96 RNA samples with RINE values > 
7 were analysed (Appendix A). The RNA samples were labelled using the 3’ IVT 
Express Kit (P/N 901229, Affymetrix, High Wycombe, UK). The extended protocol can 
be located at http://www.affymetrix.com. The samples were hybridised to the Affymetrix 
Human U219 96 well plate in the GeneTitan ® machine (Affymetrix standard 
hybridisation, wash and stain protocols).  
2.3.5.1 Normalisation of microarray data 
A total of 96 .CEL files (samples listed in Chapter 9, Appendix A) supplied by 
Edinburgh Genomics after microarray analysis were loaded into the Affymetrix 
Expression Console (Affymetrix) and the HG_U219 library file of probe annotations was 
downloaded. Normalization was performed using 3’ Expression Arrays-RMA (Robust 
Multi-Array average) procedure. The quality control metrics were examined. The 
analysis rendered a tabular report that assessed the 96 samples across a range of intensity, 
signal and housekeeping probes. Suitable samples for further analysis are defined as 
“within bounds” and those that fail one or more of the QC checks are classified as 
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“outside bounds”. A total of 95 samples were found to be within bounds, while Sample 
M0080 was outside bounds (Chapter 9, Appendix A). This sample contained human ES 
cells at Day 0. The sample failed at both Housekeeping_AFFX-HSAC07/X00351_5 and 
Housekeeping_AFFX-HUMANGAPDH/M33197_5, though the sample passed for all 
other housekeeping probes. Though M0080 was designated as outside bounds, the sample 
was used in further analysis because it did not appear to be a consistent outlier according 
to further QC, including Principle Component Analysis (PCA) (Figure 2.1), and the 
signal box plot visualisation (Figure 2.2).  
 
Figure 2.1. A three-way PCA plot of RNA samples analysed with the Affymetrix U219 human 
microarray. The figure displays the 96 RNA samples and their PCA clustering based on signal 
intensity expression using three components depicted as PCA1, PCA2 and PCA3. The image was 
rendered from the Affymetrix Expression Console (www.affymetrix.com). See Section 2.3.5.1.  
The PCA-RMA mapping was obtained from the Affymetrix Expression console, and 
showed that 52.2% of the cases (96 RNA samples) fell into the PCA variable confines 
(PCA1, PCA2 and PCA3) (Figure 2.1). The analysis showed similar cell types clustering 
together yielding only two expression outliers (Figure 2.1). The MG63 cell type RNA 
samples clustered together, with sample U219M0095 somewhat distant from the other 
replicates. This sample was treated with mineralizing reagents (Chapter 4), therefore the 
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sample was cultured under different conditions, reflected in the PCA analysis.  In 
addition, samples of early mesenchyme origin ADMSC and hESMP samples clustered 
along with NHDF (neonatal fibroblast cells). This was indicative of the primitive 
differentiation of the fibroblast cell type. There appeared to be a single outlier in this 
cluster, U219M0077, representing the hESMP Day 3 control sample, similar to results 
presented in the signal box plot tool (Figure 2.2). 
The signal box plot tool displays a box plot visualization of the ratio of individual probe 
intensity against the median probe intensity, across the entire microarray (Figure 2.2). 
Sample U219M0077 appeared to have lower signal intensities (similar to U219M0008), 
though the samples passed all the quality control and was defined as  “within bounds” by 
the Affymetrix Expression Console. Therefore, all samples were included in the analysis. 
  
Figure 2.2. Logarithmic expression box plot of microarray intensities across the 96 samples 
(Appendix A). The only obvious variations are within sample M0008 and M0077 (Appendix A), 
though the samples passed the quality control (QC) analysis of the Affymetrix Expression Console 
(http://www.affymetrix.com).  
 
2.3.6 BioLayout Express 3D 
The normalised results were annotated using the Affymetrix annotation file in the 
Affymetrix Expression Console. The annotated normalised results were imported into 
Microsoft Excel and further filtered using Microsoft Excel (filtration parameters 
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described in Chapter 3, 4 and 5, respectively). The normalised results were exported 
from the Expression Console as log2, and all probe intensity values were unlogged prior 
to analysis. The filtered spreadsheets were saved as tab delimited files (.expression) and 
imported into BioLayout Express 3D (Chapter 9, Appendix B)(All files are accessible 
via the compact disc in rear cover of this thesis). The layout was created at p values of 
≥0.80-0.95 (p values for each analysis are provided in Chapters 3, 4 and 5) using Fast 
Multiple Multilevel Method (FMMM) graph layout format. The analysis was clustered at 
a Markov Cluster Algorithm (MCL) inflation value of ≥ 1.7 (see Chapters 3, 4, and 5). 
The clustering analysis shows a network of nodes (vertices) statically connected by edges 
(links). All clustering images presented in this thesis were obtained from the “snapshot” 
function within BioLayout Express 3D and formatted in Microsoft Power Point.  
 
2.3.7 DAVID analysis, evaluation of GO terms  
Database for Annotation, Visualisation and Integrated Discovery (DAVID) analysis 
(Huang da et al., 2009a) was used to explore the functions of genes in the clusters 
identified by BioLayout Express3D. Cluster gene lists were individually placed into the 
upload tool bar of DAVID 6.7 functional annotation tool 
(http://www.david.abcc.ncifcrf.gov/)  (Huang da et al., 2009b, Huang da et al., 2009a).  
OFFICIAL_GENE_SYMBOL was selected from the drop down menu as the identifier 
for the gene list. The background selected was “Homo sapiens” and the minimum cluster 
of genes and terms was set at the default of 2. P-values were calculated using adopted 
Fisher Exact methodology, accounting for enrichment values of genes associated with the 
categorized GO term. The P-value threshold was set to the default of p ≤ 0.1. Terms for 
each cluster were collected and analysed under the following categories: Biological 
Pathways, Cellular Components, and Disease. 
2.4 Protein Analysis  
2.4.1 Determining a fixative for immunocytochemistry (ICC) 
To study fibrillin-1 protein, 4% paraformaldehyde (PFA) was inappropriate for cell 
fixation as it destroys the epitope detected by the anti-fibrillin-1 antibody  (personal 
communication, Professor Kim Summers). A range of alternate fixative agents were 
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tested including, 100% CH3OH (methanol), 100%  (CH3)2CO (acetone) and 95% 
CH3CH2OH (ethanol/EtOH) / 5% CH3COOH (acetic acid). MG63 cells were cultured in 
standard tissue culture 12 well plates (NUNC, Thermo-Scientific, Leicestershire, UK) on 
EtOH treated glass slides (Provided by Dr. Mark Barnett) for 14 days. Cells were fixed 
with l ml of 100% methanol, 100% acetone or 95% EtOH/5% acetic acid, and placed at -
20ºC for 15 minutes. Cells were washed three times with phosphate buffered saline (PBS) 
for 5 minutes. It was determined that acetone was inappropriate as it began to break down 
the culture vessel structure after 10 minutes. Therefore, 95% EtOH  / 5% acetic acid and 
100% methanol were compared for fibrillin-1 fluorescent staining (Figure 2.3)(Section 
2.4.2).  
 
Figure 2.3.  Testing fixative agents for cell cultures. The image depicts fibrillin-1 immunofluorescent 
staining (Section 2.4.2 ) of Day 14 MG63 cells in culture. A) MG63 cells fixed with 100% methanol 
(20x)B) MG63 cells fixed with 95% ETOH / 5% acetic acid (20x). The fibrillin-1 fibres are shown in 
green. The cells were mounted with ProLong Gold (Invitrogen). The cells were visualised using a 
Zeiss confocal microscope. The microscope bars (white) represent 50µm.  
It was determined that 95% ETOH / 5% acetic acid provided better defined fibres in 
imaging results then when compared to 100% methanol (Figure 2.3), and this was 
subsequently used for all fluorescent immunocytochemistry (ICC) experiments.  
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2.4.2 General Staining Method for Fluorescent ICC  
PBS washed live cells, in 8 well chamber slides (Lab-Tek® Chamber Slides™ 8 well 
glass slides, Rochester, NY, USA), were fixed with ice cold 95% ETOH/ 5% acetic acid 
(Section 2.4.1) and placed at -20°C for 10 minutes, washed 3x for 5 minutes with PBS 
and blocked with 1% BSA (bovine serum albumin)(Sigma-Aldrich) in PBS for 1.5 hours 
at room temperature.  Primary antibody (Table 2.3) was added following blocking, and 
the slides were placed at 4°C, overnight in a humidified chamber.  The corresponding 
secondary antibody (Table 2.3) was added following 3x 5 minute PBS washes, and the 
slides were incubated at room temperature for 1 hour.  
Protein  Primary Antibody (Supplier) 
(Dilution Used) 
Secondary Antibody (Supplier) 
(Dilution Used) 
FBN1 (Fibrillin-1) Anti-fibrillin-1 Mouse 
monoclonal IgG1 (Abcam3090) 
(1:100) 
AlexaFluor488® Goat anti- 
mouse IgG (Invitrogen) (1:1,000) 
FBN2 (Fibrillin-2) Anti-fibrillin-2, clone 48 Mouse 
monoclonal (Millipore, 
Temecula, CA,USA) (1:50) 
AlexaFluor488® Goat-anti-
mouse IgG (Invitrogen) (1:1,000) 
ACTA2 (Smooth muscle actin 2) Anti-ACTA2 Rat monoclonal 
IgG (Abcam15684) (1:100) 
Texas Red Goat anti-Rat IgG 
(Invitrogen) (1:1,000) 
BGN (Biglycan) Anti-biglycan rabbit polyclonal 
(Abcam49701) (1:100) 
Alexa Fluor568 Goat anti-Rabbit 
IgG (Invitrogen) (1:1,000) 
COL1 (Collagen type 1) Anti-collagen I goat polyclonal 
(Abcam19811) (1:100) 
Alexa Fluor633 Donkey-anti-
Goat IgG (Invitrogen) (1:1,000) 
Table 2.3. ICC antibodies. All primary antibody dilutions were chosen based on serial antibody 
testing from 1:50-1:500. All secondary antibodies were tested in serial dilutions 1:1000-1:10,000 with 
their respective primary antibody and without a primary antibody to record background readings. 
In addition, antibodies were tested against the following isotype controls: Mouse IgG1 purified 
isotype control (Invitrogen), Rat IgM kappa monoclonal [RTK2118] isotype control (Abcam, 
Cambridge, UK)(Data not shown). Isotype controls were not done for BGN or COL1 antibodies, 
though the secondary antibody testing and additional appropriate controls were negative (Data not 
shown). All antibody testing was performed on MG63 cells, and completed as outlined in Section 
2.4.2.  
The cells were then washed with PBS, and mounted with ProGold + DAPI (Invitrogen). 
Samples were viewed using Zeiss LSM 710 confocal microscope and analysed with ZEN 
software at standard settings (Zeiss, Cambridge, United Kingdom). 
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Chapter 3. The fibrillin gene family in early and later 
differentiation. 
3.1 Introduction 
The three fibrillin proteins are very similar in structure (Chapter 1, Figure 1.4), but they 
are present at different stages in development (reviewed by (Davis and Summers, 2012)). 
The study in this chapter investigated the expression of mRNA from each of the three 
genes during two developmental processes, the early differentiation of embryonic stem 
cells towards the mesoderm lineage and the differentiation of mesenchymal stem cells to 
adipocytes.  
 
3.1.1 Embryonic stem cell differentiation  
Human embryonic stem cells (hESC) are pluripotent cells that can differentiate into all 
the cell types in the body. hESCs can be cultured to produce embryoid bodies, which then 
further differentiate into ectoderm, mesoderm or endoderm specific lineages, which can 
produce the cell types present in the adult human (Chapter 1, Section 1.1). The study of 
hESCs has allowed for the examination of both gene expression and protein synthesis 
during human embryonic development and differentiation.  
This chapter will explore the role of the fibrillin gene family through this very early stage 
of development and differentiation. The first analysis was performed on mRNA from 
hESC cell line H1. H1 stem cells were originally derived in 1998 from a cleavage staged 
human embryo donated from an in vitro fertilisation (IVF) clinic (Thomson et al., 1998). 
Thomson et al. (1998) allowed the embryo to develop to blastocyst stage and isolated the 
inner cell mass to create the H1 line. H1 hESCs have a stable XY karyotype, high levels 
of telomerase activity demonstrating a highly proliferative life span and positive staining 
for several markers of undifferentiated human ESC cells, for example SSEA-3/4 (stage 
specific embryonic antigens -3 and -4), TRA-1-60, TRA-1-80 (human pluripotent stem 
cell antigens) and ALPL (alkaline phosphatase) (Thomson et al., 1998). A second hESC 
line, RH1, was used for some analyses. This line originated from a Day 6 post-
insemination human blastocyst, cultured in an animal-product free culture system and ES 
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cell validation is described in Fletcher et al., (2006). These cells were used to determine 
the role of members of the fibrillin gene family in early development.  
  
3.1.2 From mesoderm to mesenchyme  
The three embryonic germ layers that develop during embryogenesis are the ectoderm, 
endoderm and mesoderm (Figure 3.1).  Mesenchymal stem cells are derived from the 
mesoderm layer through a relatively unknown mechanism, though specific characteristics 
are beginning to be understood. The process begins with pluripotent cells that have 
epithelial characteristics within a blastocyst (Lamouille et al., 2014). These epithelial-like 
cells have upregulated laminin and cytokeratin, form tight adherens junctions through E-
cadherin (OMIM: 192090)(Schafer et al., 2014, von Gise and Pu, 2012), and have a well-
structured basement membrane (Figure 3.1A). 
 
Figure 3.1. The epithelial- mesenchyme transition (EMT). The process is described in the Section 
3.1.2. Adapted from (von Gise and Pu, 2012). 
The EMT is described as the loss of epithelial traits accompanied by the gaining of 
mesenchymal traits such as upregulation of vimentin and myosin, and cellular motility 
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(Hay, 2005). During EMT the basement membrane is disassembled, a downregulation of 
the adherens junctions occurs, there is a loss of cellular polarity and cells become 
migratory (von Gise and Pu, 2012) (Figure 3.1B). Evseenko et al., (2010) performed a 
large-scale genetic study of the early stages of mesoderm differentiation, demonstrating 
an upregulation of several key early genes and transcription factors. For example, they 
confirmed the importance of upregulation of FGF2 (human fibroblast growth factor 2) 
(Ciruna and Rossant, 2001, Tsutsumi et al., 2001) and additional genes, SNAI1 (snail 
family zinc finger1)(OMIM: 604238), SNAI2 (snail family zinc finger 2)(OMIM: 
602150), TWIST1 (twist family BHLH transcription factor 1)(Martin and Cano, 2010), 
EOMES (eomesodermin)(OMIM: 604615)(Russ et al., 2000), MESP1 (mesoderm 
posterior 1) (OMIM: 608689)(Saga et al., 1996), and MESP2 (mesoderm posterior 
2)(OMIM: 605195)(Evseenko et al., 2010). Further studies have also shown that during 
the EMT, levels of FSP1 (fibroblast specific protein 1) (Strutz et al., 1995) and FN1 
(Chapter 1, Section 1.2.4)(Park and Schwarzbauer, 2013) are increased, contributing to 
the MSC characteristics of the cells (Figure 3.1C). Once the MSC population is formed, 
differentiation can continue as described in Chapter 1, Section 1.1, and specifically for 
adipocyte formation below.  
 
3.1.3 Adipose differentiation 
As previously discussed (Chapter 1, Section 1.1), mesenchymal stem cells can be 
differentiated into multiple connective tissue lineages including adipocytes (Chapter 1, 
Section 1.1.2). Adipocytes are cells that store fat in the adipose tissue, both brown (BAT) 
and white (WAT). BAT is mainly associated with early development (Gilsanz et al., 
2012), while WAT is maintained well into and throughout adulthood (Peirce et al., 2014). 
Adipose tissue develops through a cascade of events leading to production of 
preadipocytes, which then terminally differentiate to mature adipocytes (Chapter 1, 
Figure 1.1). The major transcription factors responsible for turning on the cascade of 
adipose specific genes include master adipose regulator gene, PPARG (Tontonoz et al., 
1994) and CEBP Chapter 1, Section 1.1.2)(Miller et al., 1996). As reviewed by 
Mariman and Wang (2010), there are over 65 proteins shown to be components of 
adipocyte ECM, including fibrillin-1, fibronectin, collagen type I alpha 2, osteonectin and 
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transforming growth factor binding protein 1.  These proteins are involved in not only the 
maintenance of the ECM in adult adipose tissue, but also in early and late differentiation 
(Mariman and Wang et al., 2010). It is currently understood that there are two phases of 
ECM reorganisation during adipogenesis, (1) during preadipocyte formation where the 
fibrillar (i.e. collagen VI) matrix is highly expressed and important in providing a 
scaffold for the lipid monolayer leading to, (2) ECM reorganisation to increase storage 
space facilitating adult adipose energy-storing properties (Chapter 1, Section 
1.1.2)(Mariman and Wang, 2010, Catalan et al., 2012). In addition, the ECM in adult 
adipose tissue is under constant overturn to accommodate storage space (Mariman et al., 
2010). Though fibrillin-1 is secreted by adult rat adipocytes (Lim et al., 2008), the 
function of fibrillin-1 in adipogenesis has yet to be understood. There has been increasing 
interest in the development and function of adipose tissue, as the incidence of obesity in 
the population increases (Wang and Beydoun, 2007). Understanding the role of fibrillins 
in the formation of adipocytes has the potential to contribute more widely to 
understanding and treatment of obesity.  
 
3.1.4 Adipose depletion in MFS and CCA 
Though interest in adipose tissue is mostly associated with the obesity epidemic, adipose 
tissue depletion is a common phenotype of Marfan syndrome and CCA patients 
(Summers et al., 2005, Kumta et al., 1976). In addition, lipodystrophy, a disorder causing 
severe adipose depletion, has been recently identified in patients with mutations in the 
carboxyl terminus of fibrillin-1 (Takenouchi et al., 2013, Horn and Robinson, 2011, 
Goldblatt et al., 2011, Graul-Neumann et al., 2010). These four patients shared similar 
phenotypes, such as progeroid (prematurely aged) appearance, arachnodactyly, 
retrognathia (abnormal maxilla or mandible) and eye proptosis (bulging eyes). They 
varied in the extent of phenotypic characteristics of Marfan syndrome, including severe 
myopia (severe nearsightedness), cardiovascular complications and ectopia lentis 
(dislocating lens) (Takenouchi et al., 2013). The presence of lipodystrophy in patients 
with similar FBN1 exon 64 mutations suggests an important role of fibrillin-1 in the 
development and differentiation of adipose tissue. This chapter studies the role of the 
fibrillin gene family in primary adipose derived mesenchymal stem cells (ADMSC) and a 
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human embryonic stem cell derived mesenchymal stem cell line (hESMP) differentiating 
to the adipose lineage.  
The ADMSC cells were extracted from a female liposuction patient in accordance with 
the ethical clearance outlined in (West et al., 2014), and were supplied by Dr Paul De 
Sousa (Chapter 2, Section 2.1.1.7). In brief, the extracted adipose tissue was digested 
and centrifuged to pellet the stromal vascular fraction (SVF). The mesenchyme derived 
cells were selected from the SVF based on adherence to tissue culture vessels and flow 
cytometry for mesenchyme specific markers (West et al., 2014) such as CD105, CD73 
and CD90 (Lin, 2012). Furthermore, to be classified as mesenchyme, the cells were 
shown to be capable of differentiating to osteogenic, adipogenic and chondrogenic 
lineages (Lin, 2012). The hESMP mesenchymal stem cells were commercially produced 
from hESC cell lines by CellartisAB (Cellectis Bioresearch) (Chapter 2, Section 
2.1.1.8). The hESMP cells have upregulated expression of CD166, CD105, CD13 and 
CD10 (www.cellectis-bioresearch.com), common mesenchyme specific markers (Halfon 
et al., 2010, Rahman et al., 2013, Mariotti et al., 2008).  
 
3.1.5 Aims of the chapter  
The overall aim of this study was to understand the role of the fibrillins in early 
development and mesenchymal differentiation. Protein and mRNA levels were examined 
in ADMSC and hESMP cells differentiating to the adipose lineage and  undifferentiated 
RH1 hESCs and H1 hESCs differentiating to mesoderm. Genes that co-express with 
fibrillin genes in these models of differentiation and development were used to confirm 
the likely function of the fibrillins through association.  The study will show that each 
fibrillin has a distinct pattern of expression and distinct co-expression partners. 
3.2 Materials and Methods 
3.2.1 Human H1 embryonic stem cell samples  
Formation of embryoid bodies from the H1 stem cells (WiCell Inc. Madison, Wisconsin, 
USA) was carried out in the laboratory of Professor Lesley Forrester, Scottish Centre for 
Regenerative Medicine, University of Edinburgh, as shown in Figure 3.2. Embryoid 
body formation was initiated through the hanging drop method (Huang et al., 2013). At 
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day 3, the embryoid bodies were disaggregated and cultured with hematopoietic 
cytokines to progress to the mesoderm lineage. RNA from Day 0, Day 3 and Day 5 of 
culture was kindly supplied by Professor Forrester.  
 
Figure 3.2. H1 differentiation protocol. Diagram supplied by Professor L. Forester, Scottish Centre 
for Regenerative Medicine, University of Edinburgh.  
 Dr. Paul DeSousa (Scottish Centre for Regenerative Medicine, University of Edinburgh) 
provided a cell pellet from Day 2 and Day 5 cultures of human embryonic stem cell line, 
RH1 (Fletcher et al., 2006). The cells had been grown in media designed to suppress 
differentiation (Personal communication, Dr. Paul DeSousa).  Day 2 RH1 RNA was 
extracted using the RNABee method described in Chapter 2, Section 2.3.1. Day 5 cell 
culture samples (in 8 well chamber slides (NUNC)) were fixed by Cairnan Duffy 
(Scottish Centre for Regenerative Medicine, The University of Edinburgh) with 95% 
ethanol and 5% acetic acid (ice cold) for 20 minutes and washed three times with PBS. 
The samples were stored at 4˚C in PBS until used for ICC studies.  
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3.2.2 Adipose differentiation  
 StemPro® Adipogenesis Differentiation Medium (Gibco) consisted of prewarmed 
(37ºC) StemPro® Adipogenesis Differentiation Basal Medium (90mL), thawed 
StemPro® Adipogenesis Supplement  (10mL) and 50µl of 1xGlutaMAX. This adipose 
differentiation medium will be referred to as adipose media throughout the remainder of 
the thesis. The adipose media was filtered through a 100mL 75mm filter unit (Thermo 
Scientific, Leicestershire, UK). ADMSC and hESMP cells were cultured, separately, as 
follows: 20,000 cells/ well were placed into 8 well chamber slides (NUNC), and 250,000 
cells were placed in T25 cell culture flasks (NUNC).  Both the 8 well chamber slides and 
T25 cell culture vessels had been coated in 0.1% Gelatin. The cells were grown in 
standard ADMSC/hESMP media (Chapter 2, Section 2.2, Table 2.1) for 24 hours at 
37ºC in 5% CO2 to achieve 75-80% confluency. 100µl (NUNC 8 well chamber slides) 
and 2mL (T25 flasks) of adipose media was added to the differentiating ADMSC’s and 
hESMP cultures, and the same volume of normal ADMSC/hESMP media was added to 
the undifferentiating samples. Samples for ICC fluorescent staining (8 well chamber 
slides) were fixed with 95% Ethanol and 5% acetic acid (20 minutes at -20ºC) at the 
following time points (days after induction of adipogenesis) Day 0, Day 1, Day 3, Day 7 
and Day 14. Cells in T25 flasks were lifted at Day 1, Day 2 and Day 18 with 1mL of 
RNABee for RNA extraction (Chapter 2, Section 2.3.1).  
 
3.2.3 Oil Red O staining  
Oil Red O stock solution was prepared with 0.7g Oil Red O (Sigma-Aldrich) and 200ml 
of isopropanol, stirred over night and filtered through a 0.2µm filter unit. Solution was 
stored at room temperature. Oil Red O working solution was prepared with 6 parts Oil 
Red O stock solution and 4 parts dH2O, mixed and incubated at room temperature for 20 
minutes, then filtered through a 0.2µm Millex syringe filter unit (Millipore, Cork, 
Ireland).  
ADMSC (Passage 4-6) and hESMP (passage 2-6) cells were plated at 50,000 cells per 
well in a 1% gelatin coated 6 well plate and cultured in DMEM (Chapter 2, Table 2.1) at 
37ºC in 5% CO2 for 24 hours to achieve 75-80% confluency. The media was replaced 
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with 1ml of adipose media or normal ADMSC/hESMP culture media (Chapter 2, Table 
2.1) for the undifferentiating samples and the media was changed every 48 hours. 
Samples were fixed at Day 1, Day 3, Day 6, Day 8 and Day 18 post induction of 
adipogenesis for both differentiating and nondifferentiating ADMSC and hESMP cell 
types. Cells were fixed with 10% neutral buffered formalin solution (Sigma-Aldrich for 5 
minutes, then replaced with fresh 10% formalin and incubated at room temperature for 1 
hour. The 10% formalin fixative was removed and the wells were briefly washed with 
60% isopropanol, and allowed to air dry completely at room temperature. 200µl Oil Red 
O working solution was added to each well for 10 minutes at room temperature, then 
removed and wells were immediately washed with dH2O four times for 10 minutes. 
Wells were imaged using Axio Lab.A1 microscope (Zeiss). 
 
3.2.4 Analysis of samples 
All ICC techniques were carried out as described in Section 2.4.2 of Chapter 2. Initial 
mRNA expression levels were quantified using qPCR techniques described in Section 
2.3.1 of Chapter 2.  
Gene expression levels in RNA samples were determined using the U219 human 
microarray platform (as described in Chapter 2, Section 2.3.5) for the following 
samples: ADMSC at Day 1, Day 2 and Day18 for both adipose differentiating and control 
samples, hESMP at Day 1, Day 2 and Day 18 for both differentiating and control 
samples, H1 samples at Day 0, Day 3 and Day 5 for CD34+ differentiation and RNA 
from Day 2 RH1 cells (Chapter 9, Appendix B). The results were normalised as 
described in Chapter 2, Section 2.3.5.1. Probes were removed from the data set that did 
not show a difference of at least two fold across samples, removing 26.6% (13,171) of the 
low dynamic range probes. The remaining 36,214 probeset intensity results were loaded 
into BioLayout Express 3D.  The clustering analysis was run at r ≥ 0.95 at an MCL 
inflation value of 1.7, producing 1,147 clusters. 
Cluster gene lists for large Cluster003, Cluster006 and Cluster008 were individually 
placed into the upload tool bar of DAVID 6.7 functional annotation tool 
(www.david.abcc.ncifcrf.gov/) (Chapter 2, Section 2.3.7). 
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3.3 Results  
3.3.1 Fibrillin gene family expression in the H1 timecourse  
Initial qPCR analysis performed on differentiating H1 cells at Day 0, Day 3 and Day 5 
time points demonstrated distinctive fibrillin gene expression (Figure 3.3). FBN1 
expression was highest at Day 5, FBN2 showed increased expression at Day 3 which 
remained steady at Day 5 (Figure 3.3). Though FBN3 mRNA showed the lowest overall 
expression (maximum about half that of FBN2 and one quarter that of FBN1), the highest 
expression was found at Day 0, with steadily declining values and lowest expression at 
Day 5 (Figure 3.3).  
 
 
Figure 3.3. qPCR results for the H1 timecourse. Expression of FBN1, FBN2 and FBN3 at Day 0 
(H1_D0), Day 3 (H1_D3) and Day 5 (H1_D5). Expression levels were normalised using the 
housekeeping gene GAPDH and mean standard error is displayed (technical replicates=3). Y-axis: 
target/housekeeping gene ratio.  The x-axis depicts the samples.  
qPCR results for FBN1, FBN2 and FBN3 mRNA in undifferentiated RH1 hESC at Day 2 
of culture showed variation among the three genes. FBN2 had the highest expression, 
followed by FBN1 and FBN3 (Figure 3.4).  Fibrillin-1 and fibrillin-2 protein staining 
patterns were different at Day 5 of RH1 cell culture (Figure 3.4). There were visibly high 
levels of fibrillin-2 expressed intracellularly, while only very low levels of fibrillin-1 
fibres could be detected (Figure 3.4).  
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Figure 3.4. Fibrillin gene and protein expression in undifferentiated human RH1 embryonic stem 
cells. (A) Expression patterns of FBN1, FBN2 and FBN3 mRNA at Day 2 of culture. Expression 
levels were normalised using the housekeeping gene GAPDH and mean standard error is displayed 
(technical replicates=3). Y axis = target/housekeeping gene ratio. (B) ICC of fibrillin-1 and fibrillin -2 
in undifferentiated RH1 cells at Day 5 of culture. The green fluorescence shows the distribution of 
fibrillin-1 (left panel) and fibrillin-2 (right panel). (C) Fibrillin-1 and fibrillin-2 isotype controls 
(Chapter 2, Section 2.4.2) The nuclei (blue) were counterstained with DAPI. Magnification 20X. The 
scale bars (white) show 50µm, n=2. 
3.3.2 Validation of adipogenesis in the hESMP and ADMSC 
adipose differentiation time courses 
Oil Red O staining was used to validate adipose differentiation (Section 3.2.3). The 
undifferentiated ADMSCs showed slight red staining at day 8 and day 18 (Figure 3.5).  
The ADMSC differentiated cells developed stainable lipid droplets by day 3, which was 
maintained with increased number and size of droplets by Day 18 (Figure 3.5). Cell line 
hESMP treated with the adipose medium showed different results (Figure 3.6). The 
nondifferentiated cells showed no Oil Red O staining or lipid droplet formation, while the 
hESMP cells being driven towards the adipose lineage showed a small amount of lipid 
accumulation (Figure 3.6). The lipid droplet formation was comparable to that of 
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ADMSC undifferentiated samples at Day 3 (Figure 3.5 and Figure 3.6). Hence, over this 
time period, very little adipogenesis had occurred in this cell line. 
 
Figure 3.5. Lipid droplet formation in the ADMSC timecourse.  ADMSC control cells (left panel) and 
ADMSC cells differentiating to adipose (right panel) stained with Oil Red O at Day 1, Day 3, Day 6, 
Day 8 and Day 18. The red color shows Oil Red O binding with lipid droplets forming within the 
cells. The images were taken using a Zeiss AX10 microscope at magnification of 20x. The scale bars 
show 50µm, n=2. 
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Figure 3.6. Lipid droplet formation in the hESMP timecourse.  hESMP control cells (left panel) and 
hESMP cells differentiating to adipose (right panel) stained with Oil Red O staining at Day 1, Day 3, 
Day 6, Day 8 and Day 18. The red color shows Oil Red O binding with lipid droplets forming within 
the cells. The images were taken using a Zeiss AX10 microscope at magnification of 20x. The scale 
bars show 50µm, n=2. 
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3.3.3 Identifying Fibrillin-1 protein expression patterns during 
adipose differentiation.  
The presence of fibrillin-1 proteins was assessed across the adipose differentiation time 
course using ICC (Chapter 2, Section 2.4.2).  
Fibrillin-1 fluorescent ICC of ADMSC and hESMP was performed at the following times 
after induction of adipogenesis: Day 0, Day 1, Day 3, Day 7 and Day 14 (Figure 3.7). 
ADMSC cells undergoing adipose differentiation showed an extensive network of 
fibrillin-1 fibrils at Day 1, decreasing at Day 3, with very little fibrillin-1 staining after 
the completion of differentiation (Figure 3.7). These results differed from the 
undifferentiated cells where staining of the fibrillin-1 matrix increased over the time 
course. The hESMP differentiating culture demonstrated a vast fibrillin-1 matrix at Day 1 
that was maintained through to Day 14 (Figure 3.7). Quality images of hESMP controls 
for Day 3, 7 and 14 were unable to be processed. Further replicates would be required to 
determine fibrillin-1 fibre formation in hESMP cells. The lack of lipid droplet formation 
in hESMP and the resemblance of fibrillin-1 protein staining to that of the untreated 
ADSMC suggest that the hESMP cells were not being pushed towards the adipose 
lineage. The cells were further assessed using microarray analysis to better determine the 
lineage progression of the hESMP cells.  
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Figure 3.7. Fibrillin-1 immunofluorescence staining of the ADMSC and hESMP undergoing adipose 
differentiation. ADMSC control shows untreated ADMSC cells across the timecourse, ADMSC and 
hESMP differentiation shows ADMSC and hESMP cells progressing to the adipose lineage.  hESMP 
controls for Day 3, 7 and 14 are unavailable (n=1). Fibrillin-1 is shown by green fluorescence 
(Chapter 2, Section 2.4.2). The nuclei are shown in blue (ProLong gold + DAPI (Invitrogen)). Images 
show results representative of n=3 replications. Magnification at 40x and the scale bars represent 
20µm. 
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3.4 Gene clustering using BioLayout Express 3D  
 
Figure 3.8. Network visualization and clustering of the transcriptomes of the H1, ADMSC and 
hESMP cells undergoing differentiation. The image depicts the network diagram produced by 
BioLayout Express 3D using data from the Affymetrix U219 gene expression microarray platform. 
Spheres (nodes) represent individual probesets and the lines between them (edges) show correlations 
in expression pattern of r ≥ 0.95. The nodes were clustered using an MCL inflation value 1.7 
(Chapter 2, Section 2.3.6). The background of the image displays the whole network and clusters 
discussed in the text are highlighted. Cluster357 and Cluster 039 contained FBN1 probes, Cluster003 
had FBN3 probes, Cluster008 had FBN2 probes and Cluster006 was specific to adipose lineage. 
Probeset intensity values obtained using the human U219 microarray platform were used 
to determine clusters of genes that were co-expressed across the early and adipose 
differentiation timecourses using the tool BioLayout Express 3D , which groups genes 
based on similarity of expression pattern across a sample set. This showed a large 
network of clusters containing a total of 21,098 nodes and 673,702 edges (Figure 3.8). 
Visual inspection of the clusters revealed probes for fibrillin genes in 5 clusters (Figure 
3.8). Cluster 357 contained three probes for fibrillin-1 (FBN1: 11720507, FBN1: 
11720509_a_at and FBN1: 11758093_s_at) and Cluster 039 contained a single fibrillin-1 
probe (FBN1: 11754368_a_at) (Table 3.1).  
Chapter 3. The fibrillin gene family in early and late differentiation 
 67 
 
Gene  Probset ID Chromosome position Region covered Cluster 
FBN1 11720509_a_at 15:48700505-48938046 Whole transcript  (237,541bps) 357 
 1175368_a_at 15:48702269-48758055 Exon 39 through the 3’UTR region 
(55,786bps) 
039 
 11720507_at 15:48700505-48938046 Whole transcript  (237,541bps) 357 
 1758093_s_at 5:48700504-48700908 Downstream of exon 65 within the 
3’UTR (404bps) 
357 
Table 3.1. Fibrillin-1 probe identification on Human U219 Affymetrix microarray.  
Cluster 008 contained a single probe for fibrillin-2 (FBN2: 11763384_at, NM_01999) 
and Cluster003 had the probe for fibrillin-3 (FBN3: 11732438_a_at, NM_032447). 
Clusters008 and 003 were specific to embryonic expression and were located close to 
each other in the network graph, while the clusters containing FBN1 probesets showed 
expression in the mesenchymal stem cells (ADMSC / hESMP) as well as in the 
differentiated state for both mesenchymal cells and embryonic stem cells. In addition, 
Cluster006 consisted of multiple adipocyte markers expressed at high level towards the 
end of the ADSMC differentiation time course. The content of the clusters is described in 
detail in the following sections.  
 
3.4.1 FBN1 is co-expressed with ECM related genes in both Cluster039 
and Cluster357 
FBN1 probesets were found in two gene clusters (Cluster039 and Cluster357). The mean 
expression patterns of all genes in the clusters are illustrated in Figure 3.9. In the early 
development time course, FBN1 showed highest levels of expression at Day 5 of hESC 
development/differentiation (Figure 3.9). The only discrepancy between the two clusters 
in the hESC samples was the level of expression in RH1 cells (undifferentiated) (Figure 
3.9). The earlier qPCR analysis validated the microarray information, showing the same 
expression patterns (Figure 3.3). The majority of the genes associated with the FBN1 
clusters were of mesenchyme origin and active in the extracellular matrix, and highly 
expressed in ADMSC and hESMP cell types. 
Cluster 039 contained a total of 34 nodes, corresponding to 11 unique genes, including 
one probeset for FBN1 (FBN1: 11754368_a_at), joined by 163 edges. The genes in the 
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cluster mainly encoded components of the extracellular matrix and extracellular 
interacting proteins (Table 3.2). The mean expression of the genes remained unchanged 
regardless of differentiation stage (Figure 3.9).  Cluster 357 consisted of 8 nodes, 
representing a total of 5 genes (Table 3.2), and 12 edges. The mean and individual probe 
expression patterns of all 8 nodes remained consistent in Cluster357 (Figure 3.9). There 
was a slight decrease in expression at Day 18 of adipose differentiation that was not 
found at Day 18 of the undifferentiated sample.  
Cluster039   
Gene symbol Gene name OMIM 
CAV1 Caveolin 1 601047 
COL1A2 Collagen type 1 alpha 2 120160 
FN1 Fibronectin 1 135600 
KCTD10 Potassium channel tetramerization domain containing 
protein 10 
613421 
MKRN2 Makorin 2 608426 
MXRA7 Matrix remodelling associated 7 Veiga-Castelli et al., 2010 
RSU1 Ras suppressor protein 1 179555 
SPARC Osteonectin  182120 
TGFB1 Transforming growth factor beta 1 190180 
TRAM2 Translocation- associated membrane protein-2 608485 
Cluster357   
ADAM19 ADAM metallopeptidase domain 19 603640 
APPBP2 Amyloid beta precursor binding protein 2 605324 
CCDC176 Coiled-coil domain containing 176 Ota et al., 2004 
GTF2H5 General transcription factor IIH polypeptide 5 608780 
Table 3.2. Genes that co-expressed with FBN1 in Cluster039 and Cluster357.  
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Figure 3.9. Plots of average expression profiles of genes in Cluster039 and Cluster357 following 
analysis using BioLayout Express 3D (See Figure 3.8). Y axis shows the normalised intensity value. X 
axis shows the samples from which the RNA was extracted.  + Diff indicates cells undergoing adipose 
differentiation. Control indicates untreated cells. The last four samples on the histogram represent 
the expression patterns of differentiating H1 cells and the single RH1 cell sample at Day 2 of culture.  
(A) Cluster039 containing a total of 11 genes, including FBN1. (B) Cluster357 containing a total of 5 
genes, including FBN1.  
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To further validate the expression patterns of FBN1 in the ADMSC differentiating 
samples, qPCR analysis of FBN1 mRNA expression across Day 1, Day 2 and Day 18 of 
adipose differentiated and undifferentiated samples was performed (Figure 3.10). The 
FBN1 mRNA levels were not assessed for the hESMP timecourse because they did not 
differentiate to the adipose lineage (See Section 3.3.2). The qPCR results indicated a 
slight decrease in expression of FBN1 during differentiation at Day 18 with an 
upregulation of expression at Day 18 in the undifferentiated culture (Figure 3.10A). 
These results were somewhat consistent with the FBN1 mRNA probe intensity 
expression profiles (Figure 3.10B) and the protein staining (Figure 3.7). The mRNA 
levels differed between the qPCR and microarray analysis mainly at Day 18 in the 
undifferentiated samples (Figure 3.10). 
 
Figure 3.10. mRNA expression levels of FBN1 during ADMSC differentiation to the adipose lineage. 
Expression patterns of FBN1 at Day 1, Day 2 and Day 18 during differentiation (+Diff) and the 
control samples. (A) qPCR validation analysis. Expression levels were normalised using the 
housekeeping gene GAPDH and mean standard error is displayed (technical replicates=3). Y axis = 
target/housekeeping gene ratio. (B) Average of mRNA expression of the four FBN1 probesets 
microarray data for ADMSC both differentiating and nondifferentiating to adipose lineage. The Y-
axis represents the expression intensity detected by the U219 microarray analysis. The error bars 
represent standard errors determined in Microsoft excel across the average expression values.  
 
3.4.2 FBN2 is co-expressed with developmental genes in Cluster008 
Cluster008 had a total of 232 nodes, representing 181 genes, and 4846 edges, with the 
highest overall expression of the genes in Day 3 of embryoid body 
development/differentiation (Figure 3.11). A single fibrillin-2 probe (FBN2: 
11763384_a_at) was co-expressed with the cluster. The probe was designed to target 
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Chr5.127663780-127702115, which incorporates exon 23 through to exon 40 of 
transcript NM_001999. The high expression at Day 3 in H1 samples was consistent with 
the qPCR results (Figure 3.3), while there was very low and stable expression detected 
by FBN2: 11763384_a_at, across both hESMP and ADMSC adipose differentiation 
timecourses (Figure 3.11).  
 
Figure 3.11. Plots of average expression profiles of genes in Cluster008 following analysis using 
BioLayout Express 3D (See Figure 3.8). Y axis shows the normalised intensity value. X axis shows the 
samples from which the RNA was extracted.  + Diff indicates cells undergoing adipose 
differentiation. Control indicates untreated cells. The last four samples on the histogram represent 
the expression patterns of differentiating H1 cells and the single RH1 cell sample at Day 2 of culture 
(shown in bold).  Cluster008 contained 181 genes.  
DAVID GO terms analysis of the 181 genes within this fibrillin-2 early development 
cluster revealed the highest biological pathway GO terms associated with developmental 
process, multicellular organism development and anatomical structure development 
(Table 3.3). There were also multiple terms relating to embryogenesis as well as limb 
development (Table 3.3). 




Table 3.3. A selection of GO terms associated with genes in Cluster008.  
FBN2 was co-expressed with many genes associated with early embryogenesis and 
mesoderm formation (Table 3.4). 
Cluster008   
Gene Ontology  Number of Genes P-value  
Biological Pathway (n=85)   
Developmental process 47 3.00E-3 
Multicellular organismal development 46 7.40E-4 
Anatomical structure development 41 1.40E-3 
Embryonic Development 16 5.50E-4 
Regulation of multicellular organismal process 15 8.50E-2 
Embryonic morphogenesis  11 1.00E-3 
Embryonic appendage morphogenesis 3 2.10E-1 
Embryonic limb morphogenesis 3 2.10E-1 
Appendage morphogenesis 3 2.10E-1 
Limb morphogenesis 3 2.10E-1 
Appendage development 3 2.10E-1 
Limb development 3 2.10E-1 
Cellular Compartment (n=7)   
Nucleus 58 5.20E-2 
Microtubule cytoskeleton  10 7.10E-2 
Occluding junction  4 3.10E-2 
Tight junction 4 3.10E-2 
Apical junction complex 2.2  6.50E-2 
Disease (n=1)   
Psychiatric   12  5.10E-2 
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Cluster008   
Gene symbol Gene name  OMIM 
EOMES Eomesodermin 604615 
MESP1 Mesoderm posterior 1 608689  
MESP2 Mesoderm posterior 2 605195 
T T, brachyury homolog 601397 
WNT8A Wingless-type MMTV integration site family member 8A 606360  
NKD1 Naked cuticle drosophila homolog 1 607851 
CFC1 Cryptic protein 1 605194 
Table 3.4. Representative genes that co-expressed with FBN2 in Cluster008. 
 Key early development genes co-expressing with FBN2 included EOMES, an essential 
gene in mesoderm formation, MESP1 and MESP2, important early developmental 
markers in cardiac development (Kitajima et al., 2000), involved in early initiation of 
embryo segmentation (Saga et al., 1997) and mesoderm development gene and 
mesoderm marker, T (brachyury) (Table 3.4). Furthermore, the cluster contained some 
genes involved in Wnt signalling, an important pathway in limb development. These 
genes included WNT8A, NKD1 and CFC1 (Table 3.4). 
 
3.4.3 FBN3 is co-expressed with early embryonic development, 
neurological and ECM related genes in Cluster003.  
A single Affymetrix probe for FBN3 was found in Cluster003 of the original clustering 
data (Figure 3.9).  FBN3: 11732438_a_at detected the full NM_032447 transcript of 
FBN3 from chr.19: 8130287- 8214730 though did not include the 5’ or 3’ UTR regions. 
Cluster003 consisted of 1326 nodes totalling 900 genes and 133,058 edges. 
 Consistent with initial qPCR results, FBN3 and other genes in Cluster003 showed 
elevated expression levels at Day 0 with a steady decrease to Day 5 (Figure 3.3 and 
Figure 3.4 and Figure 3.12). RH1 untreated samples at Day 2 showed lower expression 
than H1 Day 1 and higher expression when compared to H1 Day 5 (Figure 3.12). There 
was very little expression of FBN3 in the ADMSC or hESMP samples, regardless of their 
differentiated state.  
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Figure 3.12 Plots of average expression profiles of genes in Cluster003 following analysis using 
BioLayout Express 3D (See Figure 3.8). Y axis shows the normalised intensity value. X axis shows the 
samples from which the RNA was extracted.  + Diff indicates cells undergoing adipose 
differentiation. Control indicates untreated cells. The last four samples on the histogram represent 
the expression patterns of differentiating H1 cells and the single RH1 cell sample at Day 2 of culture.  
Cluster003 contained a total of 900 genes.  
The 900 genes were subjected to DAVID GO term analysis, revealing multiple neuronal 
specific and embryonic biological pathway GO terms (Table 3.5). Though general 
cellular component terms such as nucleus and plasma membrane were associated with the 
highest number of genes, three extracellular matrix specific terms (extracellular region 
part, extracellular matrix and proteinaceous extracellular matrix) were also retrieved 
(Table 3.5). Two neurological diseases were associated with the cluster: neural tube 
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Gene Ontology (Fbn3) Number of Genes P-value  
Biological Pathway (n=140)   
Nervous system Development 75 6.30E-4 
Embryonic development 37 3.10E-2 
Neuron Differentiation 33 7.20E-3 
Neuron Development  27 8.10E-3 
Neuron Projection Development  23 3.90E-3 
Neural Crest cell differentiation 5 6.40E-2 
Primary neural tube formation 5 6.40E-2 
Neural crest development  5 6.40E-2 
Cellular Components (n=23)   
Nucleus  259 1.10E-2 
Plasma Membrane  193 3.20E-2 
Plasma Membrane part 134 2.30E-4 
Extracellular region part  56 4.00E-2 
Cell junction 53 5.60E-8 
Synapse  37 5.10E-6 
Extracellular matrix 26 1.40E-2 
Proteinaceous extracellular matrix 25 1.10E-2 
Disease (n=4)   
Neural tube defect 5 9.20E-2 
Dementia 4 6.00E-2 
Cervical artery dissection, spontaneous 3 3.50E-2 
Angina 3 7.90E-2 
Table 3.5. A selection of GO terms associated with genes in Cluster003.  
FBN3 co-expressed with many genes (r≥0.95) that were either ECM specific, active in 
early embryogenesis, markers of pluripotency or neuronal genes. This was further 
validated in the GO term ontology (Table 3.5). These genes are presented in Table 3.6. 
The high correlation of the early developmental genes, especially pluripotency marker 
NANOG, suggests the possible importance for FBN3 expression in early development. 
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Cluster003   
Gene Symbol Gene Name  OMIM 
ECM related   
ADAMTS16 A disintegrin-like and 
metalloproteinase with 
thromobospondin type 1 motif 16) 
607510 
ADAMTS19 A disintegrin-like and 
metalloproteinase with 
thromobospondin type 1 motif 19 
607513 
MMP9 Matrix metalloproteinase 9  120361 
MMP15 Matrix metalloproteinase 15 602261 




WNT3 Wingless type MMTV integration 
site family member 3 
165330 
LAMA5 Laminin alpha 5 601033 
GPC2 Glypican 2 (Kurosawa et al., 2001) 
LAMC3 Laminin gamma 3 604349 
Embryogenesis / pluripotency 
markers 
  
FOXH1 forkhead box H1 603621 
NANOG Nanog homeobox transcription factor 607937 
OCT4 Octamer-binding transcription factor 
4 
164177 
SOX2 Sry-box 2 184429 
UTF1 Undifferentiated embryonic cell 
transcription factor 1 
604130  
NODAL Nodal 601265 
Neuronal associated    
CBS Cystathionine beta-synthase 613381 
CRABP1 Cellular retinoic acid binding protein 
1)  
180230 
CYP26A1 Cytochrome P450 family 26 
subfamily A polypeptide 1 
602239 
Table 3.6. Genes that co-expressed with FBN3 in Cluster003.  
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3.4.4 ADMSC adipose differentiation, Cluster006 
Cluster006 consisted of a total of 283 nodes, representing 167 unique genes, and 21,878 
edges, with mean expression being the highest in Day 18 ADMSC differentiated mRNA 
samples (Figure 3.13). 
 
Figure 3.13. Plots of average expression profiles of genes in Cluster006 following analysis using 
BioLayout Express 3D (See Figure 3.8). Y axis shows the normalised intensity value. X axis shows the 
samples from which the RNA was extracted.  + Diff indicates cells undergoing adipose 
differentiation. Control indicates untreated cells. The last four samples on the histogram represent 
the expression patterns of differentiating H1 cells and the single RH1 cells at Day 2 of culture.  
Cluster006 contained a total of 167 genes.  
 Most importantly the cluster contained adipocyte master regulatory genes, PPARG 
(encoding peroxisome proliferator-activated receptor gamma) and CEBPA (encoding 
CCAAT/enhancer-binding protein alpha). DAVID GO term analysis of the genes in 
cluster006 showed multiple lipid specific and differentiation terms, including lipid 
metabolic process and lipid localisation and several extracellular matrix terms (Table 
3.7). Diseases association with the genes were diabetes and obesity (Table 3.7).  
 
 
Chapter 3. The fibrillin gene family in early and late differentiation 
 78 
Go terms  Number of genes P value 
Biological pathway (n=419)   
Cellular process 116 4.7E-2 
Lipid metabolic process 37 2.0E-14 
Cellular lipid metabolic process 30 4.7E-14 
Carbohydrate metabolic process 16 2.9E-4 
Lipid localisation 6 2.1E-2 
Cellular component (n=54)   
Cytoplasm  82 3.5E-2 
Extracellular region 48 1.8E-9 
Extracellular region part 35 1.6E-11 
Extracellular space  24 1.3E-7 
Extracellular matrix 15 5.3E-6 
Disease (n=45)   
Diabetes, type 2 14 3.5E-3 
Obesity  12 2.0E-5 
Table 3.7. A selection of GO terms associated with genes in Cluster006. 
Go terms for genes associated the lipid metabolic process and genes correlated with ECM 
are listed in Table 3.8.  
Cluster006   
Gene Symbol  Gene Name  OMIM 
Lipid associated   
PPARG Peroxisome proliferator-activated receptor gamma 601487 
CEBPA CCAAT/enhancer-binding protein alpha 116897 
ADIPOQ Adiponectin 605441 
FABP4 Fatty acid binding protein 4- adipocyte 600434 
GHR Growth hormone receptor 600946 
LEP Leptin 164160 
LIPE Lipase, hormone sensitive 151750 
LPL Lipoprotein lipase 609708 




TIMP4 Tissue inhibitor of metalloproteinase 4 601915 
COMP Cartilage oligomeric matrix protein 600310 
COL5A3 Collagen type V alpha 3 120216 
DPT Dermatopontin 125597 
MM19 Matrix metallopeptidase 19 601807 
Table 3.8. Adipose and ECM specific genes in Cluster006.  
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The presence of these genes at Day 18 of the ADSMC differentiation is consistent with 
transformation into fat producing cells (Figure 3.5 and Figure 3.13). Their absence from 
the hESMP differentiation time course (Figure 3.13) confirms that those cells did not 
differentiate.  
3.5 Discussion 
This chapter examined the expression of the fibrillin gene family in early human 
embryonic development and in the differentiation of stem cells to the adipose lineage. 
The results for fibrillin-1 (Clusters039 and 357), fibrillin-2 (Cluster008) and fibrillin-3 
(Cluster003) provided a detailed view of the fibrillins and co-expressing genes in the 
differentiation of the hESC (H1) cells to a mesoderm lineage. The mean expression 
patterns show that expression of genes in Cluster003 was highest at Day 0 and decreased 
over the time course, while Cluster008 genes were upregulated at Day 3 and 
Cluster039/357 expression was upregulated at Day 5, implying the differing functions of 
the fibrillin gene family during differentiation. Initial qPCR analysis validated the 
microarray findings of the H1 timecourse showing FBN2 expression increased as FBN3 
levels declined, and FBN1 mRNA expression was upregulated at Day 5 (Figure 3.3). 
These results were further validated through an analysis of data from publicly available 
database Functional Genomics of Embryonic Stem Cells (FunGenES, 
http://biit.cs.ut.ee/fungenes), a database containing microarray expression data in mice 
(Schulz et al., 2004). Raw data file named “FungenES_UK0E-1” was downloaded and 
expression values for Fbn1 and Fbn2 were extracted. The file contained A-Affy-45 
affymetrix geneChip mouse 430 .CEL files of mouse ES cells differentiating to embryoid 
bodies, with time points taken daily for 10 days. The results showed Fbn1 levels to 
increase later than Fbn2 levels (Figure 3.14). The Fbn3 gene is degenerate in mice 
(Chapter 1, Section 1.3) and therefore Fbn3 mRNA levels were not measurable.  
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Figure 3.14. mRNA expression of Fbn1 and Fbn2 during mouse ESC differentiation to embryoid 
body formation. The graphs display microarray data from FunGenES, A-affy-45 affymetrix 
geneChip mouse 430 (2.0) analysis (See Section 3.4.1).  The X-axis depicts the timepoints of the 
samples, and the y-axis shows the expression intensity.  
3.5.1 Limitations of differentiation studies  
The major limitation throughout the chapter was the low number of samples that could be 
assessed. The chapter illustrated preliminary results depicting the expression patterns of 
the fibrillin gene family and other key genes in adipose and early differentiation. To 
further support this chapters initial findings, the studies would need to be repeated 
(minimum of n=3 replicates) in the ES cell types. In addition, using multiple donors of 
ADMSC cells would assist in validating the observations of fibrillin expression patterns 
and developing the hypothesis about the role of fibrillin expression during adipose 
differentiation.  
 
3.5.2 Fibrillin-1 in early differentiation and adipose 
differentiation  
ADSMC were successfully differentiated to the adipose lineage, as demonstrated through 
both Oil Red O staining (Figure 3.5) and analysis of genes expressed at the end point 
(Day 18) (Section 3.4.4). This differentiation study showed that FBN1 was co-expressed 
with many genes associated with later development and mesenchymal lineage specific 
markers in ADMSC cells. There were slight differences in expression of the clusters 
containing FBN1 (Figure 3.9) though overall the expression pattern remained stable. 
Quantification of FBN1 mRNA through qPCR showed that at Day 1, Day 2 and Day 18 
of both differentiating and control ADMSC samples, the mRNA expression remained 
unaltered (Figure 3.10), although the level of fibrillin-1 protein was very low after day 3 
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(Figure 3.7). This suggests upregulation of enzymes that degrade fibrillin-1 rather than 
down regulation of FBN1 during differentiation, consistent with the upregulation of 
MMP19 in Cluster006 at Day 18 of adipose differentiation (Figure 3.13)(Table 3.8). In 
humans with FBN1 mutations there can be a generalized lack of adipocytes and fat 
deposition, indicating that normal fibrillin-1 is important in adipogenesis. The results 
here suggest that fibrillin-1 is present early in adipogenesis but is then possibly degraded 
as differentiation progresses. Therefore, further functional studies, such as knockdowns 
or genome editing, would need to be conducted to better understand the role of the 
fibrillin-1 protein in adipogenesis (Chapter 8).  
The study also showed that FBN1 was co-expressed with many key ECM related genes 
during adipogenesis including CAV1, COL1A2, FN1, SPARC, TGFB1 and ADAM19 
(Table 3.2). There is currently no evidence for a role of ADAM19 in adipogenesis or any 
possible interactions with the fibrillin gene family. It is highly associated with 
embryogenesis (Yan et al., 2011), neurological processes, cardiovascular development, 
inflammatory response and possibly with Alzheimer’s disease (Qi et al., 2009). 
SPARC is a key protein in maintaining the structure and affecting the synthesis of the 
ECM (OMIM: 182120) (Bradshaw et al., 2003) and in addition to Col1a2, the gene has 
been shown to co-express with Fbn1 in mice (Summers et al., 2010) (Chapter 1, Section 
1.4.2). SPARC may play a key role in homeostasis of the adipose ECM. SPARC null 
mice have increased adipose tissue, suggesting that SPARC assists in maintaining normal 
adipose levels (Bradshaw et al., 2003). The co-expression of both FBN1 and SPARC 
demonstrated in this study is consistent with the involvement of both proteins in adipose 
maintenance.  
FN1 is a key component of the ECM and provides essential functions in embryogenesis 
(Chapter 1, Section 1.2.4). FN1 null mice die in utero with multiple complications 
including defects of mesenchyme derived tissues, neural tube formation and heart vessel 
malformation (George et al., 1993, Pankov and Yamada, 2002, Lee et al., 2012). 
Decreased FN1 mRNA levels have been demonstrated in severe (morbid) obesity (Lee et 
al., 2012), suggesting that FN1 and FBN1 maybe be involved in adipose homeostasis. 
COL1A2 is generally a key component of the ECM in bone and cartilage tissue, though 
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the gene is expressed in adipose (http://biogps.org), and mRNA of COL1A2 increases 
following insulin induction in mouse adipocytes (Wang et al., 2006). In the U219 
microarray analysis described in this chapter, FN1 and COL1A2 levels remained stable, 
similar to FBN1 levels across the timecourse (Section 3.4.1). It has been established that 
fibrillin-1 requires fibronectin to produce an ECM in fibroblasts (Kinsey et al., 2008, 
Sabatier et al., 2009)(Chapter 1, Section 1.2.4), and fibronectin may facility deposition 
of collagen 1 (Velling et al., 2002), so the stability and co-expression of FBN1, FN1 and 
COL1A2 mRNA may be necessary to maintain the dynamic ECM composition required 
to adjust to the production of lipid within the cytoplasm.   
CAV1 (OMIM: 601047) encodes the protein caveolin-1, which produces pits within the 
plasma membrane called caveolae, which are specialised “lipid rafts”.  CAV1 is highly 
expressed in adipocytes and bronchial epithelial cells (http:/biogps.org) and mutations in 
CAV1 have been associated with multiple adipose and lung specific disorders such as 
congenital generalized lipodystrophy type 3 (MIM: 612526), partial lipodystrophy, and 
primary pulmonary hypertension 3 (MIM: 615343) as well as congenital cataracts and 
neurodegenerative syndrome (MIM: 606721). Previous research suggests that CAV1 may 
be a marker of later adipocyte development (Fernandez-Real et al., 2010, Blouin et al., 
2008).  
FBN1 and CAV1 in the regulation of TGFB were further considered, given that TGFB1 
was also co-expressed with these genes. An increase in TGFB1 levels has been associated 
with an increase in the adipose tissue (Choy and Derynck, 2003). In this study TGFB 
mRNA expression remained stable, in parallel to FBN1 mRNA. As adipose 
differentiation occurs, TGFB receptors become less available, leading to a 
downregulation in SMAD signalling (Choy et al., 2000).  
When CAV1 is upregulated, it suppresses TGFB signalling by binding to the TGFBR1, 
which inhibits the signal cascade of SMAD2 phosphorylation and SMAD4 activity 
(Razani et al., 2001) (Chapter 1, Section 1.3.3). In addition, Razani et al., (2001) 
showed that a decrease in CAVI transcription led to an increase in TGFB signalling. 
While fibrillin-1 has not been shown to interact with the TGFB receptors, it aids in 
sequestering TGFB, thereby preventing binding to the receptor (Chapter 1, Section 
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1.3.3). Both FBN1 and CAV1 mutations cause lipodystrophy, and the genes are co-
expressed in adipose differentiation, suggesting that fibrillin-1 and CAV1 may be 
involved in regulating TGFB signalling in adipogenesis. 
 
3.5.3 Fibrillin-2 in early differentiation  
Cluster008 included multiple markers for formation of mesoderm, one of the three 
primary germ layers of the early embryo (Section 3.1.2). These markers included 
EOMES (eomesodermin), MESP1 (mesoderm posterior 1), MESP2 (mesoderm posterior 
2), and T (T, brachyury homolog), and some cell division genes, for example CEP70 
(centrosomal protein 70kDa).  
T and EOMES are essential genes in mesoderm formation (Ninomiya et al., 2004, Russ et 
al., 2000). The embryonic development of EOMES deficient mice is halted at the 
blastocyst stage leading to spontaneous abortion (Russ et al., 2000), demonstrating the 
gene’s essential function in mesoderm formation. T mutant mice were found to be 
embryonic lethal, presenting with fragmented notochord and abnormal cardiac formation 
(Abe et al., 2000). MESP2 is highly involved in the NOTCH signalling pathway that 
leads to segmentation in early embryogenesis (Takahashi et al., 2000, Morimoto et al., 
2005, Saga et al., 1997). Mutations in MESP2 also lead to autosomal recessive 
spondylocostal dysostosis 2 (MIM: 608681), a disorder that results in abnormal vertebral 
segmentation beginning in utero (Cornier et al., 2008). MESP1 is less well characterised 
but is also implicated in cardiac mesoderm development (Kitajima et al., 2000).  
The presence of FBN2 in this cluster suggests that it is associated with mesoderm 
formation. This is consistent with previous reports that FBN2 is activated before FBN1, 
leading to the hypothesis that fibrillin-2 provides a scaffold for elastin deposition while 
fibrillin- 1 maintains the homeostasis of the microfibrils into adult life (Zhang et al., 
1994, Mariencheck et al., 1995, Quondamatteo et al., 2002).  
In addition to mesoderm formation, Cluster008 contained many genes involved in the 
WNT signalling pathway, including WNT8A, NKD1, CFC1 and PTCH1 (Discussed in 
Section 3.4.2). This pathway is involved in limb development (reviewed in (Church and 
Francis-West, 2002)), and limb development related GO terms were highly correlated 
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with Cluster008 (Table 3.3). PTCH1 (OMIM: 601309) had a direct edge to FBN2 in the 
BioLayout Express 3D network graph, and was grouped with FBN2 and PDX1 in multiple 
limb development GO terms (Table 3.3). PTCH1 is the receptor for sonic hedgehog 
(SHH) (Ming et al., 2002), the pathway that is crucial for limb development (Anderson et 
al., 2012). PTCH1 mutations are associated with many human diseases listed in OMIM 
including somatic basal cell carcinoma (MIM: 605492), basal cell nevus syndrome 
(MIM: 109400) and forebrain abnormality holoprosencephaly 7 (MIM: 610828).  
In adult cells and tissues, fibrillin-2 is a mesenchyme specific gene, highly expressed in 
cells of bone and cartilage (Chapter 1, Section 1.4.2). Its expression level was low 
during adipogenesis (Figure 3.11). This BioLayout Express 3D analysis further validates 
the known expression pattern trends of FBN2 in early development and identified several 
FBN2 co-expressing genes involved in limb development.  
 
3.5.4 Fibrillin-3 in early differentiation 
The 900 genes found to co-express with FBN3 in the BioLayout Express 3D analysis were 
associated with embryogenesis, neurological function, and ECM localization (Table 3.6). 
Fibrillin-3 has been characterized as an ECM gene and the gene is expressed early in 
development (Corson et al., 2004), as well as in foetal lung and brain (http:/biogps.org). 
Cluster003 contained many pluripotency markers with decreasing expression across the 
time course (Figure 3.12). Well established pluripotency markers included POU5F1 
(POU class 5 homeobox 1 (also known as OCT4)), and SOX2 (SRY sex determining 
region Y-box 2) (Niwa et al., 2000, Rais et al., 2013, Tay et al., 2008)(Table 3.6). In 
addition, DPPA2/3/4/5 (developmental pluripotency associated 2/3/4/5), JARID2/1C 
(Jumonji, AT rich interactive domain 2/ domain containing 1C), NODAL (nodal growth 
differentiation factor), and UTF1 (undifferentiated embryonic cell transcription factor 1) 
were included in Cluster003.  
Two key embryonic marker genes were found to be highly correlated with FBN3 and 
present within Cluster003. NANOG (OMIM: 607937) is a key gene marker for 
pluripotency (Tay et al., 2008, Abranches et al., 2014). FOXH1 (OMIM: 603621) is 
involved in NODAL signalling, an important signal transduction pathway directly related 
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to differentiation during embryogenesis.  The co-expression of FBN3 with these 
pluripotency markers suggests that it is important early in development.  
 Cluster003 contained TERF1 (telomeric repeat binding factor (NIMA-interacting) 1), 
and TERT (telomerase reverse transcriptase), which encode major proteins involved in 
maintenance of telomere length (OMIM: 600951)(OMIM: 187270). Key DNA 
methylation and cell division genes, for example DNMT3A/3B (DNA (cytosine-5)-
methyltransferase 3 alpha / beta) (OMIM:602769)(OMIM: 602900)(Yanagisawa et al., 
2002) and MAP7 (microtubule-associated protein-7) (OMIM: 604108), were also in this 
cluster. The decreasing mRNA level for these pluripotency-associated genes 
demonstrated that the cells were switching from a pluipotent state to a lineage specific 
state.  
There were multiple genes that were derived from the DAVID GO term analysis under 
neurological specific terms including CBS (OMIM: 613381), CRABP1 (OMIM: 180230) 
and CYP26A1 (OMIM: 602239). CBS is a gene that encodes cystathionine ß synthase that 
is involved in the transsulfuration pathway that converts methionine to cysteine in many 
cell types (OMIM: 613381)(McBean, 2011). CBS mutations are associated with B6-
responsive and nonresponsive homocystinuria and thrombosis  (OMIM: 236200). The 
phenotype associated with a deficiency in CBS includes some signs and symptoms 
similar to Marfan syndrome, including ectopia lentis (Sadiq and Vanderveen, 2013) and 
myopia (MIM: 236200) (Mudd, 2011, Perry, 1999, Lim and Lee, 2013), as well as 
developmental delay and other neurological manifestations. CRABP1 is a cellular 
retinoic acid binding protein (Kainov et al., 2014). It has high mRNA expression in 
neuroblastoma cells (Plum and Clagett-Dame, 1995) though there were no specific 
neurological disorders associated with the gene. CYP26A1 is a retinoic acid inactivating 
protein essential to regulating retinoic acid levels during embryo development 
(Niederreither et al., 2002) and Cyp26a1 null mice exhibit many neural crest deformities 
(Maclean et al., 2009). Retinoic acid (a derivative of vitamin A) is predicted to be 
involved in segmentation and hindbrain formation in mouse embryos (Rhinn et al., 
2011). The co-expression of these neural specific genes with FBN3, is consistent with the 
expression of FBN3 in foetal brain and suggests a role for fibrillin-3 in neurological 
development.   
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MMP9, MMP15 and MMP25 had direct edges to FBN3. MMPs are key ECM 
disassembly proteases required for ECM homeostasis. MMP9 (OMIM: 120361) is a 
catalyst of ECM degradation and has been associated with connective tissue disease 
metaphyseal anadysplasia 2 (MIM: 120361), which affects both bone and cartilage 
formation (Lausch et al., 2009). MMP9 is also associated with bone and cartilage 
formation and repair (Huang et al., 2014). MMP15 (OMIM: 602261) is a widely 
expressed gene, and its product is involved in the EMT during early development 
(Chapter 3, Section 3.1.2). MMP25 (OMIM: 608482) encodes an ECM degradation 
protein involved in embryonic growth, tissue remodelling, ovulation and wound healing.  
More recently MMP25 has been implicated in downstream interactions with TGFB3 in 
early mouse embryonic development (Brown and Nazarali, 2010). While the MMP genes 
associated with FBN3 have varying functions in embryonic development, they are all 
associated with maintaining ECM homeostasis and early ECM development.   
There were several other genes encoding proteins involved in ECM synthesis and 
maintenance including LAMA5 (OMIM: 601033), ENTPD2 (OMIM: 602012), 
ADAMTS16 (OMIM: 607510), ADAMTS19 (OMIM: 607513), LAMC3 (OMIM: 604349) 
and GPC2. LAMA5 is a key laminin gene that was originally discovered in many adult 
mouse tissues and later identified in embryogenesis (Miner et al., 1995, Miner et al., 
1998) (Chapter 1, Section 1.2.3). Lama5 null mice have severe skeletal and neurological 
defects prior to premature embryonic death (Miner et al., 1998). LAMC3 is a widely 
expressed laminin gene and its product is predicted to be present in a stable ECM (Koch 
et al., 1999). Expression was further identified within the retina (Cserhalmi-Friedman et 
al., 2001) and mutations have been associated with occipital cortex malformations (MIM: 
614115)(Barak et al., 2011). ADAMTS16 shows prominent expression in the kidney and 
has been linked to inherited hypertension (Joe et al., 2009).  Very little is known about 
low expressing ADAMTS19, though expression has been detected in foetal lung and it has 
more recently been identified as a possible candidate gene in premature ovarian failure 
(Cal et al., 2002, Knauff et al., 2009). Interestingly, both FBN3 and ADAMTS19 genes 
are candidates for ovarian disorders (Chapter 1, Section 1.3.6). ENTPD2 was associated 
with the proteinaceous ECM based on DAVID GO term analysis, and is also involved in 
Chapter 3. The fibrillin gene family in early and late differentiation 
 87 
ocular development (Masse et al., 2007). GPC2 is a heparan sulfate proteoglycan (Stipp 
et al., 1994), involved in neurological growth (Kurosawa et al., 2001). 
The ECM genes found to co-express with FBN3 had varying functions, but they all assist 
in maintaining ECM homeostasis. The function and predicted mechanisms of the co-
expressed genes highlight the role of fibrillin-3 in the ECM, specifically in embryonic 
ECM development.  
3.6 Conclusions 
In summary, FBN1 was predominant in early adipose differentiation and later 
embryogenesis, co-expressing with several genes involved in adipogenesis (Section 
3.4.1). FBN2 was highly correlated with genes involved in mesoderm formation and limb 
development (Section 3.4.2). Furthermore, FBN3 was highly associated with genes in 
early embryogenesis, pluripotency, neuronal development and ECM maintenance 
(Section 3.3.3).  Therefore, this chapter has identified several key genes that co-express 
with FBN1, FBN2 and FBN3 in early differentiation and later differentiation of MSCs to 
adipose, though further studies will be required to support the relationships (dicussed in 
Chapter 8). The studies described here focussed on two time courses of differentiation 
and development. As described in Chapter 1, Section 1.1, MSCs are capable of 
differentiating into multiple connective tissue lineages. The expression of the fibrillin 
gene family will be further explored in other connective tissue cell types in Chapter 4.  
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Chapter 4. Fibrillin expression in human connective tissue cell 
types 
4.1 Introduction 
In the previous chapter, the expression of the three fibrillin genes in two models of 
differentiation was examined. FBN3 was strongly associated with pluripotency and its 
level declined in a model of early human development, while FBN2 was associated with 
markers of mesoderm and FBN1 appeared latest in embryonic development, but was 
strongly expressed in undifferentiated mesenchymal stem cells and in the early stages of 
adipogenesis. Since mesenchymal stem cells can differentiate in multiple other lineages, 
for example, chondrocytes, osteoblasts and fibroblasts (Chapter 1, Section 1.1), this 
chapter explores the expression of fibrillins in other mesenchyme derived cell types, 
using a number of human cell lines: neonatal fibroblasts (NHDF), chondrocyte cell lines 
(C20A4, C28I2 and TC28A2), osteosarcoma cell lines (SAOS2 and MG63), a human 
embryonic kidney cell line (HEK293) and human monocyte cell line (THP1)(Chapter 2, 
Sections 2.1.1-2.1.5). 
Mutations in fibrillin-1 and fibrillin-2 affect multiple connective tissues outlined in 
Chapter 1, Section 1.3.4 and 1.3.5, including long bone, cartilage and dermal fibroblast 
formation. Marfan syndrome is the most frequent result of fibrillin-1 mutations and is 
diagnosed in patients based on the revised Ghent criteria, which include familial 
inheritance and FBN1 mutations as well as physical abnormalities (Aalberts et al., 2012, 
Loeys et al., 2010, De Paepe et al., 1996, Summers et al., 2012). Both previous (De 
Paepe et al., 1996) and current Ghent criteria (Loeys et al., 2010) describe the skeletal 
and cartilage deformities as follows, pectus carinatum, pectus excavatum, increase long 
bone formation (upper and lower segments) arachnodaclyly, joint hypermobility, and 
facial appearance. This chapter will use osteosarcoma cell lines and chondrocyte cell 
lines to investigate the role of the fibrillin gene family in a bone and cartilage model 
system.   
SAOS2 cells are capable of mineralisation and show upregulation of multiple osteoblast 
specific proteins such as, osteocalcin, bone sialoprotein (BSP), decorin, collagen 1, 
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collagen type III and osteoprotegerin (Chapter 2, Section 2.1.1)(Pautke et al., 2004). 
Due to the lack of primary human bone cells available, SAOS2 cells were used as a 
model system for bone development and formation. The fibrillin gene family was also 
investigated in a non-mineralising human osteosarcoma cell line, MG63 (Chapter 2, 
Section 2.1.1). While these cells are considered more immature in comparison to SAOS2, 
there was low but measurable expression of bone specific proteins osteocalcin, bone 
sialoprotein and decorin (Pautke et al., 2004). The comparison of fibrillin expression in 
MG63 and SAOS2 cells could elucidate the role of fibrillins in calcifying tissues, by 
investigating expression in both mineralisation capable and non-capable cell lines.    
Chondrocyte cell lines, C20A4, C28I2 and TC28A2 were used to better understand the 
role of the fibrillins in cartilage (Chapter 2, Section 2.1.2). As previously described, the 
cells were derived from the costal cartilage of patients undergoing pectus excavatum 
repair (Goldring et al., 1994). Furthermore, the cells behaved as typical chondrocytes, 
expressing expected levels of COLII, COLIX and COLX1 (collagen type 2, type 9 and 
type 11, respectively), as well as responding to IL-1ß (interleukin 1-beta)(OMIM: 
147720), which is essential for chondrocyte metabolism (Goldring et al., 1994, Busschers 
et al., 2010).  Given the presence of key cartilage markers and the tissue region from 
which the cells were derived, these cell lines were to be used to look at expression in 
cartilage.  
It has been established that patients with diagnosed MFS have abnormal dermal fibroblast 
assembly and structure (Kielty and Shuttleworth, 1994, Kielty et al., 1994, Brenn et al., 
1996, Macek et al., 1966) (Chapter 1, Sections 1.3.4). Human neonatal fibroblasts, 
NHDF, were used to better define the fibrillin gene family in nonmutant fibroblasts. The 
cells were obtained from Dr. Finn Grey (Chapter 2, Section 2.1.3), and derived from 
neonatal circumcision material (Grey et al., 2007). Driskell et al., (2013) showed that 
PDGFRA (platelet-derived growth factor receptor, alpha) and PDPN (podoplanin) are 
candidate fibroblast markers, both of which were upregulated in the NHDF cells used in 
this thesis (obtained from the U219 microarray data (Chapter 2, Section 2.3.5)).  
Given the controversy surrounding the use of HEK293 cells in the study of fibrillin 
(Chapter 2, Section 2.1.4), these cells were included to ascertain their origin and 
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suitability.  The origin of the HEK293 cell line was introduced in Chapter 2, Section 
2.1.4 and will be discussed further in Section 4.6 of this Chapter. THP-1 was analysed as 
a negative control (Chapter 2, Section 2.1.5). THP-1 is a hematopoietic-derived cell line 
that has been used as a model system in macrophage and monocyte studies (Qin, 2011).  
4.2 Aims of the Chapter  
A survey was made of mRNA and protein expression of the fibrillin family and other 
extracellular matrix genes across various connective tissue types, aiming to identify co-
expressed genes that could assist in the maintenance and development of a fibrillin-rich 
ECM. Expression microarray, qPCR and immunocytochemistry (ICC) techniques were 
used to determine key genes co-expressing with fibrillin-1 and fibrillin-2. Identifying 
genes co-expressed with fibrillins could provide further candidate modifier genes for 
Marfan syndrome and other connective tissue disease with similar phenotypes.   
4.3 Materials and Methods 
4.3.1 Cell culture and RNA extraction  
RNA samples were obtained from Day 7 (seven days after plating) cell cultures of 
SAOS2, MG63, C20A4, TC28A2, C28I2, NHDF, THP1 and HEK293 (Chapter 2, 
Section 2.2). Single replicates were collected for C28I2, HEK293 and THP1. In addition, 
Ailsa Carlisle and Prof Kim Summers (The Roslin Institute) provided RNA samples of 
SAOS2 and MG63 cells after 14 days in calcification medium containing 50µg/ml 
ascorbic acid (Sigma-Aldrich) and 2.5mM ß-glycerophosphate (BGP) (Sigma-Aldrich). 
RNA was extracted and validated as described in Chapter 2, Section 2.3.1). 
 
4.3.2 qPCR and ICC 
Initial mRNA expression levels were quantified using qPCR techniques previously 
described in Section 2.3.4 of Chapter 2. All ICC technique was carried out as described 
in Section 2.4.2 of Chapter 2. 
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4.3.3 BioLayout Express 3D analysis  
Genome-wide expression profiles were obtained using the U219 human microarray and 
BioLayout Express 3D analysis was completed on the dataset for the following Day 7 
mRNA samples: SAOS2, MG63, C20A4, TC28A2, and NDHF (all n=2), C28I2, THP1, 
SAOS2 calcified, MG63 calcified and HEK293 (all n=1)(Chapter 9, Appendix A). 
Microarray results and files for BioLayout Express3D were subjected to quality control 
and filtering as described in Chapter 2, Section 2.3.6.  Probes were removed from the 
data set if the normalised intensity value (equivalent to expression levels) was below 20 
(unlogged), removing 13,613 probes (27.6%). The intensities for the remaining 35,772 
probesets were loaded into BioLayout Express 3D.  The co-expression analysis was run at 
r≥0.92 and an MCL inflation value of 2.0 (Chapter 9, Appendix B).  
 
4.3.4 DAVID GO term analysis  
Cluster gene lists for Cluster001, Cluster002, Cluster003, Cluster004, Cluster005, 
Cluster008 and Cluster034 from the BioLayout Express3D analysis were individually 
placed into the upload tool bar of DAVID 6.7 functional annotation tool 
(www.david.abcc.ncifcrf.gov/) and analysis was performed as described in Chapter 2, 
Section 2.3.7. 
4.4 Results  
4.4.1 ECM Gene expression in cell lines 
Previous research suggested that Fbn1 and Fbn2 share the same expression patterns as 
Ltbp2, Acta2, Bgn, Col1a1 and Col1a2 in many mouse cell types (Summers et al., 2010). 
Therefore, initially qPCR was performed on the human cell lines to examine expression 
patterns of these genes across human connective tissue cell types. The analysis also 
included LTBP1, LTBP3 and LTBP4, the other members of the fibrillin-LTBP gene 
family (Chapter 1, Section 1.3.2). The qPCR analysis revealed varying levels of gene 
expression across the cell line samples (Figure 4.1). 
The highest expression of FBN1 was seen in chondrocyte line C20A4, while C28I2 
displayed moderate levels (Figure 4.1A). Similarly, osteosarcoma MG63 had higher 
levels of FBN1 expression when compared to mineralising osteosarcoma cell line SAOS2 
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(Figure 4.1A). Differing from FBN1, FBN2 displayed the lowest overall expression in 
C20A4 and MG63 cell lines and measureable levels of expression in SAOS2 (Figure 
4.1B). NHDF (fibroblasts) showed moderate expression of both FBN1 and FBN2 (Figure 
4.1). The overall expression pattern of FBN2 was similar across the cell types, other than 
MG63. FBN3 expression was undetected in all cell types.  
There was no measureable expression of LTBP1 in either chondrocyte cell line (C20A4 
and C28I2) (Figure 4.1C). Figure 4.1C-F shows that SAOS2 had the highest expression 
of LTBP1, though no measureable expression of LTBP2, very low levels of LTBP3 and 
moderate levels of LTBP4. SAOS2 also had very low levels of COL1A1 and COL1A2 
expression (Figure 4.1G and H). NHDF had the highest expression of LTBP2 and 
LTBP3, with similar expression of LTBP4 to MG63 (Figure 4.1D-F). NHDF and SAOS2 
had the highest expression of ACTA2, while C20A4 showed considerably higher levels of 
BGN expression (Figure 4.1 I and J). C20A4 had the highest expression of BGN and 
COL1A1 genes and very low expression in ACTA2 (Figure 4.1G and J). 
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Figure 4.2. qPCR results for ECM gene expression in human cell lines. Expression patterns of (A) 
FBN1, (B) FBN2, (C) LTBP1, (D) LTBP2, (E) LTPB3, (F) LTBP4, (G) COL1A1, (H) COL1A2, (I) 
ACTA2, and (J) BGN in NHDF, (fibroblasts) MG63, SAOS2 (osteosarcoma cells), C20A4 and C28I2 
(chondrocytes) at day 7 of culture. Expression levels were normalised using the housekeeping gene, 
GAPDH. Y-axis shows the ratio of target to housekeeping gene. (Chapter 2, Section 2.3.4) and mean 
standard error is displayed (N=3 biological replicates). Davis et al., 2012.  
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4.4.2 Localisation of ECM and cytoskeletal proteins 
ICC studies were performed to better define the nature and extent of the fibrillin matrix in 
the different cell lines (Chapter 2, Section 2.4.2). Immunofluorescent staining of 
fibrillin-1 and fibillin-2 microfibrils in NHDF revealed extensive deposition of the 
proteins in the extracellular matrix (Figure 4.2A and B). Fibrillin-2 microfibrils formed 
linear, thin strands, while fibrillin-1 microfibrils appeared less organised and had more 
bundled fibres (Figure 4.2 A and B). Fibrillin-1 and -2 ICC images at 20x magnification 
illustrate the vast microfibril formation. ACTA2 staining displayed a rich network of 
intracellular actin filaments, possibly involved in cell-to-cell connections (Figure 4.2C). 
Biglycan and collagen type 1 staining was localised within the cell (Figure 4.2D and E). 
The intracellular staining of collagen 1 was likely due to the lack of ascorbic acid in 
culture, necessary for collagen secretion.  
 
Figure 4.3. ICC of NHDF cells at Day 7 of culture. (A) Fibrillin-1 (20x) (green) n=3(B) Fibrillin-2 
(20x) (green)n=3 (C) Smooth muscle actin (40x) (red) n=2, intracellular fibre formation is further 
highlighted with a white arrow (D) Biglycan (40x) (red) n=2 (E) Collagen type 1 (40x) (pink) n=2 . 
Antibody and technique information is given in Chapter 2, Section 2.4.2. The nuclei were 
counterstained with DAPI (blue). Images were captured using the Zeiss confocal microscope Scale 
bars (white) in A and B represent 50µm and scale bars in C, D and E represent 20µm.  
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The fluorescent ICC staining of fibrillin-1 protein revealed a vast fibrillin-1 microfibril 
matrix in MG63 at Day 7 and Day 14, while fibrillin-1 was intracellular within SAOS2 at 
both Day 7 and Day 14 (Figure 4.3). The extracellular fibrillin-1 matrix of MG63 cells 
became denser with time and fibrillin-1 staining of SAOS2 cells was more intense at Day 
14, indicating increased protein, though no extracellular fibres had developed. These 
results are consistent with the relative mRNA levels measured by qPCR (Figure 4.1A 
and B, Section 4.4.1). 
 
Figure 4.4. Fibrillin-1 ICC in osteosarcoma cell lines. (A) MG63 at Day 7, (B) SAOS2 at Day 7, (C) 
MG63 Day 14 (no DAPI), (D) SAOS2 at Day 14. (all x40)  Green fluorescence shows fibrillin-1 
protein, and nuclei were counterstained with DAPI, seen in blue. Antibody and technique 
information is given in Chapter 2, Section 2.4.2. Images were captured at 40x using the Zeiss confocal 
microscope (Chapter 2, Section 2.4.2). Scale bars (white) represent 20µm. 
Like the osteosarcoma cell lines, chondrocyte cell lines C20A4 and C28I2 had differing 
expression levels of FBN1 mRNA (Figure 4.1A). Fibrillin-1 ICC showed that C20A4 
created a rich, thick and structurally organised fibrillin-1 microfibril matrix (Figure 
4.4A). In comparison, C28I2 (Figure 4.4B) and the derived cell line TC28A2 (Figure 
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4.4C) did not produce a fibrillin-1 matrix, though protein was detected in the intracellular 
region (Figure 4.4). 
 
Figure 4.5. Fibrillin-1 ICC in chondrocyte cell lines. (A) C20A4 at Day 7, (B) C28I2 at Day 7, (C) 
TC28A2 at Day 7. Green fluorescence shows fibrillin-1 protein, nuclei were counterstained with 
DAPI. Antibody and technique information is given in Chapter 2, Section 2.4.2. Images were 
captured at 40x using the Zeiss confocal microscope (Chapter 2, Section 2.4.2). Scale bars (white) 
represent 20µm. 
4.5 Microarray analysis  
mRNA and protein analysis (Sections 4.4.1 and 4.4.2) showed that the two osteosarcoma 
lines were discordant for fibrillin expression as were the three chondrocyte lines. This 
suggested that there might be differential associations with other genes, which could 
provide insight into the interactions of the fibrillins in ECM formation. The Affymetrix 
human gene expression microarray platform U219 was therefore used to define the 
expression of key extracellular matrix genes in NHDF, MG63, SAOS2, C20A4, TC28A2, 
C28I2, THP1 and HEK293 cell lines at day 7 after plating (Chapter 2, Section 
2.3.5)(Chapter 9, Appendix A).  
To identify gene co-expression patterns, a total of 35,772 probes and their expression  
(intensity) values were placed into network clustering analysis software BioLayout 
Express3D (See Section 4.3.3). The analysis was run at r ≥0.92 and clustering was 
performed at an MCL of 2.0. At this relatively high P-value there were a total of 24,149 
nodes (probes) and 627,371 edges included in the final graph (Figure 4.5). A total of 
1,842 clusters were defined by the analysis. Seven clusters had high levels of expression 
in specific cell lines (Cluster001, Cluster002, Cluster003, Cluster004, Cluster005, 
Cluster008 and Cluster034)(Figure 4.5). Two unique clusters contained probesets 
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(nodes) for the FBN1 gene (Cluster022 and Cluster700) and Cluster704 had the same 
expression pattern as Clusters022 and 700, with a direct link to Cluster022. Fibrillin-2 did 
not cluster, and fibrillin-3 did not remain in the data set following filtering to remove low 
expression probes and those that were uncorrelated with any other probe (Section 4.3.3).  
 
 
Figure 4.6. Network visualization and clustering of the transcriptomes of the cell lines (Day 
7)(Section 4.3.5)(Appendix A). The image depicts the network diagram produced by BioLayout 
Express 3D using data from the Affymetrix U219 gene expression microarray platform. Spheres 
(nodes) represent individual probesets and the lines between them (edges) show correlations in 
expression pattern of r ≥ 0.92. The nodes were clustered using an MCL inflation value 2.0 (Chapter 
2, Section 2.3.6). The background of the image displays the whole network and clusters discussed in 
the text are highlighted and labelled.   
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4.5.1 Analysis of BioLayout Express 3D  derived cell line specific clusters  
In addition to identifying two clusters containing FBN1 probesets, the 
BioLayoutExpress3D analysis yielded clusters where the set of genes had highest 
expression in a single cell line (Figure 4.6). For example, for genes in the largest cluster, 
Cluster001 (835 nodes) (Figure 4.6A), the highest overall expression was seen in THP1 
macrophage cell line, and the genes identified contained macrophage and immune 
markers such as CSF1R (encoding colony stimulating factor receptor 1), CD33 and CD4 
(Figure 4.6A). GO terms for Cluster001 confirmed the high incidence of immune and 
defence response genes and general cell component terminology (Table 4.1). 
 
Gene Ontology  Number of Genes P-value  
Biological Pathway (n=271)   
Regulation of biological process 254 5.6E-2 
Regulation of cellular process 245 5.1E-2 
Immune system process 79 6.5E-13 
Immune response  61  5.7E-12 
Defence response  45 1.1E-3 
T cell activation  13 9.7E-4 
Disease classification (n=2)   
Immune 58 4.8E-6 
Infection 21 2.6E-2 
Table 4.2. A selection of GO terms associated with genes in Cluster001-THP1. Biological pathways 
terms were identified for 80.9% of genes within the cluster. 
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Figure 4.7. Plots of average expression profiles of genes in cell line specific clusters following analysis 
using BioLayout Express 3D (See Figure 3.8). Y axis shows the normalised intensity value. X axis 
shows the samples from which the RNA was extracted.  Characteristics of each cluster was 
determined using the class viewer tool in BioLayout Express 3D. (A) Cluster001- THP1,  
(B)Cluster002-SAOS2,(C) Cluster003-MG63, (D)Cluster004-NHDF, (E) Cluster005-HEK293, (F) 
Cluster008-TC28A2/C28I2, and (G) Cluster034- C20A4.  The colors were arbitrarily assigned to 
clusters  during the BioLayoutExpress3D MCL clustering (p≥0.92, MCL inflation value 2.0). Each 
cluster contains genes with high expression only in a specific cell line (boxed in). The genes listed are 
representative examples of ECM related genes, except for Cluster001 where representative genes 
reflect the hematopoietic lineage of THP1 cells.  
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Cluster003 and Cluster004 were in close proximity in the network graph to the more 
generally expressed fibrillin-1 clusters (Cluster022 and Cluster700, see Figures 4.5). 
Cluster003 and Cluster004 contained many genes that are involved with the structure, 
function or maintenance of the ECM, in addition to some genes implicated in connective 
tissue disease, similar to the phenotype produced by fibrillin-1 and fibrillin-2 mutations 
(Figure 4.6CandD). Cluster003 contained a total of 567 nodes that were highly 
expressed in MG63 cells (Figure 4.6C). There were no edges with Cluster022 or 
Cluster700 genes. Cluster003 included ECM related genes such as COL14A1 (encoding 
collagen, type XIV, alpha 1), FGFR4 (fibroblast growth factor receptor 4), nuclear 
membrane gene LMNA (lamin  A/C), and several transmembrane genes (TMEM14A, 
TMEM63B, TMEM74 and TMEM8B) (Figure 4.6C). Multiple GO terms were identified 
for the genes in Cluster003, including muscle development and tooth development 
(odontogenesis) (Table 4.2). Surprisingly there were no GO terms associated with bone 
formation, consistent with the observation that this is an immature osteoblast phenotype. 
Gene Ontology  Number of Genes P-value  
Biological Pathway (n=83)   
Biological regulation 136 5.5E-2 
Organ development 40 2.5E-2 
Anatomical structure morphogenesis 29 3.5E-2 
Regulation of growth 11 5.4E-2 
Muscle development 8 5.8E-2 
Odontogenesis 4 5.8E-2 
Cellular Component (n=20)   
Cell part 246 3.8E-3 
Cell 246 3.8E-3 
Intracellular  187 5.8E-2 
Membrane  134 1.3E-2 
Neuron projection 10 9.5E-2 
Table 4.2. A selection of GO terms associated with genes in Cluster003-MG63. Biological pathways 
were identified in 75.3% of genes and cellular component terms were identified in 82.1% of genes 
within the cluster. 
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Cluster004 had 556 nodes highly expressed in NHDF cells (Figure 4.6D). A single gene, 
VIM (vimentin), highly characteristic of fibroblasts, shared an edge with a FBN1 node in 
Cluster022 (Figure 4.7). There were many ECM related genes in Cluster004, including 
three different ADAM metallopeptidase domain genes (ADAM10, ADAM33, ADAMTS2), 
genes encoding collagen type XX1, alpha 1 (COL21A1) and elastin (ELN), three fibulin 
genes (FBLN1, FBLN12, FBLN5) and several matrix metallopeptidase genes (Figure 
4.6D). GO terms associated with extracellular functions were overrepresented (Table 
4.3). Cluster004 also showed co-expression of ACTA2 and TGFBR2 (encoding 
transforming growth factor beta receptor 2).  
Gene Ontology Number of Genes P-value 
Biological Pathway (n=231)   
Multicellular organism process 111 1.5E-4 
Developmental process 105 9.4E-10 
Tissue development 29 7.6E-5 
Cell adhesion 29 1.8E-4 
Skeletal system development 20 1.2E-5 
Wound healing 13 3.1E-4 
Cellular component (n=52)   
Membrane 156 2.7E-2 
Extracellular region 81 4.4E-11 
Extracellular region part 54 1.6E-12 
Extracellular space 32 7.0E-6 
Extracellular matrix 30 2.0E-11 
Disease classification (n=0)   
Table 4.3. A selection of GO terms associated with genes in Cluster004-NHDF. Biological pathways 
were identified for 78.6% of genes and cellular component terms were identified for 89.3% of genes 
within the cluster. 
Cluster002 (725 nodes) was highly expressed in the SAOS2 cell line (Figure 4.6B). It 
was located in close proximity to the THP1 Cluster001 and distant from the other 
osteosarcoma MG63 (Figure 4.5), although it contained multiple osteoblast lineage 
markers such as IBSP (integrin-binding sialoprotein), RUNX2 (runt-related transcription 
factor 2), and PHOSPHO1 (phosphatase, orphan 1) (Figure 4.6B). In addition, multiple 
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bone and cartilage specific GO terms were correlated with Cluster002, including 
osteoblast differentiation, skeletal and cartilage development (Table 4.4). 
Gene Ontology  Number of Genes P-value  
Biological Pathway (n=132)   
Cellular process 272 2.2E-4 
Metabolic Process 194 4.2E-2 
Phosphorylation 29 2.0E-2 
Skeletal system development 20 1.7E-4 
Cartilage development 7 7.3E-3 
Osteoblast differentiation 7 3.8E-4 
Cellular Component (n=30)   
Cell part 337 4.8E-3 
Cell 337 4.9E-3 
Intracellular  275 3.3E-5 
Intracellular membrane –bounded organelle  190 6.6E-2 
Transcription factor complex 10 4.2E-2 
Disease classification (n=1)   
Developmental 15 5.8E-3 
Table 4.4. A selection of GO terms associated with genes in Cluster002-SAOS2. Biological pathways 
were identified for 77.9% of genes and cellular component terms were identified for 82.9% of genes 
within the cluster. 
Cluster008 (192 nodes) and Cluster034 (35 nodes) showed the highest expression in the 
chondrocyte cell lines, TC28A2/C28I2 and C20A4 (Figure 4.6F and G), though they did 
not have any edges between them or any other analysed cluster. Both contained very few 
ECM associated genes, listed in Figure 4.6F and G. GO analyses of Cluster008 and 
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Gene Ontology  Number of Genes P-value  
Biological Pathway (n=30)   
Developmental process 28 6.2E-2 
Anatomical structure development 24 4.9E-2 
System development 22 6.5E-2 
Nervous system development 14 2.2E-2 
Regulation of signal transduction 11 5.6E-2 
Cellular component  (n=8)   
Intracellular part 82 4.1E-2 
Intracellular organelle 70 7.0E-2 
Organelle 70 7.2E-2 
Membrane bound organelle 63 8.0E-2 
Disease database (n=1)   
Cerebral infarct, atherothrombotic 2 6.7E-2 
Table 4.5. A selection of GO terms associated with genes in Cluster008-TC28A2/C28I2. Biological 
pathways were identified for 75.4% of genes and cellular component terms were identified for 89.3% 
of genes within the cluster.  
Gene Ontology  Number of Genes P-value  
Biological Pathway (n=13)    
Protein complex assembly 4 4.2E-2 
Intracellular transport  4 4.2E-2  
Dephosphorylation 3 2.4E-2 
Cellular component (n=10)   
Membrane part 17 3.0E-2 
Extracellular region part 5 6.8E-2 
Proteinaceous extracellular matrx 4 1.5E-2 
Extracellular matrix 4 1.8E-2 
Table 4.6. A selection of GO terms associated with genes in Cluster034-C20A4. Biological pathways 
were identified for 39.7% of genes and cellular component terms were identified for 45.9% of genes 
within the cluster.  
Cluster005 contained 308 nodes highly expressed in HEK293, with the majority of genes 
representing early differentiation, particularly of neuronal systems, and a small number of 
ECM related genes (Table 4.7) such as transcription factors homeobox D10 (HOXD10), 
homeobox D13 (HOXD13) and ECM protease ADAMTS13 (Figure 4.6E).  
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Gene Ontology  Number of Genes P-value  
Biological Pathway (n=131)   
Cellular process 145 4.5E-3 
Nervous system development 31 2.1E-5 
Embryonic development 16 4.3E-3 
Neurogenesis 16 7.1E-3 
Generation of neurons 16 3.7E-3 
Neuron differentiation 13 7.8E-3 
Cellular component (n=4)   
Ion channel complex 8 6.3E-3 
Cation channel complex 5 5.2E-2 
Cytosolic part 5 7.9E-2 
Microtubule associated complex 4 9.5E-2 
Disease classification (n=2)   
Psychiatric  11 9.0E-2 
Developmental  7 6.8E-2 
Table 4.7. A selection of GO terms associated with genes in Cluster005-HEK293. Biological pathways 
were identified for 74.4% of genes and cellular component terms were identified for 81.2% of genes 
within the cluster.  
 
4.5.2 Fibrillin-1 co-expression clusters    
The human Affymetrix microarray U219 platform contained five probesets for FBN1, all 
mapping to transcript NM_00138 (Chapter 3, Table 3.1). Four of the five clustered in 
the analysis. Cluster022 contained a total of 54 nodes, two of which were FBN1 
probesets, FBN1: 11720509_a_at and FBN1: 1175368_a_at. Cluster700 contained a total 
of 5 nodes, and had lower expression in comparison to Cluster022 (Figure 4.7 and 4.8). 
Two of the nodes were FBN1 probesets, FBN1: 11720507_at and FBN1: 11758093_s_at 
(Chapter 3, Table 3.1). 
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Figure 4.7. Plots of average expression profiles of genes in Cluster022, Cluster700 and Cluster704 
following analysis using BioLayout Express 3D (See Figure 4.5). Y axis shows the normalized intensity 
value. X axis shows the samples from which the RNA was extracted.  Characteristics of each cluster 
was determined using the class viewer tool in BioLayout Express 3D. (A) 54 nodes in Cluster022, (B) 5 
nodes in Cluster700, (C) 5 nodes in Cluster704. The bars depict the standard error of the mean.  
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Figure 4.8. Visualization of clusters containing FBN1 probes and related clusters. Cluster700, 
Cluster022, Cluster704 and Cluster004 were selected and reoriented for ease of interpretation from 
Section 4.5.1, Figure 4.5. FBN1 probesets are outlined in black.  
There were edges that directly connected Cluster022 to Cluster700 (Figure 4.8) including 
connections between nodes for fibrillin-1 probes, FBN1: 11758093_s_at (Cluster700) and 
FBN1: 1175368_a_at (Cluster022) (Figure 4.8). 
Cluster022, Cluster700 and Cluster704 had similar expression patterns (Figure 4.7), 
being high in NHDF, MG63 and C20A4 cell lines, that had been shown to have high 
levels of FBN1 mRNA and protein (Figures 4.1, 4.2, 4.3 and 4.4) and were located quite 
close to each other in the network (Figure 4.5). Cluster004 was the NHDF-specific 
cluster (Figure 4.6D), though it was highly correlated with Clusters022, 700 and 704 
(Figure 4.8). The co-expressed genes were down regulated in SAOS2, TC28A2, C28I2, 
THP1 and HEK293 cell lines. The edges (connections) between the clusters suggested 
that though the expression of both Cluster022 and Cluster700 varied slightly, they had a 
correlated expression pattern (Figure 4.7). Cluster022 and Cluster700 contained multiple 
genes with ECM function (Table 4.8). 
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Cluster Gene  Gene Name  Function / Disease Associated  
Cluster022    
 ARHGAP29 Rho GTPase activating 
protein 29 
Activator of cytoskeleton, RHO (OMIM: 
600582) / Cleft Lip (Leslie et al., 2012) 
 ASPH Aspartate beta-hydroxylase Post- translational modifier of proteins / 
Traboulsi syndrome (OMIM: 600582) 
 CAV1 Caveolin 1 Caveolae formation (OMIM: 601047) / 
Lipodystrophy  (OMIM: 612526, 606721) 
Pulmonary hypertension (OMIM:615343) 
 CAV2 Caveolin 2 Involved in adipose stabilisation (Scherer et 
al., 1996) / NA 
 COL6A3 Collagen, type VI, alpha 3 Extracellular matrix gene / Bethlem 
myopathy, Ullrich Congential muscular 
dystrophy (OMIM:120250) 
 KIAA1033  Actin polymerization / Wiskott-Aldrich 
Syndrome (Ropers et al., 2011) 
 LOX Lysyl oxidase ECM copper enzyme, crosslinking to 
collagen and elastin (Hamalainen et al., 
1991) / NA 
 MYOF Myoferlin  Calcium and phospholipid-binding protein 
(OMIM: 604604) / Muscular dystrophy and 




Heparan sulphate biosynthesis (Thompson 
et al., 2008) / NA 
 PXDN Peroxidasin homolog 
(Drosophila) 
ECM organisation (Horikoshi et al., 1999) / 
Corneal opacification and other ocular 
anomalies (MIM: 269400) 
 TWF1 Twinfilin actin-binding 
protein 1 
Actin binding gene (Bockhorn et al., 2013) 
/ NA 
Cluster700    
 ARRDC3 Arrestin domain containing 
3 
Implicated function in adipocyte 
differentiation and function (OMIM: 
612466) / Obesity implications (gender 
specific) (Patwari et al., 2011)  
 EPG5 Ectopic P-granules 
autophagy protein 5 
Regulation of Autophagy pathway (OMIM: 
615068)(He and Klionsky, 2009) / Vici 
disease (OMIM: 242840) 
Table 4.8. A selection of co-expressed genes in Cluster022 and Cluster700 from BioLayoutExpress3D. 
The gene functions and disease associations are listed. If the gene function or disease association are 
unknown, it is marked as NA.  
The majority of the genes in Clusters022 and 700 were associated with disease 
phenotypes that present with phenotypes also associated with fibrillin-1 and fibrillin-2 
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mutations (Chapter 1, Section 1.3.4 and 1.3.5). For example, CAV1 mutations are 
common in lipodystrophy (Chapter 3, Section 3.5.1), MYOF mutations cause severe 
cardiac abnormalities (Davis et al., 2000), ARHGAP29 mutations can cause craniofacial 
abnormalities (Leslie et al., 2012), and ASPH mutations can cause Tranoulsi syndrome, 
which presents with lens dislocation, craniofacial and segment formation abnormalities 
(MIM: 601552)(Table 4.8). The remainder of the identified genes have an association 
either directly (PXDN, COL6A3 and CAV1) or indirectly (LOX, NDST1 and TWF1) with 
the function or stabilisation of the ECM (Table 4.8). Cluster704 had the same average 
expression pattern as Cluster022 and was similar to Cluster700 (Figure 4.7). It contained 
a total of four genes (6 probes) of which two genes had ECM associations: COL3A1 
(collagen type 111, alpha 1) and SPARC. 
4.6 Discussion 
This chapter surveyed gene expression in human cell lines of mesenchymal origin. Both 
mRNA and protein levels were shown to be variable across the cell types, for a number 
of genes previously shown to co-express with Fbn1 in mouse cell types (Summers et al., 
2010)(Figure 4.1-4.4). Transcriptomic analysis of gene expression revealed that the cell 
lines were quite distinct, even those originating from the same primary cell type. A 
cluster of genes co-expressed with FBN1 was identified and these genes are discussed 
further below. 
Fibroblast cell line NHDF, MG63 osteosarcoma line and C20A4 chondrocyte line 
produced a vast and rich fibrillin-1 matrix (Figure 4.2-4.4) mimicking a phenotypically 
normal cellular system (Godfrey et al., 1990). Previous studies on the fibrillin-1 matrix in 
developing cartilage detected a loose network of fibrillin fibres in human foetal tissue as 
early as 20 weeks and this was maintained throughout adulthood within the 
perichondrium (Keene et al., 1997). The chondrocytes used in this study were retrieved 
form the costal cartilage of one patient aged 5 and the other 15 years (Goldring et al., 
1994). C20A4 maintained a more mesenchyme like cell phenotype by producing an 
extensive and organised fibrillin-1 matrix, while C28I2 and its subclone TC28A2 did not. 
Developing bone was represented by osteosarcoma lines MG63 and SAOS2. This study 
and others have shown that MG63 produces a fibrillin-1 matrix (Summers et al., 2009), 
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similar to primary human osteoblast fibrillin-1 matrices (Kitahama et al., 2000). In 
contrast, this study showed that SAOS2, considered to be a more mature bone cell type 
(Pautke et al., 2004), did not produce an extracellular fibrillin-1 matrix. Thus 
immortalised cells deriving from the same primary cell type (osteoblasts or chondrocytes) 
do not necessarily retain the ability to form fibrillin-1 microfibrils (Alberts B et al., 
2002). Previous work had shown that HEK293 cells do not produce a fibrillin-1 matrix 
(Summers et al., 2009), although these cells have been used to examine FBN1 gene 
expression and promoters (Guo et al., 2008)(Chapter 2, Section 2.1.4).  
 
4.6.1 Description of fibrillin-1 clusters  
The transcriptome-wide microarray analysis identified two clusters of genes co-expressed 
with FBN1, Cluster022 (32 genes) and Cluster700 (4 genes).  According to the GO terms, 
11 of the genes in Cluster022 (Table 4.8) were relevant to ECM maintenance and 
function or had been associated with connective tissue diseases presenting with similar 
phenotypes to those seen with FBN1 mutations (Section 4.5.2).  These ECM specific 
genes were found to be upregulated in MG63, NHDF and C20A4 cell lines, while 
expression levels remained low for SAOS2, TC28A2, C28I2, HEK293 and THP1.  
One Cluster022 gene was ARHGAP29, encoding a protein associated with the regulation 
of small GTP binding proteins, including Ras homology gene family member A (RhoA) 
(OMIM: 610496)(Saras et al., 1997). RhoA is a downstream effecter of TGFB signalling 
and involved in cytoskeleton remodelling (Kardassis et al., 2009). ARHGAP29 depletion 
in endothelial cell culture inhibited blood vessel lumen formation through increased 
RhoA expression and decreased integrin binding potential (Xu et al., 2011). Adhesion 
between endothelial cells and ECM was disrupted, associated with low levels of integrin 
activation and dissociation of the endothelium in developing blood vessels from the 
underlying mesenchymal cells. ARHGAP29 had been recently implicated in the 
development of cleft lip following mutation screening in over 1000 cases, consistent with 
the localization of gene expression to craniofacial structures in the mouse (Leslie et al., 
2012). Cleft lip and palate are not a feature of FBN1 mutation phenotypes, although facial 
dysmorphism is common, but have been reported for other connective tissue conditions 
Chapter 4. Fibrillin expression in human connective tissue cell types 
 110 
with disrupted TFGß signalling, such as TGFB3 mutation (Takahashi et al., 1987), and 
Loeys-Dietz syndrome (mutation in TGFBR1 or TGFBR2)(Tan et al., 2009, Loeys et al., 
2006, Okamura and Matsumoto, 1984) as well as some forms of Ehlers- Danlos 
syndrome (mutations in genes for collagen molecules and other connective tissue 
proteins).   
FBN1 was co-expressed with the two members of the caveolin gene family (CAV1 and 
CAV2) in Cluster022. FBN1 was also shown to co-express with CAV1 during 
adipogenesis as discussed in Chapter 3. CAV1 and CAV2 encode components of the 
caveolae, modified lipid rafts that form in membrane of multiple cell types including 
fibroblasts, adipocytes, endothelial and smooth muscle cells (Briand et al., 2011, Razani 
and Lisanti, 2001). CAV1 has been implicated in lipodystrophy, pulmonary hypertension 
and lipotrophic diabetes (OMIM: 612526)(OMIM: 615343) (Briand et al., 2011) and 
involved in TGFß signalling (Chapter 3, Section 3.5.1)(Chapter 1, Figure 1.5). This 
suggests that if CAV1 transcription is downregulated, TGFB levels will increase (Razani 
et al., 2001), similar to the effect of FBN1 mutation increasing active TGFß protein 
levels.  The co-expression analysis along with previously published research indicates 
that CAV1 and ARHGAP29 (through RhoA interactions) along with fibrillin-1 may play a 
vital role in maintaining TGFβ homeostasis, and further studies would be necessary to 
determine a co-functional mechanism of action for these genes.  
In addition to ARHGAP29 (discussed above), Cluster022 contained several other genes 
involved in maintaining cytoskeletal structural integrity. TWF1 binds to actin monomers 
that inhibit actin filament formation and KIAA1033 is involved in actin polymerisation 
through interactions with integrin molecules (Table 4.8). These two genes could control 
the balance of actin monomers (G-actin) and actin polymers (F-actin), thereby assisting 
in the maintenance of actin fibre formation in the cytoskeleton (Dominguez and Holmes, 
2011).  The maintenance of actin is vital to communication between the ECM and the 
cytoskeleton (Bockhorn et al., 2013, Ropers et al., 2011) (Chapter 1, Figure 1.3 and 
Section 1.2.6).  
COL6A3 was also co-expressed with fibrillin-1 within Cluster022. COL6A3 is a 
connective tissue gene, mainly expressed in cells/tissue of mesenchyme origin 
Chapter 4. Fibrillin expression in human connective tissue cell types 
 111 
(http://fantom.gsc.riken.jp/zenbu/). Mutations cause moderate to severe Bethlem 
myopathy and Ullrich congenital muscular dystrophy (OMIM: 120250)(Bushby et al., 
2014, Demir et al., 2002). Ullrich congenital muscular dystrophy is a connective tissue 
disorder that causes hyper-mobility, muscle weakness, joint contractures, and spinal 
defects (including scoliosis and rigid spine) leaving many patients immobile (OMIM: 
254090). Bethlem myopathy is a less severe phenotype presenting with similar but milder 
symptoms (OMIM: 158810). These connective tissue disorders mimic some aspects of 
the Marfan syndrome phenotype (Chapter 1, Section 1.3.4), reflecting the similar 
expression patterns of COL6A3 and FBN1 in Cluster022.  
Also present in Cluster022 was myoferlin (MYOF), a gene associated with skeletal and 
cardiac muscle development (OMIM: 604603) (Davis et al., 2000, Doherty et al., 2005) 
and more recently implicated in the regulation of epidermal growth factor receptors 
(EGFR) in breast cancer models (Turtoi et al., 2013). Demonbreun et al., (2009) 
demonstrated that Myof null mice were unresponsive to insulin-like growth factor-1 
(Igf1) stimulation, compared to the control mice which had a 25% increase in muscle 
fibre diameter when treated with myoferlin, suggesting that MYOF may be important in 
muscle growth and maintenance. Muscle weakness and change in muscle fibre integrity 
are seen in patients with Marfan syndrome (Behan et al., 2003), consistent with co-
expression of MYOF and FBN1.  
Two additional genes found within Cluster022 have known functions in maintaining 
collagen structure in the ECM. Lysyl oxidase (LOX) is involved in collagen crosslinking 
to collagen (Hamalainen et al., 1991), elastin to elastin (Chapter 1, Section 1.2.2) and 
peroxidasin (PXDN) is involved in collagen crosslinking to the ECM (Peterfi et al., 
2013). LOX was found in the same cluster as FBN1 in the previous analysis of gene 
expression in mouse cells (Summers et al., 2010). Another structurally important gene, 
NDST, is involved in heparan sulphate biosynthesis. Fibrillin-1 has heparan sulphate 
binding sites throughout the protein (Ritty et al., 2003, Tiedemann et al., 2001, Cain et 
al., 2005) and interruption of heparan sulphate binding has been associated with 
connective disease, such as Weill Marchesani Syndrome (Cain et al., 2012).  
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4.6.2 Transcriptomic characterisation of cell lines   
In conjunction with the results for specific genes and proteins, transcriptomic analysis 
showed that each cell line had a unique set of highly expressed genes. Cluster003, 
Cluster004, and Cluster034 contained genes highly expressed in the osteosarcoma cell 
line MG63, fibroblast cell line NHDF and chondrocyte cell line C20A4, respectively 
(Figure 4.6) and included many genes involved in ECM assembly and function or 
implicated in multiple connective tissue disorders (Section 4.5.1). All three of these cell 
lines showed high expression of FBN1 (Figure 4.1). Cluster004 displayed a different 
average expression pattern to the FBN1 specific clusters, though it was located close by 
(Figure 4.6 and 4.7). ACTA2 (OMIM: 102620) and TGFBR2 (OMIM: 190182) were 
located within Cluster004 and both have been implicated in thoracic aortic aneurysm 
leading to acute aortic dissections (TAAD), a common and lethal phenotype in Marfan 
syndrome patients (Guo et al., 2007, Pannu et al., 2005). In addition mutations in 
TGFBR2 have been identified in Loeys-Dietz syndrome, which shares many features with 
Marfan syndrome (Loeys et al., 2006, Pannu et al., 2005, Loeys et al., 2005, Mizuguchi 
et al., 2004).  The high expression of these genes in NHDF cells suggests that fibroblast 
cell types are of primary importance in establishing and maintaining aortic structure, and 
that it is the impact of FBN1 mutation on fibroblasts that contributes the high risk of 
aortic aneurysm (in the elastic medial layer) in Marfan syndrome patients. 
Multiple members of the ADAM metallopeptidase domain gene family were in 
Cluster003 and Cluster004. ADAM genes are transmembrane proteases, while ADAMTS 
genes are specific to ECM protease activity (Primakoff and Myles, 2000). ADAMTS2 
(OMIM: 604539) co-expressed with genes in Cluster004 and has been implicated in 
connective tissue disease Ehlers-Danlos syndrome type VII (Colige et al., 2004, Colige et 
al., 1999). ADAMTSL1 (OMIM: 609198), in Cluster003, encodes the ECM protein 
punctin found in skeletal muscle (Hirohata et al., 2002).  
Cluster004 had multiple members of the matrix metallopeptidase gene family including 
MMP10, MMP11, MMP19, MMP27 and MMP7. These genes are involved in degrading 
ECM proteins and are regulated by the tissue inhibitor of metalloproteinases (TIMP) gene 
family, (reviewed by (Primakoff and Myles, 2000)) of which TIMP3 was co-expressed 
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with Cluster004.  MMPs are thought to degrade fibrillin-1 and fibrillin-2 either before or 
after microfibril formation (Hindson et al., 1999). The co-expression of these genes in 
fibroblasts suggests possible mechanism that maintains fibrillin microfibril homeostasis.  
There were multiple fibulin genes in Cluster004 including FBLN1, FBLN12 and FBLN5. 
Recessive mutations in FBLN1 have been implicated in synpolydactyly (webbed fingers) 
and mutations in FBLN5 are implicated in cutis laxa (OMIM: 614434)(OMIM: 219100). 
Fibulins are ECM specific glycoproteins that bind to collagen and/or elastin (encoded by 
the ELN gene) (Argraves et al., 1989, Argraves et al., 1990, Xie et al., 2007). ELN and 
collagen-related genes COL21A1 and collagen binding protein gene, COL4A3BP were 
also found in Cluster004 and had the same expression pattern as the fibulin genes 
described above. Cluster004 also contained follistatin –like 1 (FSTL1), which had been 
previously identified in the Fbn1-associated cluster identified using in mouse cells 
(Summers et al., 2010). 
Similar to Cluster004, Cluster003 contained some genes involved in ECM maintenance, 
repair (ADAMSTL1 described above) and connective tissue disease including COL14A1, 
FGFR4, and LMNA. COL14A1 (OMIM: 120324) is an integral component of collagen 
fibrillogenesis, affecting formation of skin and collagenous tendons and recently 
implicated in myocardium formation (Ansorge et al., 2009, Tao et al., 2012).  Due to the 
nature of MG63 cells that lack the ability to form a calcified matrix, the upregulation of 
COL14A1 could indicate that they have a phenotype more closely resembling fibroblasts, 
consistent with the close proximity of the MG63 and NHDF clusters in the network 
layout (Figure 4.5).  
In addition, nuclear intermediate filament gene, LMNA (OMIM: 150330), was 
upregulated in the MG63 cell line. LMNA has been implicated in multiple biological 
pathways. For example, it has been found as a key component in adipocyte differentiation 
(Lloyd et al., 2002) and myotube formation and differentiation (Favreau et al., 2004, Ho 
et al., 2013), as well as inhibition of fibroblast proliferation through interactions with 
TGFβ1 (Van Berlo et al., 2005). The gene is involved in 10 connective diseases. Several 
diseases caused by LMNA mutations mimic similar phenotypes of fibrillin-1 and fibrillin-
2 associated diseases, such as Emery-Dreifuss muscular dystrophy (OMIM: 181350), 
Chapter 4. Fibrillin expression in human connective tissue cell types 
 114 
Hutchinson-Gilford progeria (OMIM: 176670), and restrictive dermopathy, lethal 
(OMIM: 275210). The disorders cause destructive phenotypes in multiple connective 
tissue systems including skeletal, cardiovascular, skin and cartilage formation. As 
discussed in Chapter 3, LMNA mutations are also associated with lipodystrophy 
(Capanni et al., 2005). 
Though Cluster034, which showed high expression in chondrocyte cell line C20A4, was 
noticeably smaller and more distant from the fibrillin-1 clusters in the network (Figure 
4.5), it contained some ECM specific genes such as FBLN7 and MTMR2 (Figure 4.6). 
FBLN7 is a fibulin gene required for tooth formation (de Vega et al., 2007), and the 
cluster was highly correlated with ECM related GO terms (Table 4.6) possibly relating to 
the collagen in the periodontal ligament that gives an association with tooth formation. 
Myotubularin- related protein 2 (MTMR2) is associated with one form of demyelinating 
neuropathy (Bolino et al., 2000) and is involved in production and function of normal 
myelin by Schwann cells, cells in the nervous system that support neurons. There has 
been evidence to suggest that chondrogenic activity supports the formation of 
epibranchial ganglia in the central nervous system (CNS)(Culbertson et al., 2011). The 
epibranchial ganglia transmit important signals to the CNS and are developed in early 
embryogenesis. Therefore, upregulation of MTMR2 in C20A4 cell lines could be 
suggestive of a role for cartilage in CNS development.  
In contrast to NHDF, C20A4 and MG63 there were five cell lines analysed that did not 
show high levels of FBN1 mRNA or fibrillin-1 protein expression (Figure 4.1 and 4.8). 
Human monocyte derived cell line, THP1, was expected to have very little or no fibrillin-
1 expression, which was verified following the BioLayout Express 3D overall clustering 
analysis (Figure 4.7). There was a high level of hematopoietic specific lineage markers, 
high incidence of DAVID determined GO terminology associated with immune/ defence 
response or T cell activation, and a large portion of genes associated with the THP1 
specific cluster were related to immune and infectious diseases (Table 4.1). The lack of 
ECM related genes and the distance to the fibrillin-1 specific clusters, indicates that 
THP1 is a good negative control. 
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Surprisingly, mineralising human osteosarcoma cell line SAOS2 did not express FBN1 
mRNA or develop a fibrillin-1 ECM, similar to human chondrocyte cell lines TC28A2 
and C28I2 (Figure 4.1, 4.3 and 4.4). The overall BioLayout Express 3D analysis showed 
that the SAOS2 specific cluster was more closely related to THP1 (Figure 4.5). The 
relationship between SAOS2 and THP1 could be related to the process of bone 
regeneration. SAOS2 contained multiple osteoblast markers such as IBSP, RUNX2 and 
PHOSPHO1 (Figure 4.6), while cancerous cell line THP1, by nature, is derived from 
precursor cells that can also create osteoclasts (Chapter 2, Section 2.1.5), cells 
responsible for the degradation of bone (Chapter 1, Section 1.1.4). The close expression 
profiles between these cell lines could represent the need of macrophages for osteoblasts 
to calcify (Chang et al., 2008). While both MG63 and SAOS2 human osteosarcoma cell 
lines were of mesenchyme origin, the expression of fibrillins varied between the two cell 
lines. As shown in Figure 4.1 and Figure 4.3, FBN1 mRNA was extremely low in 
SAOS2 cells, and there were no visible SAOS2 fibrillin-1 microfibrils, in comparison to 
the high levels of both mRNA and fibrillin-1 microfibrils in MG63. This is consistent 
with the observation in Chapter 3 that fibrillin 1 was associated with the less mature 
state during adipogenesis and disappeared as the lineage differentiated further. The lack 
of bone-associated GO terms for the MG63 cluster and its distance from SAOS2 in the 
network supports the concept that MG63 is a more immature (or dedifferentiated) cell 
line than SAOS2. 
The chondrocyte cell line TC28A2 and its derivative C28I2 (Cluster008) were in close 
proximity to the chondrocyte cell line C20A4 cluster (Cluster034), as shown in Figure 
4.5, though the lack of a fibrillin-1 matrix in TC28A2 and C28I2 (Figure 4.4) could 
suggest that they originated from an undiagnosed Marfan syndrome patient. As described 
previously (Section 4.1), C20A4 and TC28A2 were derived from the costal cartilage of 
patients undergoing corrective surgery for pectus excavatum (Goldring et al., 1994), a 
common symptom of Marfan syndrome (OMIM: 154700)(Summers et al., 2012). Pectus 
excavatum is described as a skeletal and cartilage deformity resulting in a hollow chest. 
The 5 year old male whose tissue yielded the cell line C20A4 may have had a sporadic 
deformity of pectus excavatum, while the donor of TC28A2 and subsequently C28I2 may 
have had Marfan syndrome with an undiagnosed FBN1 mutation, explaining the lack of a 
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fibrillin-1 ECM. Further experiments such as exon sequencing would be needed to 
confirm this.  
The human U219 microarray analysis revealed low levels of FBN1 mRNA expression in 
HEK293 cell line, consistent with past research (Summers et al., 2009, Guo et al., 2013, 
Wang et al., 2012)(Figure 4.7). BioLayout Express 3D analysis revealed that Cluster005 
contained genes that were highly upregulated in HEK293 (Figure 4.6). As described 
previously, there were a few ECM related genes in this HEK293 cluster, including 
ADAMTS16, HOXD10 and HOXD13. ADAMTS16 mutations are commonly associated 
with thrombotic thrombocytopenic purpura (MIM: 274150) a disorder involving mainly 
cells of neonatal epithelial origin, consistent with the derivation of HEK293 from human 
embryonic kidney. HOXD10 mutations have been implicated in a foot deformity, vertical 
congenital talus. It encodes a transcription factor linked to limb development (OMIM: 
192950). HOXD13, like HOXD10, is a transcription factor associated with limb 
development and mutations cause multiple forms of both brachydactyly and 
synpolydactyly (OMIM: 142989). HEK293 was not expected to have high expression of 
many ECM related genes, since it was derived from embryonic epithelial cells. This is 
consistent with genes found in the cluster to be associated with the GO term embryonic 
development (Table 4.7). In addition, the DAVID GO term analysis produced several 
differential terms including nervous system development, neurogenesis, generation of 
neurons and neuron differentiation.  A previous study suggested that HEK293 may have 
had a neuronal origin (Shaw et al., 2002) which is supported by the presence of genes 
associated with these GO terms.  
 
4.6.3 Limitations of cell line expression studies  
This chapter demonstrated the expression patterns of the fibrillin gene family across a 
variety of connective tissue cell lines. Future expression arrays on primary cell types 
would need to be performed to validate the cell line findings outlined above.  
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4.7 Conclusions  
Given the severe multisystem phenotype associated with FBN1 mutations it was possible 
that fibrillin-1 was a central regulator of ECM formation. The analysis presented in this 
chapter showed that many ECM and cytoskeletal genes were co-regulated with FBN1. 
The co-expression of these genes implies possible co-operative functions between the 
ECM, cytoskeleton genes and fibrillin-1 in maintaining ECM homeostasis in C20A4 
(chondrocyte cell line), MG63 (osteosarcoma cell line) and NHDFs (fibroblast primary 
line).  
Therefore it was important to investigate whether fibrillin-1 controlled expression of any 
of these above defined genes. Based on the high expression of many ECM related genes 
including FBN1 and association with ECM related GO terms, NHDF, C20A4 and MG63 
were chosen for further studies.  
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Chapter 5. Investigating the functional role of fibrillin-1 in cell 
lines 
5.1 Introduction 
As discussed in Chapter 1 (Section 1.3.4) and Chapter 4 (Section 4.1), mutations in 
FBN1 cause major multisystemic phenotypic effects in humans, natural animal models 
and engineered mouse models. These include abnormalities in the bone, cartilage, 
adipose and skin formation. The study presented in Chapter 3 demonstrated that 
fibrillin-1 protein was present in mesenchymal stem cells but declined rapidly when these 
cells were directed towards adipogenesis. The findings suggest that fibrillin-1 may be a 
regulator in mesenchyme type cells, as has been proposed previously (Summers et al., 
2010). In Chapter 4, it was shown that C20A4 (chondrocyte), NHDF (neonatal 
fibroblast) and MG63 (osteosarcoma) cell lines produced a vast fibrillin-1 matrix and 
showed high levels of FBN1 expression, co-expressed with genes implicated in ECM and 
cytoskeleton maintenance. These three cells lines were therefore chosen for a preliminary 
investigation of the effect of reducing FBN1 using gene silencing by RNA interference 
(RNAi). Knocking down FBN1 in these cells was expected to simulate the phenotype of 
MFS patients in vitro and therefore reveal genetic interactions important to the phenotype 
in this disease.  Microarray analysis of RNA levels and ICC techniques using fluorescent 
tags for both fibrillin-1 and actin polymers were used to examine the effect on gene 
transcription and cell morphology of reducing the level of FBN1 mRNA and hence 
fibrillin-1 protein.  
RNAi is a technique for post-transcriptional gene silencing, shown to be effective in 
mammalian cells (Elbashir et al., 2001). It involves introducing a double stranded RNA 
(dsRNA) that contains a sequence homologous to the targeted gene into the cells (Figure 
5.1A). The dsRNA is cleaved within the cell into small interfering RNA (siRNA) and the 
antisense strand is integrated into the RNA induced silencing complex (RISC). The 
complex is recruited to the sense strand of the targeted mRNA, interfering with 
translation and causing premature degradation of the mRNA.  The gene is therefore said 
to be silenced (Figure 5.1B)(Birmingham et al., 2006, Anderson et al., 2008).  This 
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process of reducing gene expression through inactivation of the mRNA has been termed 
“knockdown” (KD)(Figure 5.1). 
 
Figure 5.1. Gene knockdown (KD) mechanism using RNAi. (A) The overall structure of the siRNA 
duplex. The siRNA is constructed from the homologous sequence of the targeted gene to include both 
a 5’ and 3’ overhang. (B) Knockdown of gene expression. The dsRNA (siRNA) is unwound and the 
antisense strand is incorporated into the RISC (RNA induced silencing complex), initiating binding 
to the target mRNA strand and causing mRNA degradation. The passenger (sense) strand of the 
dsRNA is degraded. Image adapted from (Clark and Whitelaw, 2003).  
Several studies have used this RNAi technique to examine the relationship between ECM 
molecules. For example, Choudhury et al., (2009) used RNAi to study the role of ECM 
gene FBLN4 (fibulin-4). They reduced FLBN4 mRNA expression by 70% in a retinal 
pigmented epithelial cell line (ARPE19) and saw an increase in desmosine, a biomarker 
of elastin degradation (Choudhury et al., 2009). Similar knockdown studies on FBLN4 in 
neonatal foreskin fibroblasts (NHDF) showed that fibulin-4, considered a structural 
protein, also has a regulatory role and controls levels of tropoelastin via ELN (elastin) 
gene expression (Chen et al., 2009). Knockdown studies of MFAP4 (microfibril 
associated protein-4) in human dermal cell culture demonstrated that this protein could 
regulate levels of FBN1 and MMP1 (matrix metalloproteinase, a collagenase of the ECM) 
mRNA (Kasamatsu et al., 2012)(Chapter 3, Section 3.5.3). Furthermore, knockdown 
studies have been used to better understand the function of fibrillin-1 and fibronectin in 
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fibroblast cell cultures. Kinsey et al., (2008) used RNAi to deplete FN1 mRNA levels, 
showing little to no effect on FBN1 mRNA expression. However, protein analysis 
performed on the KD samples showed a major depletion in fibrillin-1 microfibril 
formation.  
5.1.1. Aims of the Chapter  
In this chapter, the functions of FBN1 were explored by using RNAi techniques to reduce 
the amount of FBN1 mRNA and hence protein in the three cell lines with normally high 
levels of fibrillin-1, NHDF, MG63 and C20A4. The aim was to understand the 
interactions of fibrillin-1 with other ECM related genes in mesenchyme derived cells. 
Following the reduction of FBN1 mRNA, gene and protein expression patterns as well as 
cell morphology were analysed to determine any downstream effects of fibrillin-1.  
 
5.2 Materials and Methods 
5.2.1 Transfection efficiency  
Initially transfection efficiency was tested using Lipofectamine 2000 reagent (Invitrogen) 
and transfection indicator reagent siGLO (Thermo Scientific). EtOH treated glass cover 
slips (1.3mm, sterile, sonicated)(kindly supplied by Dr. Mark Barnett) were placed into 
three wells of a 24 well plate (NUNC), and allowed to air dry in a sterile hood. Once 
dried, the wells (with coverslips) were coated with 0.1% gelatin for 5 minutes. NHDF 
cells were seeded at 60% confluence (40,000 cells/well of a 24 well plate) and cultured 
overnight in normal media conditions (Chapter 2, Section 2.2).  
20µM siGLO (Thermo Scientific) was added to Opti-MEM 1x (Gibco) media for a final 
concentration of 1µM and incubated for 5 minutes. Simultaneously, Lipofectamine 2000 
reagent (Invitrogen) was added to Opti-MEM 1x  (at 1:10) and incubated for 5 minutes. 
The siGlo and Lipofectamine solutions were combined and incubated for 25 minutes at 
room temperature. DMEM + 10%FBS was added for a final concentration of 
siGlo/lipofectamine mixture of 90nM. 200µl of this solution was added to each well of 
the 24 well plate which was then placed at 37°C and 5% CO2 for 5 hours. The 
transfection mix was removed and cells were incubated at 37°C in 5% CO2 for 24 hours. 
The glass slides were fixed with 4% PFA for 20 minutes, washed 4 x for 5 minutes with 
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PBS, removed and mounted with Prolong GOLD + DAPI (Invitrogen) on Superfrost 
glass slides (Fischer Scientific). Samples were viewed using Zeiss LSM 710 confocal 
microscope and analyzed with ZEN software at standard settings (Zeiss)(Figure 5.2).  
 
Figure 5.2. Transfection efficiency of Lipofectamine 2000 in NHDF cells. The image depicts the 
siGLO (red) tranfection indicator in NHDF cells. The nuclei are shown blue. The image was taken at 
20x using a Zeiss confocal microscope (Section 5.2.1). The scale bar represents 50µm. The 
transfection efficiency was estimated at 90%. 
 
5.2.2 FBN1  knockdown with siRNA 
MG63, C20A4 and NHDF cells were plated at 60% confluence: 10,000 cells/well in 8 
well chamber slides (Thermo Scientific) which would be used later for ICC, and 60,000 
per well in 6 well plates (NUNC) which would be used for RNA extraction, and cultured 
for 24 hours in conditions outlined in Chapter 2, Section 2.2. After 24 hours, the cells 
were checked using the inverted light microscope for 85-95% confluence. A 20µM 
working stock solutions was made of siGENOME SMART pool Human FBN1 siRNA 
(Thermo Scientific) and siGENOME SMARTpool non-targeting reagent (Thermo 
Scientific) and stored at -20°C. The siGENOME Human FBN1 siRNA SMART pool 
consists of four individual double-stranded RNA duplexes, D-011034-04, D-011034-03, 
D-011034-02 and D-011034-01 (Table 5.1) that are designed to target different regions 
of FBN1 mRNA to silence gene expression (Table 5.1). Experiments were performed 
using all 4 duplexes targeting four regions.  
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Target Name Target Sequence 5’-3’ Location of targeted sequence in 
FBN1 
D-011034-01 CCAGAUAUGUCCUUAUGGA Exon 52 
D-011034-02 GAAUGAAGAUACACGAGUG Exon 40 
D-011034-03 AUACAACACUGCAAUAUUC Exon 5 
D-011034-04 CGAAUGAGCUACUGUUAUG Exon 51 
Table 5.1. FBN1 SMARTpool siRNA targets.  
20µM siRNA targeting human FBN1 mRNA (and non-targeting control) was added to 
Opti-MEM 1x media (final concentration of 2.5µM) and incubated for 5 minutes. 
Simultaneously, Lipofectamine 2000 was prepared and transfections were performed as 
described above (Section 5.2.1). The siRNA reagent and Lipofectamine solutions were 
combined and incubated for 25 minutes at room temperature. DMEM + 10%FBS was 
added for a final concentration of 50nM (and both 50nM and 90nM for NHDF) of both 
the siRNA human FBN1 and siRNA non-targeting control. 100µl of the appropriate 
transfection mix was added to a well of the 8 well chamber slides, and 200µl to a well of 
the 6 well plates and incubated as described in Section 5.2.1 (Figure 5.3).  
 
Figure 5.3. A schematic illustrating the experimental timeline and treatments used. The experiment 
was done using the following cells, MG63, C20A4 and NHDF. RNA was collected at all the timepoints 
shown (Chapter 2, Section 2.3.1), for all three treatments. ICC fluorescent staining (Section 5.2.4) 
was done at Day 4 and Day 7 for all cell types undergoing all three treatments.    
The transfection reagent was removed from the well and replaced with normal culture 
media (Chapter 2, Section 2.2) and the cells were incubated until RNA extraction. RNA 
was extracted (Chapter 2, Section 2.3.1) at Day 1, Day 2, Day 3, Day 4 and Day 7 
(Figure 5.3). RNA was also extracted from all cell types immediately prior to 
transfection, 24 hours after plating, (Day 0) and prior to culture in the 6 well plates (Day -
1) (Figure 5.3). Two controls were included. Firstly, the non-targeting siGENOME 
SMARTpool (Invitrogen) was used at 50nM with Lipofectamine. Secondly, parallel cell 
cultures remaining in normal culture media throughout the time course were included. 
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RNA was collected for both controls as outlined above (Figure 5.3).  FBN1 knockdown 
experiments (50nM FBN1 SMARTpool) were replicated for RNA extraction as follows, 
NHDF n=2, MG63 n=1 and C20A4 n=1.  
5.2.3 qPCR 
mRNA expression levels were quantified using qPCR techniques previously described in 
Section 2.3.4 of Chapter 2. Statistical significance was calculated by using a standard 
student two-sample t-test. The analysis used the mean ∆CT of the technical replicates 
(Chapter 2, Section 2.3.4.1), comparing for example Day 1 NT values to Day 1 FBN1 
knock down (FBN1KD) values.  
5.2.4 ICC 
The fibrillin-1 fluorescent staining was carried out as described in Section 2.4.2 of 
Chapter 2. ICC experiments were repeated at n=2. 
5.2.4.1 Actin Staining  
MG63, NHDF and C20A4 cells cultured in 8 well chamber slides  (Chapter 2, Section 
2.2) were fixed through the timecourse (Figure 5.3) with 4% PFA for 10 minutes then 
washed 3 x for 5 minute with PBS. Fixed cells were permeabilized with 0.1% Triton X-
100 (Sigma-Aldrich) in PBS for 20 minutes at room temperature then washed 3 x for 5 
minutes and blocked with 1% BSA in PBS for 1.5 hours at room temperature. 40x Texas 
Red X- Phallodin (Invitrogen) was added to the cells for 30 minutes at room temperature. 
The cells were then washed with PBS, and mounted with ProGold + DAPI (Invitrogen). 
Samples were viewed using Zeiss LSM 710 confocal microscope and analyzed with ZEN 
software at standard settings (Zeiss). 
5.2.5 BioLayout Express 3D 
Gene expression levels in RNA samples were determined using the U219 human 
microarray platform (Chapter 2, Section 2.3.5) for FBN1KD, normal media (control) 
and non-targeting siRNA (NT control) at Day -1, Day 0, Day 1, Day 2, Day 3, Day 4 and 
Day 7 for MG63, C20A4 and NHDF samples (Chapter 9, Appendix B). Probes were 
removed from the data set that had expression intensity values under 16 (Chapter 2, 
Section 2.3.6), removing 12, 811 of the low expressing probes, including the FBN3 probe 
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(25.6%). Intensity results for the remaining 36,574 probeset were loaded into BioLayout 
Express 3D. The clustering analysis was run at r ≥ 0.87 at an MCL inflation value of 2.2, 
producing 951 clusters (Chapter 2, Section 2.3.6).  
Fold change of expression was determined using the U219 microarray expression values 
obtained from BioLayout Express3D . The average expression of all the probes within a 
cluster at a specific time point was obtained. The ratio between the NT control and 
FBN1KD treated sample was used to demonstrate difference in expression between the 
two samples. A fold change of >1.5 (upregulated) or < -1.5 (downregulated) was 
considered to show differential gene expression. 
 
5.2.6 GO terms 
The gene list for large Cluster002 (Section 5.3.3) was placed into the upload tool bar of 
DAVID 6.7 functional annotation tool (www.david.abcc.ncifcrf.gov/)(Chapter 2, 
Section 2.3.6).  
5.3 Results 
5.3.1 siRNA reduced FBN1 mRNA levels in cell lines 
Initial transfection efficiency was calculated at 90% using siGLO and Lipofectamine 
2000 reagents (Section 5.2.1). Therefore, FBN1 knockdown studies were performed on 
chondrocyte cell line (C20A4), fibroblasts (NHDF), and osteosarcoma cell line (MG63). 
The RNAi construct was introduced into the cells 24 hours after plating (D0)(Figure 
5.3). qPCR analysis at specific time points throughout the timecourse was used to 
determine if the levels of FBN1 had been depleted compared with both the NT control 
and normal media control samples (Figure 5.4).  
There was an estimated 83% knockdown when comparing Day 1 FBN1 knockdown and 
NT samples in C20A4 cells. The results of the qPCR analysis of FBN1 mRNA in C20A4 
cells are shown in Figure 5.4A. While control and NT samples maintained relatively high 
levels of FBN1 mRNA, with a peak at Day 4, the FBN1 knockdown samples revealed a 
decrease in FBN1 mRNA expression at Day 4 and Day 7. In addition, the Day 7 
FBN1KD sample was significantly lower (p = 0.009) than Day 7 NT control in this cell 
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line (Table 5.2). The results demonstrated that FBN1 mRNA levels had been reduced by 
the siRNA transfection. Based on similar nucleotide and amino acid sequences of FBN1 
and FBN2 (http://www.ensemble.org; see Chapter 7), off-target effects would most 
likely have affected fibrillin-2. qPCR analysis showed that even within the FBN1 
knockdown samples, FBN2 mRNA levels remained relatively unchanged, demonstrating 
that FBN2 expression was not altered in the FBN1 knockdown system (Figure 5.4B). 
Furthermore there was no statistically significant variation calculated (p ≤ 0.1) between 
the NT control and FBN1KD samples for FBN2 expression.    
As for C20A4, FBN1 mRNA decreased after siRNA treatment of MG63 cells (Figure 
5.4C). Day 1 of the knockdowns was the most affected (approximately 51% decrease 
when comparing knockdown and NT samples), with FBN1 levels increasing at Day 2 and 
remaining static at Day 3 and Day 7, different to the control and NT control samples (p ≤ 
0.1)(Figure 5.4C)(Table 5.2). Though expression levels varied between the control and 
NT control samples, the FBN1 knockdown samples showed a consistent decrease in 
FBN1 expression to less than half that in untreated cells. FBN2 expression showed no 
significant differences across the control, NT control and FBN1KD sample time courses, 
though it did show a non significant increase of expression at Day 3 in the FBN1 
knockdowns (p ≤ 0.1)(Figure 5.4D). 
 The impact of the FBN1 siRNA treatment was most obvious in the fibroblast cells, 
NHDF (Figure 5.4E). FBN1 levels decreased in the knockdown samples at Day 1 by 
approximately 82% and the expression pattern across the knockdowns shows that FBN1 
mRNA level remained low throughout the timecourse when compared to both the control 
and NT control samples (Figure 5.4E). A two-sample t-test analysis comparing the NT 
control and FBN1KD samples showed statistical significance in the reduction of FBN1 
(Table 5.2). FBN2 mRNA expression was unaffected in the FBN1 knockdowns (p ≤ 
0.1)(Figure 5.4F).   
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Figure 5.4. qPCR results for FBN1 (A, C and E) and FBN2 (B, D and F) expression in C20A4 (A and 
B), MG63 (C and D) and NHDF (E and F) cells after FBN1 knockdown. The y-axis represents the 
expression values calculated by advanced relative quantification, Target/Reference ratio 
(LightCycler480, ROCHE, Chapter 2, Section 2.3.4). The reference was human GAPDH (Qiagen). 
Control samples were left untreated, +NT samples were treated with non-targeting (NT) siRNA and 
–FBN1 samples were treated with siRNA human FBN1 SMARTpool(Thermo Scientific). Day 1 
describes samples 24 hours after transfection (Figure 5.3). (A and B: Day 3 was omitted from qPCR 
analysis due to low total RNA yield, C and D: Day 4 was omitted from qPCR analysis due to low 
RNA yield.) The * over the FBN1KD samples depicts statistical significance p≤0.01 using a standard 
two sample student t-test, compared with the NT control sample at that specific time point (Section 
5.2.5)(Table 5.2).  
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Comparison  P-value  
C20A4   
Day 7 NT control and Day 7 FBN1KD 0.0099 
NHDF  
Day 1 NT control and Day 1 FBN1KD 0.007 
Day 2 NT control and Day 2 FBN1KD 0.0002 
Day 3 NT control and Day 3 FBN1KD 0.001 
Day 4 NT control and Day 4 FBN1KD 0.0152 
Table 5.2. Values of statistically significant qPCR results for FBN1KD experiments (Figure 5.4). The 
samples not shown in the above table were found to not be statistically significant (p ≤ 0.05).  
5.3.2 FBN1 mRNA knockdown reduces fibrillin-1 protein expression 
Fluorescent staining of fibrillin-1 and Texas Red X- phallodin (phallodin) staining of F-
actin molecules was done on C20A4, NHDF and MG63 cultures at Day 4 and Day 7 
(Section 5.2.4). The time points for fibrillin-1 staining were chosen because the control 
samples revealed that a fibrillin-1 matrix was visible by Day 4 after plating (Chapter 4, 
Section 4.4.2). 
The beginnings of a rich fibrillin-1 matrix were seen in the control and NT control 
samples of C20A4 cells at Day 4, while there appears to be very little production of 
fibrillin-1 microfibrils in the FBN1KD (-FBN1) samples (Figure 5.5). This was 
consistent with the reduced levels of FBN1 mRNA at early time points (Figure 5.4A). 
Phallodin staining at Day 4 showed some indication of a disruption in actin fibre 
formation in the fibrillin-1 knockdowns where the actin fibres appear less organised and 
slightly degraded compared with controls (Figure 5.5). There was also a reduction in 
actin fibres in the NT control, possibly related to the established reduction in proliferation 
induced by Lipofectamine20002. 
At Day 7 after fibrillin-1 knockdown, microfibrils had developed in the FBN1KD 
cultures (Figure 5.5). The fibres resemble those seen in the Day 4 control samples of 
C20A4 cells, suggesting that the cells were recovering from the effects of the siRNA. 
                                                
2 Personal communication with Dr. Mark Barnett, The Roslin Institute, University of Edinburgh  
Chapter 5. Investigating the functional role of fibrillin-1 in cell lines 
 128 
Interestingly, the phallodin staining shows that the cytoskeletal actin had regained the 
organisation seen in the controls at Day 7 (Figure 5.5, lower panel).  
 
Figure 5.5. C20A4 cultures at Day 4 and Day 7. The green staining (upper panels) shows fibrillin-
1detected with a monoclonal antibody (n=3)(Chapter 2, Section 2.4.2), imaged at 40x and the red 
staining (lower panels) shows cytoskeletal actin detected with Texas Red X-phalloidin (Section 
5.2.4.1)(n=2), imaged at 63x. The white arrows depict specific actin fibres (see above text). The blue 
depicts DAPI stained nuclei. The fibrillin-1 and phalloidin stained images were captured using a 
Zeiss confocal microscope and images were adjusted using Zeiss software. The scale bars represent 
20µm, n=2. 
The beginnings of a rich fibrillin-1 matrix were visible at Day 4 in MG63 control and NT 
control samples, while there was no fibrillin-1 matrix in the FBN1 knockdowns (Figure 
5.6). The phallodin staining showed organised intracellular actin formation in the 
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controls. However, the actin staining in the FBN1 knockdowns revealed disruptions in the 
actin fibres (Figure 5.6).  
An extensive fibrillin-1 matrix was seen at Day 7 in MG63 control and NT control 
samples, while there were few fibrillin-1 microfibrils in the knockdown sample indicating 
that the cells had not recovered from the siRNA treatment (Figure 5.6). The staining that 
was seen could be evidence of early fibrillin-1 matrix formation. The phallodin staining 
of cytoskeleton actin showed that the actin fibres were beginning to form the structures 
seen in the controls of both Day 4 and Day 7 and the intensity of the actin fibre stain had 
increased since Day 4 (Figure 5.6, lower panel).  
 
Figure 5.6. MG63 cultures at Day 4 and Day 7. The green staining (upper panels) shows fibrillin-
1detected with a monoclonal antibody (Chapter 2, Section 2.4.2), imaged at 40x and the red staining 
(lower panels) shows cytoskeletal actin detected with Texas Red X phalloidin (Section 5.2.4.1), 
imaged at 63x. The white arrows depict specific actin fibres (see above text). The blue depicts DAPI 
stained nuclei. The fibrillin-1 and phalloidin stained images were captured using a Zeiss confocal 
microscope and images were adjusted using Zeiss software. The scale bars represent 20µm, n=2. 
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The initiation of a fibrillin-1 microfibril matrix was seen in the control NHDF samples at 
Day 4, while no visible fibrillin-1 matrix was detected in the knockdowns (Figure 5.7). 
The phallodin staining of cytoskeletal actin showed a highly organised, linear and rich 
actin fibre composition in NHDF control cells, while in the fibrillin-1 knockdown 
samples the actin fibres appeared less linear, and showed increased intensity when 
compared to the controls (Figure 5.7).  
The fibrillin-1 results of Day 7 show the controls had developed dense fibrillin-1 
microfibrils (Figure 5.7) as seen in Chapter 4. However, the fibrillin-1 matrix of the 
knockdown samples appeared scarce and fragmented.  
 
Figure 5.7. NHDF cultures at Day 4 and Day 7. The green staining (upper panels) shows fibrillin-1 
detected with a monoclonal antibody (Chapter 2, Section 2.4.2), imaged at 40x and the red staining 
(lower panels) shows cytoskeletal actin detected with Texas Red X phalloidin (Section 5.2.4.1), 
imaged at 63x. The blue depicts DAPI stained nuclei. The fibrillin-1 and phalloidin stained images 
were captured using a Zeiss confocal microscope and images were adjusted using Zeiss software. The 
scale bars represent 20µm. n=2. 
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5.3.3 General gene expression analysis of fibrillin-1 
knockdowns  
The BioLayout Express 3D analysis of U219 microarray data (See Section 5.2.5) collected 
from NHDF, C20A4 and MG63 knockdown timecourse experiments at r ≥ 0.87 had a 
total of 19,363 nodes and 784,011 edges (Figure 5.8). FBN1 probsets did not cluster with 
any other genes (Figure 5.8) and nor did FBN2. The fibrillin-1 cluster (Cluster 763) 
contained only four fibrillin-1 probes (11731230_a_at, 11736217_at, 11745470_x_at and 
11746201_a_at). Cluster002 contained probesets for genes that were highly mesenchyme 
specific.   
 
 
Figure 5.8. Network visualization and clustering of the NHDF, C20A4 and MG63 transcriptomes.  
The image depicts the network diagram produced by BioLayout Express 3D using data from the 
Affymetrix U219 gene expression microarray platform on knockdown experiments across Day -1, 
Day 0, Day 1, Day 2, Day 3, Day 4 and Day 7. Spheres (nodes) represent individual probesets and the 
lines between them (edges) show correlations in expression pattern of r ≥ 0.87. The nodes were 
clustered using an MCL inflation value 2.2 (Chapter 2, Section 2.3.6). The background of the image 
displays the whole network and clusters discussed in the text are highlighted. Cluster002 was the 
largest mesenchyme specific cluster and Cluster763 contained FBN1 probes.  
Cluster763 revealed distinct expression of FBN1 throughout the timecourses, not 
surprising given the artificial manipulation of the FBN1 mRNA (Figure 5.9). No other 
gene had the same expression pattern, suggesting that there were no off target effects. 
The control and NT control time course samples for NHDF, C20A4 and MG63 showed 
varying but high levels of FBN1 expression across the time course with slight down 
regulation of FBN1 at Day 1 and Day 2 of C20A4 (Figure 5.9). FBN1 expression levels 
within the FBN1 knockdown timecourse showed steady downregulation of the gene 
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across all time points in the NHDF, for both replicates, while gradually increasing in 
expression levels within MG63 and C20A4 (Figure 5.9), similar to the initial qPCR 
results (Figure 5.4) The fold change comparing the NT control and FBN1KD expression 
intensity values are shown in Table 5.3. 
 
Figure 5.9. Plots of average expression profiles of genes in Cluster763 following analysis using 
BioLayout Express 3D (See Figure 5.8). Y axis shows the normalised intensity value. X axis shows the 
samples from which the RNA was extracted.  Characteristics of the cluster were determined using 
the class viewer tool in BioLayout Express 3D and plots were created in Microsoft Excel. Cluster763 
contained only the FBN1 gene probes.  
Sample C20A4 MG63 NHDF 
Day 1 NT &FBN1KD 2.54 3.6 3.70 
Day 2 NT &FBN1KD 1.16 4.98 6.97 
Day 3 NT &FBN1KD 2.97 2.85 4.59 
Day 4 NT &FBN1KD 2.29 2.02 6.47 
Day 7 NT &FBN1KD 1.65 1.81 3.08 
Table 5.3. The calculated fold change (Section 5.2.5) of the expression values obtained from the U219 
microarray data. Fold change over 1.5 was considered a differential change in gene expression. 
In total, Cluster002 consisted of 1593 nodes (888 unique genes) and 194,428 edges, and 
showed similar expression patterns across the timecourses in all three systems, with the 
highest expression in NHDF (Figure 5.10). Cluster002 contained multiple ECM related 
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genes as well as mesenchyme specific markers. Many ECM cellular component GO 
terms were associated with Cluster 002 (Table 5.4). 
GO terms  Gene count  % of Cluster P value  
Cellular component     
Extracellular region 136 15.3% 6.4E-6 
Extracellular region part 91 10.2% 1.4E-10 
Extracellular space 53 6% 4.04E-4 
Extracellular matrix  48 5.4% 3.9E-11 
Table 5.4. A selection GO terms associated with genes in Cluster002. 86.4% of Cluster002 genes were 
included in the analysis.  
The cluster contained genes that previously co-expressed with FBN1 in the static samples 
(Chapter 3 and Chapter 4) including CAV1 (caveolin 1), CAV2 (caveolin 2), LOX (lysyl 
oxidase) and MYOF (myoferlin), though these genes remained unchanged in the FBN1 
knockdowns. In addition, Cluster002 had several mesenchyme specific genes (ECM 
related terms) such as COL1A1 (collagen type 1 alpha), DCN (decorin), three fibulin 
genes FBLN1, FBLN2, FBLN5, LTBP2, TGFBR3 and TGFBR2. 
 
Figure 5.10. Plots of average expression profiles of genes in Cluster002 following analysis using 
BioLayout Express 3D (See Figure 5.8). Y axis shows the normalised intensity value. X axis shows the 
samples from which the RNA was extracted.  Characteristics of the cluster were determined using 
the class viewer tool in BioLayout Express 3D and plots were created in Microsoft Excel. Cluster002 
contained 888 genes.  
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There was no clear effect of FBN1 knockdown based on the average expression patterns 
of Cluster002 (Figure 5.10). However, after observing individual probe expression 
patterns in Cluster002, 19 genes showed upregulation in the FBN1KD NHDF cultures, 
although there were no obvious expression changes in the C20A4 or MG63 timecourse 
experiments (Figure 5.11)(Figure 5.12)(Table 5.5). The genes with this expression 
pattern were localised throughout the cluster (Figure 5.11). The upregulated genes from 
Cluster002 will be referred to as subcluster002 for the remainder of the thesis.  
 
Figure 5.11. A zoomed in view of cluster002 (see Figure 5.8). (A) Three dimensional image, (B) Two-
dimensional image. Purple nodes display expression patterns consistent with the average pattern seen 
in Figure 5.10, and the blue nodes show subcluster002. The expression pattern of subcluster002 is 
shown in Figure 5.12.  
 
Figure 5.12. Plots of average expression profiles of genes in subcluster002 (See Figure 5.11). Y axis 
shows the normalised intensity value. X axis shows the samples from which the RNA was extracted.  
Characteristics of the cluster were determined using the class viewer tool in BioLayout Express 3D 
and plots were created in Microsoft Excel. Subcluster002 contained 19 genes.  
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Gene  Gene Name  Function/Disease Association  
ACTA2 Actin, alpha-2, smooth muscle, aorta  OMIM:102620  
ACTG2 Actin, gamma-2, smooth muscle, enteric OMIM:102545 
ACTR1B Actin related protein, 1B OMIM:605144  
ADAM23 A disintegrin and metalloproteinase 
domain 23 
OMIM:603710  
AGTR1 Angiotensin receptor 1 OMIM:106165  
ANGPT1 Angiopoietin 1 OMIM:601667  
CAPN2 Calpain OMIM:114230  
CCDC81 coiled-coil domain containing 81 Strausberg et al., 2002 
CLND22 Claudin 22 Heiskala et al., 2001 
CNN1 Calponin 1  OMIM:600806 
FLT FMA-related tyrosine kinase  OMIM:165070 
GNA14 Guanine nucleotide binding protein, alpha 
14 
OMIM:604397 
GNAI1 Guanine nucleotide binding protein, alpha 
inhibiting activity polypeptide 1 
OMIM:139310 
IGF2 Insulin like growth factor-2 OMIM:147470  
MAMDC2  Mam domain- containing 2 OMIM:612879 
NEXN Nexilin OMIM: 613121  
OPN3 Opsin,3  OMIM: 606695  
PARVA Parvin alpha  OMIM: 608120  
STMN2 Stathmin- like 2 OMIM: 600621  
Table 5.5. Genes showing upregulated expression in Cluster002, forming subcluster002.  
Subcluster002 showed an increase of expression at Day 3 (average fold change:1.5) , Day 
4 (average fold change 1.6) and Day 7 (average fold change: 1.32) in NHDF cells, though 
these genes were unaltered in C20A4 and MG63 cell lines (Figure 5.12). Fold change 
over 1.5 was considered to have a differential change in gene expression when the NT 
and FBN1KD samples were analysed. The sub-cluster (summarized in Table 5.5) 
contained three different actin-related genes, ACTG2 (enteric smooth muscle actin), 
ACTR1B (actin related protein 1B) and ACTA2 (aortic smooth muscle actin). ACTA2 had 
been previously shown to be co-expressed with fibrillin-1 in mouse cells (Summers et al., 
2009) (Chapter 4). qPCR analysis of ACTA2 across the NHDF timecourse experiment 
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showed upregulated expression of ACTA2 at Day 4 and Day7 (p≤0.1) when compared to 
the NT controls (Figure 5.13), and there appeared to be increased intensity of actin fibre 
staining at Day 4 (Figure 5.7) thus further validating the microarray results (Figure 
5.12).   
 
Figure 5.13. qPCR results for ACTA2 across NHDF time course. The y-axis represents the expression 
values calculated by advanced relative quantification, target/reference ratio (LightCycler480 Roche). 
The reference was human GAPDH.  Technical replicates=3  
In addition to ACTA2, other genes implicated in cardiovascular function were upregulated 
at Day 4 and Day 7 of the fibrillin-1 knockdowns in the fibroblasts (Figure 5.12)(Table 
5.5). These genes included AGTR1 (angiotensin receptor 1), NEXN (nexilin), and 
MAMDC22 (Mam domain-containing 22). The upregulated genes within subcluster002 
also contained PARVA (parvin alpha) and CNN1 (calponin 1), which encode smooth 
muscle maintenance proteins and several genes with neurological functions were in this 
group, including STMN2  (stathmin-like 2) and OPN3 (opsin 3). Furthermore, IGF2 
(insulin like growth factor 2), as well as metabolic control genes GNA14 and GNAI1 
(encoding guanine nucleotide binding protein alpha subunit and guanaine nucleotide 
binding protein alpha subunit inhibiting, respectively) and CLND22 (claudin 22) were in 
the subcluster. The genes are summarized in Table 5.5. 
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5.3.4 Gene expression in the NHDF FBN1 knockdown timecourse. 
There were little to no differences detected in the chondrocyte or osteosarcoma cell lines 
following the reduction of FBN1 using siRNA, but changes were detected in the NHDF 
(fibroblasts) cells (Figure 5.12). Therefore, a detailed BioLayout Express 3D analysis was 
performed on the results of the NHDF timecourse alone. The NHDF samples were 
clustered at a r≥ 0.85 and at an MCL inflation value of 3.0. This is a more stringent 
analysis with greater granularity in the clusters. The analysis consisted of 11,790 nodes 
and 411,151 edges producing 2,709 clusters (Figure 5.14). The clustering analysis 
revealed two clusters containing genes with altered expression following reduction in 
FBN1 mRNA (Figure 5.14). 
 
Figure 5.14.  Network visualisation and clustering of the NHDF transcriptome.  The image depicts 
the network diagram produced by BioLayout Express 3D using data from the Affymetrix U219 gene 
expression microarray platform on knockdown experiments across Day -1, Day 0, Day 1, Day 2, Day 
3, Day 4 and Day 7. Spheres (nodes) represent individual probesets and the lines between them 
(edges) show correlations in expression pattern of r ≥ 0.85. The nodes were clustered using an MCL 
inflation value 3.0 (Chapter 2, Section 2.3.6). The background of the image displays the whole 
network and clusters discussed in the text are highlighted. Cluster597 contained FBN1 probes and 
the remaining clusters are discussed in detail in Section 5.3.4. 
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Cluster597 contained only fibrillin-1 probes which were reduced in expression (Figure 
5.9). Figure 5.15 shows these results for NHDF alone.  
 
Figure 5.15. Plot of average expression profiles of FBN1 probes (Cluster597) following analysis of 
NHDF time course results using BioLayout Express 3D (See Figure 5.14). Y axis shows the normalised 
intensity value. X axis shows the samples from which the RNA was extracted.  Characteristics of the 
cluster were determined using the class viewer tool in BioLayout Express3D and plots were created in 
Microsoft Excel.  
 
Figure 5.16. Plots of average expression profiles of genes in NHDFCluster035 and NHDFCluster100 
following analysis using BioLayout Express 3D (See Figure 5.14). Y axis shows the normalised 
intensity value. X axis shows the samples from which the RNA was extracted.  Characteristics of the 
cluster were determined using the class viewer tool in BioLayout Express 3D and plots were created in 
Microsoft Excel. The genes within both clusters are shown in Table 5.7 and fold change is shown in 
Table 5.6.   
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NHDFCluster035 was located very close to NHDFCluster597, the cluster containing 
probes for FBN1 in the network layout (Figure 5.14). This cluster contained a total of 9 
genes (Table 5.7) that were downregulated 24 hours after FBN1 mRNA expression 
decreased (Figure 5.16)(Table 5.6). The genes included scaffolding gene GIPC1 
(OMIM: 605772), involved in actin binding. NHDFCluster035 showed a gradual 
decrease in gene expression from Day 1 and Day 2, with increasing expression following 
Day 3 (Figure 5.16)(Table 5.6).  
 




Day 1 -1.46 0.97 
Day 2 -1.68 1.29 
Day 3 -1.6 2.06 
Day 4 -1.88 2.02 
Day 7  -1.31 1.59 
Table 5.6. Fold Change in NHDFCluster035 and NHDFCluster100. See Figure 5.16 . A fold change of 
>1.5 (upregulated) or <-1.5 (downregulated) was considered to show differential gene expression.  
 
NHDFCluster 100 had a very similar expression pattern to the previously identified 
subcluster002 of Cluster002 from the overall analysis (Figure 5.12)(Figure 5.16), and 
included six genes, three of which were included in subcluster002, actin genes ACTA2 
and ACTG2 as well as CNN1 encoding basic smooth muscle calponin 1 (Table 5.5)(Table 
5.7). The other three genes in NHDFCluster100 of this stringent analysis were  GALNT18 
(OMIM: 615316), IMPA2 (OMIM: 605922) and ITGA1 (OMIM: 192968). The overall 
expression of the genes within the cluster showed upregulation of expression at Day 3, 
Day 4 and Day 7 within NHDF FBN1KD samples (Table 5.6)(Figure 5.16).   
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Gene Symbol Gene Name  Disease 
Association/Reference  
NHDFCluster035    
DERL1 DER1-Like Domain Family, Member 1 OMIM: 608813 (Chen 
et al., 2013) 
EIF5A2 Eukaryotic Translation Initiation Factor 5a2 OMIM: 605782 
GIPC1 GIPC PDZ Domain-Containing Family, Member 1 OMIM: 605072 
GMFB Glia Maturation Factor, Beta OMIM:601713 
HIATL1 SLC Gene (Sreedharan et al., 
2010) 
MRPS21 Mitochondrial Ribosomal Protein S21 OMIM: 611984 
(McGivney et al., 2010) 
REEP5 Receptor Expression-Enhancing Protein 5 OMIM: 125265 
SDHAF2 Succinate Dehydrogenase Complex Assembly Factor 2 OMIM: 613019 
UBL3 Ubiquitin-Like 3 OMIM: 604711 (Huang 
et al., 2012) 
NHDFCluster100   
ACAT2 See Table 5.5  
ACTG2 See Table 5.5  
CNN1 See Table 5.5  
GALNT18 UDP-N-Acetyl-Alpha-D-Galactosamine:Polypeptide N-
Acetylgalactosaminyltransferase 18 
OMIM: 615136 (Li et 
al., 2011) 
IMPA2 Myo-Inositol Monophosphatase 2 OMIM: 605922 
ITGA1 Integrin, Alpha-1 OMIM: 192968 
(Zemmyo et al., 2003, 
Ekholm et al., 2002) 
(Maher, 1970) 
Table 5.7. A list of all the genes in NHDFCluster035 and NHDFCluster100 with altered expression 
following FBN1 mRNA KD in NHDF cells (See Figure 5.16)  
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5.4 Discussion 
5.4.1 Limitations of siRNA approach 
Using siRNA tools to reduce the level of a specific mRNA has become common in 
studies of gene function. Reduction in the level of mRNA can have three outcomes: there 
may be no change in other genes (suggesting that the target gene is an end point of 
regulation rather than a regulator of those genes), expression of other genes may go up 
(indicating that there is a negative feedback loop between the target and the genes) or 
expression of other genes may go down (consistent with a positive feedback loop). When 
FBN1 was knocked down, all three outcomes were seen. 
One limitation of the approach is that the reduction in mRNA is transient so it is not 
possible to analyze the impact of a sustained depletion of the target protein. The lack of 
response of the osteosarcoma and chondrocyte lines may be due to their ability to degrade 
the siRNA construct quickly and therefore prevent the full impact of the transient 
knockdown. Secondly, the process involves use of cell transfection which can cause cell 
death and/effect proliferation. Lipofectamine2000, used in this study, can reduce cell 
proliferation (Dr Mark Barnet, Roslin Institute, University of Edinburgh, personal 
communication) and hence some effects seen may be due to removal of cells from the 
cell cycle and then their return during the recovery period. The differences in actin 
staining between the normal control and both transfected cultures (with the non-targeting 
construct or the FBN1 siRNA) could be attributed to differences in the number of cells 
that were cycling over the time course. Thirdly, there may be off target effects, where the 
siRNA molecules bind to related mRNAs as well as the target. Given the sequence 
conservation between the human fibrillin genes (discussed further in Chapter 7) this 
could have been a problem with the present study. However, there was no apparent effect 
on FBN2 mRNA (Section 5.3.1), and it is considered unlikely that this gene was 
impacted by the treatment. 
Taking into account these limitations, it was clear that knock down of FBN1 mRNA 
resulted in upregulation and downregulation of a limited number of genes. These groups 
of genes are discussed below. 
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5.4.2 Actin and actin related genes were upregulated following depletion 
of FBN1 mRNA levels  
There were many cytoskeleton actin filament synthesis and processing genes found to be 
upregulated after FBN1 mRNA levels were reduced in fibroblast cell line, NHDF (Table 
5.5)(Table 5.7)(Figure 5.13)(Figure 5.16).  The genes identified have specific functions 
in sustaining a healthy cytoskeleton in connective tissue, thereby maintaining cellular 
homeostasis. As previously described in Chapter 1, the ECM interacts with integrin 
proteins within the plasma membrane, which connect with intercellular actin fibres and 
hence the cytoskeleton (Chapter 1, Section 1.2, Figure 1.3).   
ACTA2 mutation is a cause of thoracic aortic aneurysms and aortic dissections (Chapter 
4) (Guo et al., 2007). Interestingly, microarray and qPCR analysis showed upregulation 
of ACTA2 following the knockdown of fibrillin-1 in the fibroblast (NHDF) cell system, 
though not in chondrocyte (C20A4) or osteoblast (MG63) cell types (Figure 5.12). 
According to human microarray data available on http://biogps.org, ACTA2 was highly 
expressed in cell and tissue types of mesenchyme origin including cardiac and skin types, 
while mouse microarray data (available at the same site) showed that Acta2 is also 
strongly expressed in osteoblast cells. Previous BioLayout Express 3D analysis of single 
time point samples placed ACTA2 in Cluster004 with high levels of expression in the 
NHDF cells (Chapter 4, Section 4.5.1, Figure 4.6).  ACTA2 was the only gene from 
static sample Cluster004 to show increased expression when fibrillin-1 expression was 
decreased, contrary to its parallel expression pattern with Fbn1 in mouse cell lines 
(Summers et al., 2009).  ACTA2 is upregulated in primary rat liver stellate cells following 
hepatic injury, demonstrating a potential role in wound healing (Rockey et al., 2013). It is 
possible that one signal of wounding is the disruption of the normal fibrillin-1 ECM 
microfibrils, leading to perturbation of the intracellular ACTA2 cytoskeleton. This action 
may trigger the production of smooth muscle actin via ACTA2 upregulation, and the 
knockdown of FBN1 in NHDF cells may mimic this effect.  
Additional actin-related genes, ACTG2 and ACTR1B, were upregulated following the 
knockdown of fibrillin-1 (Figure 5.12)(Table 5.5)(Table 5.7). ACTG2 is an isoform of 
actin that is primarily expressed in tissue of both adult and foetal gastrointestinal tract, 
and has very low expression in skin (http://.biogps.org)(Szucsik and Lessard, 1995). 
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ACTG2 mutations have been associated with familial visceral myopathy, a disorder 
involving the inability of the intestines to contract normally leading to severe obstructions 
(Lehtonen et al., 2012, Thorson et al., 2013)(MIM: 155310). This is consistent with 
abnormalities of the muscle cells of the intestine, a cell type which expresses FBN1, 
again highlighting links between the intracellular cytoskeleton and the extracellular 
milieu. ACTR1B is an actin related protein that is expressed in a variety of cell types 
including mesenchyme derived and neurological tissues and had low expression in eye 
tissue (http://biogps.org).  
In the results presented in this chapter, the knockdown of fibrillin-1 in NHDF led to some 
disorganisation of actin filaments at Day 4, though this appeared to be repaired by Day 7 
(Figure 5.7). This decrease in organisation could have instigated the upregulation of 
ACTA2, ACTG2 and ACTR1B mRNA levels by Day 3 (Section 5.3.3)(Table 5.6). 
Therefore, a decrease in fibrillin-1 mRNA and protein in fibroblasts may stimulate a 
wound repair response, leading to an increase in ACTA2, ACTG2 and ACTR1B (Figure 
5.17).  
NEXN was also found to be upregulated following the knockdown of fibrillin-1 (Table 
5.5)(Figure 5.17). The gene encodes nexilin, a Z-disk protein (Ohtsuka et al., 1998). Z-
disk proteins are linear, dense fibres that bind repeated sections of sarcomeres in 
myofibrils (Luther, 2009), ultimately forming muscle tissue. Nexilin was associated with 
F-actin filaments in heart and skeletal muscle (Lee et al., 2013). HeLa cells stably 
transfected with the NEXN gene showed an increase of cellular migration and adhesion 
(Wang et al., 2005). Inactivation of NEXN in zebrafish led to heart failure (Hassel et al., 
2009)(MIM: 613122) and studies involving 121 patients diagnosed with hypertrophic 
cardiomyopathy (MIM: 192600) identified several novel NEXN mutations (Wang et al., 
2010). Muscle F-actin binding protein, PARVA (alpha parvin), which mediates cellular 
adherence (Olski et al., 2001), also showed upregulation in the fibrillin-1 knockdown 
samples of NHDF (Table 5.5)(Figure 5.17). PARVA is a highly conserved gene across 
vertebrates.  Based on northern blot analysis in mouse tissue, it is highly expressed in 
kidney, heart, liver and skeletal muscle and co-localised with actin in strong bundle 
formations of mouse fibroblasts (Tanaka et al., 1975).  Calponin 1 (encoded by the CNN1 
gene) is a smooth muscle protein thought to have a role in the regulation of smooth 
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muscle contractions (Winder and Walsh, 1990) and has been shown to bind and induce 
conformational changes in F-actin (Noda et al., 1992). It was found in Cluster002 of the 
initial analysis and in Cluster100 of the more stringent analysis of NHDF only (Table 
5.7)(Figure 5.16)(Figure 5.17). While mice with the gene inactivated do not show any 
direct smooth muscle phenotypes, there was a significant decrease of actin in the bladder 
and vas deferens (Matthew et al., 2000). The upregulation of these actin supporting genes 
could be attributed to the increase in actin mRNA (ACTA2 and ACTG2), therefore an 
indirect response to FBN1 depletion (Figure 5.17).  
This cluster also revealed upregulated expression of ITGA1 at Day 3, Day 4 and Day 7 
(Figure 5.16)(Figure 5.17)(Table 5.7). ITGA1 (integrin alpha 1)(OMIM: 192968) is an 
integrin that binds to ITGB1 (integrin beta 1) to form a heterodimer that interacts with 
laminin and/or collagen allowing for communication of the ECM with cytoskeletal actin. 
Therefore the increase of actin protein resulting from the increase in actin related mRNAs 
could have upregulated the expression of integrin binding receptors, like ITGA1 (Figure 
5.17).  
GIPC1 (OMIM: 605072) is an ECM scaffolding protein that has been implicated in actin 
filament binding in embryogenesis through growth factor signalling (through integrin 
binding sites) and cell adhesion (Katoh et al., 2002). GIPC1 is thought to have direct 
interactions with a range of FBN1 binding integrins such as ITGA6 and ITGA5 (Tani and 
Mercurio, 2001).  This gene was found to be downregulated along with FBN1 in NHDF 
FBN1KD samples (Table 5.7)(Figure 5.16)(Figure 5.17).  
Figure 5.17 summarises the proposed interactions of the actin related genes and fibrillin-
1 through a schematic of protein activity. The model shows a normal fibrillin-1 ECM and 
cytoskeleton in response to reduced FBN1 mRNA. GIPC1 levels decrease at Day 2 (24 
hours after depletion of FBN1) while the integrins and actin related genes are upregulated 
at Day 3, outlined in Figure 5.17.  




Figure 5.17. The effect of FBN1 mRNA depletion in NHDF cells, an actin model. (A) This figure 
shows the cytoskeleton and ECM with normal fibrillin-1 protein levels. (B) The proposed model of 
interactions of cytoskeleton and ECM related proteins following FBN1 mRNA and consequently 
protein depletion. The individual genes are discussed in Section 5.4.1.  
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5.4.3 Other genes that co-express with fibrillin-1 
There were several growth factors that were upregulated in the FBN1 knockdown NHDF 
cells. One example was insulin-like growth factor-2 (IGF2 gene)(Figure 5.12)(Table 
5.5). IGF2 is an insulin family member involved in cell proliferation and maintaining 
growth hormone action and functional in prenatal development (OMIM: 147470). 
Although IGF2 has not been implicated in any experimental interactions with the fibrillin 
family, it was expressed at high level in mouse mesenchymal cells in a previous analysis, 
and clustered with Fbn1 and Fbn2 (Summers et al., 2009).  Furthermore, IGF2 has been 
used to initiate osteogenic differentiation in human parthenogenetic ESCs (Kang et al., 
2011). The upregulation of IGF2 following the depletion of FBN1 mRNA suggests that it 
would be interesting to examine the relationship between fibrillins and IGF2 further, 
particularly in light of the bone overgrowth in Marfan syndrome. 
ATGR1 (angiotensin receptor 1),was upregulated in NHDF cells with reduced FBN1 
(Figure 5.12)(Table 5.5)(Section 5.3.2). The pharmaceutical Losartan, an angiotensin 
receptor 1 antagonist, is effective in preventing aortic aneurysm and dissection in 
fibrillin-1 mutant mouse models. Losartan inhibits the binding of angiotensinII (ANGII) 
to ATGR1(Matt and Eckstein, 2012, Chiu et al., 2013, Groenink et al., 2013) (Chapter 
1, Section 1.3.4).  Habashi et al., (2006) showed that Losartan reduced aortic wall 
thickening in  Fbn1C1039G/+  mice. These are phenotypically similar to human MFS 
patients and Fbn1C1039G/+  mice  present with a dilated aortic root developing as early as 2 
weeks of age, that becomes more pronounced over time (Habashi et al., 2006). Histology 
of the mice at 14 weeks further indicated abnormal thickening of the aortic root in 
Fbn1C1039G/+  mice and increased fragmentation of elastic fibres, when compared to 
normal mice. They also noted an increase in collagen fibre formation and SMAD2 level 
within the nucleus (Loeys et al., 2005) suggesting an increase in TGFB activity (Rossi et 
al., 1988, Schlumberger et al., 1991)(Figure 5.18). Losartan treated mice showed a 
significant decrease in elastic fibre fragmentation, a decrease in SMAD2 signalling and 
repair of the aortic root, correcting defects to comparable levels with the normal mice. 
The depletion of FBN1 mRNA and fibrillin-1 microfibrils in the fibroblasts could have 
induced upregulation of ATGR1 due to the possible increase in free TGFß. This would 
require further functional protein analysis for validation.  
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Stathin-like 2 (STMN2) is a neuronal specific protein involved in neurogenesis (OMIM: 
600621).  STMN2 is highly expressed in foetal brain, with slight expression in adipocytes. 
Opsin 3 (OPN3) is a G-protein- coupled retinoid receptor. In mice, northern blot studies 
showed that Opn3 expression was high in the cerebellum, frontal cortex and testes of 
adults. In situ hybridisation experiments on embryonic and foetal mice showed high 
expression in the spinal cord, pachytene spermatids, retina and pineal photosensitive 
regions (Blackshaw and Snyder, 1999). The rational for increased expression of neural 
genes following a decrease in fibrillin-1 is not obvious, though the KD of FBN1 mRNA 
and actin reorganisation could take the fibroblasts back to a less differentiated neuronal 
state (Neuhuber et al., 2004).  
There were five additional genes that were upregulated following fibrillin-1 knockdown 
in NHDF cells: CCDC81, CLND22, GNA14, GNAI1 and MAMDC2 whose precise 
functions are relatively uncharacterised. (Figure 5.13)(Table 5.5) GNA14 is a guanine 
nucleotide binding protein and GNA1I appears to inhibit polypeptide-binding activity in 
guanine nucleotide binding proteins (OMIM: 604397)(OMIM: 139310). Claudin 22 
(CLND22) was described as a transmembrane protein involved in maintaining tight 
junction interactions across the membranes in paracellular transport (Bloom et al., 1976). 
MAMDC2 was mapped during a search for genes involved in Kabuki syndrome (MIM: 
147920), though no disease association has been determined (Contento, 1991).  
Genes in NHDFCluster035 from the more stringent BioLayout Express 3D  analysis 
showed a sharp decline in expression 24 hours after FBN1 mRNA levels had been 
manipulated (Table 5.6)(Figure 5.16). This cluster contained several relatively undefined 
genes including DERL1, HIATL1, MRPS21, REEP5, SDHAF2 and UBL3 (Table 5.7). 
However, there were three genes, EIF5A2, GIPC1 and GMFB that are regulated by, or 
regulate, TGFß activity (Table 5.7). EIF5A2 is a translation initiating factor (OMIM: 
605782) that has recently been implicated in indirectly activating TGFß activity through 
interactions with STAT3 (signal transducer and activator of transcription factor 3), in 
bladder cancer (Wei et al., 2014). GIPC1 (discussed in Section 5.3.4) is proposed to 
interact with endoglin (type 1 membrane glycoprotein) enhancing TGFß1 and thereby 
increasing phosphorylation of the SMAD pathway (Figure 5.18) in endothelial cells (Lee 
et al., 2008). In addition, GMFB was shown to be not only an inhibitor of the signal 
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transduction ERK pathway (extracellular signal-regulated kinases)(Zaheer and Lim, 
1996), but also an enhancer of cell cycle pathway p38/MAPK (Lim and Zaheer, 1996). 
Both the pathways non-canonical (non-SMAD inducing) TGFß pathways (reviewed in 
(Zhang, 2009). Since FBN1, EIF5A2, GIPC1 and GMFB all have proposed functions in 
regulating TGFß, it can be proposed that the more undefined genes within the cluster may 
also have a role in TGFß activity.  
This discussion has focused on the response to FBN1 depletion in human neonatal 
fibroblast cells, NHDF. However, the FBN1KD transfections in the chondrocyte and 
osteosarcoma cell lines did not have any changes in gene expression other than FBN1 
(Figure 5.9) This could mean that FBN1 mRNA was insufficiently reduced in the MG63 
and C20A4 cell lines. While FBN1 mRNA knock down appeared equivalent to the 
NHDF cells in MG63 at Day 1, and more depleted in C20A4, both MG63 and C20A4 
cells showed recovery of FBN1 mRNA levels within the seven-day time course, while the 
NHDF cells showed little increase in FBN1 mRNA (Table 5.3)(Figure 5.9). In addition, 
only a single replicate was used for these cells, which limited the power of the study. 
Therefore, the experiment would need to be repeated with at least two replicates. 
Potentially genome editing (with the CRISPR-Cas9 or TALEN systems (reviewed in 
(Wei et al., 2013, Gaj et al., 2013)) could be used to create a stable knock out of the 
FBN1 gene, resulting in sustained loss of FBN1 mRNA, in these cells. Another 
explanation for the variation in FBN1 siRNA effect could be related to the immortal 
nature of these cell lines. MG63 is a cancer line and C20A4 was created by adenovirus 
treatment of primary chondrocytes. This means they are culture-adapted and may have 
altered requirements for cellular homeostasis that do not need the full repertoire of gene 
expression that is seen in the parent tissues. Therefore, the initial results obtained from 
the work outlined above would need to be repeated on primary chondro and osteo 
tissue/cell types for validation.  
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5.5 Conclusions  
In conclusion, through siRNA manipulation of FBN1 mRNA in NHDF cells, this study 
was able to determine a set of genes that were affected by FBN1 depletion. These results 
led to a model for fibrillin-1 interaction with the cytoskeleton in wound healing. 
Furthermore, due to the lack of change seen in FBN2 (Figure 5.4)(Section 5.3.3) and 
FBN3 (Section 5.2.5) following the reduction of FBN1 mRNA, it appears that there is no 
compensatory mechanism to upregulate an alternative fibrillin gene in the absence of 
fibrillin-1. This further supports the notion that there is a clear developmental and 
functional distinction between the members of the fibrillin gene family, and that they are 
regulated independently. Therefore, a study of the promoters of the three fibrillin genes 
was undertaken to assess key factors involved in this differential regulation (Chapter 6). 
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Chapter 6. Identification and expression of promoters of the 
fibrillin gene family  
6.1 Promoter identification and regulation 
Previous chapters (Chapter 3-5) have shown that the fibrillin gene family is 
differentially expressed. Expression is driven by gene transcription and transcriptional 
regulation. Transcription of genes is controlled by proximal and distal DNA sequences as 
well as trans-acting protein factors (transcription factors; TF). The core promoter consists 
of the region where the RNA polymerase enzyme and core TFs bind, which lies 
immediately upstream of the transcript start site (TSS). Beyond this region there can be 
additional TF binding motifs which modulate transcription and more remote up- and 
downstream elements that act as enhancers or silencers of transcription. The same gene in 
different cell types within the body can be under different regulation, depending on the 
TFs that are present in a specific cell type. Most genes have more than one TSS, with 
different regulatory elements and activity (Lenhard et al., 2012). This chapter will present 
bioinformatics data to investigate TSS regions and TF networks of the fibrillin gene 
family.  
Recently, advances in genomics and transcriptome biology have lead to the creation of 
worldwide consortia using various techniques to uncover the regulatory factors of the 
human genome. For example, widescale transcriptome studies including FANTOM 
(Functional Annotation of Mammals) and ENCODE (Encyclopedia for DNA elements) 
have established DNA elements that regulate gene expression. ENCODE is a world wide 
consortium sponsored by the US National Human Genome Research Institute, that used 
many high throughput sequence analysis methods (including promoter assays and 
computational TFBS prediction methods (RFBR (Yale ChIP-chip Regulatory Factor 
Binding Regions Analysis (Zhang et al., 2007)), to predict TSS across the human genome 
(Birney et al., 2007, Birney et al., 2012, de Souza, 2013). However, this chapter will 
investigate the data generated through the FANTOM projects. 
Recent projects by the FANTOM consortium (Chapter 1, Section 1.4.3) have delineated 
the structure and regulation of mammalian promoters (Hayashizaki and Carninci, 2006, 
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Ravasi et al., 2010, Suzuki et al., 2009, Carninci et al., 2005). The FANTOM5 project 
utilized deepCAGE technology (a form of genome-wide 5’RACE) to identify multiple 
promoters (Forrest et al., 2014). Furthermore, using deepCAGE they created a human 
cell-type specific transcriptome consisting of 975 samples (573 primary cell types, 152 
tissues, 250 cell lines) that provided detailed promoter specific expression patterns, as 
well as determining promoter structure (Forrest et al., 2014). CAGE traps the 5’end of 
mRNA via the modified guanine cap, followed by sequencing the first 20-27nt. These 20-
27nt CAGE tags are then mapped back to the whole genome sequence and identify the 
TSS of the gene (Forrest et al., 2014).   
 Past FANTOM collaborations have shown that for the majority of genes,  transcription 
was  initiated across a broad DNA sequence rather than on a single nucleotide. TSS tend 
to be found in CpG islands and the majority are not associated withi a TATA box. Genes 
can have a number of TSS clusters, associated with different promoters, which can show 
differential expression across tissues or cell states (promoter switching) (Carninci et al., 
2005). The FANTOM4 project highlighted promoter switching and TF variation in the 
activation of a monocyte cell line (THP1)(Chapter 2, Section 2.1.5)(Suzuki et al., 2009). 
THP1 cells were differentiated to macrophages using PMA (phorbol myristate acetate), 
and samples were collected at 0, 1, 4, 12, 24 and 96 hours. CAGE analysis using 454 
sequencing demonstrated time-dependent promoter switching and distinguishable 
promoter expression profiles as well as TF networks associated with specific time points 
and TSS regions.  
The current FANTOM5 project aims to look at gene expression both in single time points 
across many cell and tissue types and in a number of dynamic time courses of activation 
and differentiation (Forrest et al., 2014).  
 
6.1.1  Promoter identification and expression 
The FANTOM consortium mapped CAGE tags across the whole genome using single- 
molecule sequencing (Kanamori-Katayama et al., 2011). DPI (decomposition- based 
peak identification) was used to identify a set of transcription start sites (TSS), at 
permissive and robust levels (containing at least one nucleotide position with > 2 or > 10 
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independent single molecule observations respectively in a single library) (Forrest et al., 
2014). Expression levels were normalised using relative log expression (RLE) in edgeR 
(Robinson et al., 2009, Sillar and Plint, 1989).  The counts of the CAGE tags that mapped 
to each promoter region (Schug et al., 2005), referred to as normalised tags per million 
(TPM), reflected the expression level of the gene/promoter. Promoters were then 
numbered by expression rank at the permissive level (Forrest et al., 2014). At the more 
stringent robust level some of these promoters were lost and this accounts for gaps in the 
numbering of robust promoters. The full permissive set can be seen on the ZENBU 
browser (http://fantom.gsc.riken.jp/zenbu/) (Severin et al., 2014). Composite promoters 
are those where two or more robust peaks occur within 100 bp of each other (Forrest et 
al., 2014). 
Figure 6.1 illustrates the format of the data available from FANTOM5, using as an 
example the gene profile of ACTA2 in humans.  




Figure 6.1. Example of selected tracks on the FANTOM5 ZENBU browser showing ACTA2 promoter 
usage and expression level in humans.  (A) Displays the direction of the transcript and the location on 
the chromosome. This shows that ACTA2 is transcribed off the reverse strand (3’-5’) and located at 
Chr10: 90694830-90751146. (B) Depicts the two reference sequences for this gene, the shorter 
NM_001613 and the longer transcript NM_001141945. (C) Displays the track identifying CpG 
islands, imported from the UCSC browser (http://genome.ucsu.edu/). The ACTA2 gene contains one 
CpG island, CpG:62 associated with NM_001141945. (D) Illustrates the promoters associated with  
ACTA2, based on CAGE analysis. There are 11 in total, three supporting transcript NM_ 001613 and 
eight supporting NM_001141945 (outlined in black). (E) Shows histograms of the corresponding 
CAGE tags associated with the identified promoters (outlined in black). The purple vertical lines are 
proportional to the number of CAGE tags associated with the promoters and hence to expression of 
the gene from that promoter.  
Figure 6.1 illustrates selected tracks that will be used in this chapter, identifying 
promoters and expression data for the fibrillin gene family. ACTA2 is transcribed on the 
reverse strand of chromosome 10, in humans, and has two reference sequences (RefSeqs) 
for transcripts, NM_001613 and NM_001141945 (Figure 6.1A & 6.1B). There were 11 
promoters identified by CAGE analysis, labelled pX@ACTA2 with the X depicting the 
promoter number given by the FANTOM5 consortium. The highest expressing promoter 
(determined by CAGE tag technology) begins with the number one or p1@ACTA2 while 
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p14@ACTA2 displays the lowest number of tags (Figure 6.1D). Promoters are defined 
as the region immediately upstream of TSSs. In addition, the browser reveals which 
transcription initiation sites are in CpG islands, visualized on a single track (Figure 
6.1C). The quantitative nature of the CAGE data is illustrated by the histogram rendering 
of the number of tags supporting the identified promoters (Figure 6.1E). The FANTOM5 
data show promoter expression across many human primary cells, tissue and cultured cell 
lines. ACTA2 has two major TSS regions (Figure 6.1D and 6.1E), which are supported 
by the two different RefSeqs. These transcripts are expressed in different tissues at 
different expression levels. For example the TSS region (three promoters in total) 
supporting NM_001613 was most highly expressed in fibroblast-like synoviocytes, 
adipocytes, aorta, smooth muscle and umbilical cord. In addition this TSS region was 
more highly expressed overall, based on the peak height in comparison to the alternate 
TSS region associated with NM_001141945, where there were eight promoters identified 
(Figure 6.1). This TSS region was most highly expressed in MSCs, fibroblasts, cord 
blood, adipocytes and smooth muscle. Therefore, FANTOM5 defined alternate promoters 
and TSS regions and supported two major transcripts of ACTA2 across approximately 
900 human samples.  
The data provided by the FANTOM5 project via the Zenbu browser will be used to 
analyze promoters of the fibrillin gene family to determine alternate promoter usage and 
transcript specific expression patterns within the family.  
 
6.1.2 Identifying TFs  
As part of the FANTOM5 project, the whole-genome alignment of the human genome 
along with 45 other vertebrate genomes was downloaded from the UCSC Genome 
Browser database (Meyer et al., 2012). Alignments between the human, macaque, mouse, 
rat, cow, horse, dog, opossum, and chicken genomes, were done using the T-Coffee 
alignment tool (Notredame et al., 2000). Members of the FANTOM5 consortium, then 
ran MotEvo (Arnold et al., 2012) on the genome alignments to predict the TF binding 
sites (TFBSs) in the human genome, using a background prior probability of 0.98, a UFE 
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(unidentified functional element) motif length of 8bp, and a uniform background 
sequence probability.  
In addition, Motif Activity Response Analysis (MARA) was applied on these TFBS 
predictions to infer the regulatory network (Suzuki et al., 2009). MARA is an analysis 
technique that operates on the assumption that TFs will bind to specific DNA sequence 
elements close to the TSS of the gene (Suzuki et al., 2009). The expression of the TSS is 
then assumed to be correlated with the number of TF binding motifs within the region. A 
linear based model is then applied to infer the regulators of the promoters (Suzuki et al., 
2009).  
6.1.3 Aims of the Chapter  
The FANTOM5 data will be used to explore the promoter activity and regulation of the 
three fibrillin genes in single time point samples. The aim of the study in this chapter was 
to identify major promoters, alternate (tissue-specific) promoters and regulatory elements 
that could support the differential expression of the fibrillin gene family.  
6.2 Materials and Methods  
6.2.1 Analysis of TSSs 
The FANTOM5 database was used to identify TSS yielding promoters for the fibrillin 
gene family. Using the publicly available genome browser, ZENBU 
(http://fantom.gsc.riken.jp/zenbu) the TSS regions and expression patterns across the 
human samples were determined. The terms FBN1, FBN2 and FBN3 were entered, 
separately, into the search bar yielding the results of deepCAGE analysis. Tracks were 
selected as follows: (1) Entrez gene hg19 (Figure 6.1A) (position on the chromosome), 
(2) UCSU_RefSeq_hg19 (Figure 6.1B) (transcript structure), (3) 
UCSC_CpGislands_hg19 (Figure 6.1C) ( CpG island identification), (4) FANTOM5 
PHASE 1 FREEZE DPI Clusters human (robust)(Figure 6.1D)  (robust promoter 
location and identification) and (5) FANTOM5 CAGE Phase 1 CTSS human tracks 
pooled filtered with 3 or more tags per library and RLE normalised (Figure 6.1E) 
(expression peak). 
Chapter 6. Identification and expression of promoters of the fibrillin gene family 
 156 
Expression profiles were extracted by manually highlighting the area of the cage peaks 
within the browser using the track, FANTOM5 CAGE Phase 1 CTSS human tracks 
pooled filtered with 3 or more tags per library and RLE normalised. Once the area was 
highlighted, an expression profile track was automatically generated within the browser 
yielding expression values quantified as RLE normalised tags per million 
(TPM)(Balwierz et al., 2009)(Forrest et al., 2014). The expression data was organized 
using Microsoft excel.   
 
6.2.2 Identifying TFs controlling fibrillin genes 
The MARA and MotEvo analyses were downloaded from the FANTOM5 database (prior 
to public release) to infer regulators of the promoters. The files were acquired and TF 
predictions were collected for FBN1, FBN2 and FBN3. 
Because of its low expression level, the single promoter for FBN3 was not associated 
with TFs in the MARA and MotEvo analysis. Therefore TFBS were predicted for FBN3 
using the ECR browser (Evolutionary Conserved 
Regions)(htt://ecrbrowser.dcode.org/)(Ovcharenko et al., 2004). The analysis was 
completed in October 2012. FBN3 was entered into the search term gateway and the 
following link was selected for analysis: FBN3 at chr19: 8130287-8212385 
(NM_032447) fibrillin-3 precursor RefSeq.  The FANTOM5 determined promoter region 
was manually highlighted within the human genome track (region chr19: 8213992-
8215010), and the “conserved TF binding sites” link was selected, generating rVISTA 
(regulatory VISTA) analysis (http://rVISTA.dcode.org) (Loots and Ovcharenko, 2004). 
The following was selected within the rVISTA analysis: (1) TRANSFAC professional 
V10.2 library, (2) selected species: vertebrates, (3) Matrix similarities “optimized for 
function” (Ovcharenko et al., 2005) and (5) run on all TF families. The alignment 
analysis was performed across the following species, dog, mouse, opossum, chicken, fish 
and frog. The analysis generated a list of TFBS conserved across the species within the 
confines of fibrillin-3 described above.  
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6.3 Promoter Identification using FANTOM5 data 
6.3.1 FBN1 has a single major promoter region  
The promoter sequence for FBN1 in human and mouse was identified previously through 
analysis of FANTOM3 data (Summers et al., 2009). FANTOM5, which included many 
more human samples, confirmed that FBN1 had a major promoter (p1@FBN1) 
associated with transcript NM_000138 (Figure 6.2), with transcription initiating on one 
of two purine nucleotides 12 nucleotides apart.  
 
Figure 6.2. Identification of the major FBN1 promoters in human. (A) The full fibrillin-1 transcript, 
CpG island location and robust promoters at the 5’ end (outlined in black). (B) Detailed view of the 
outlined region, showing the architecture of the broad promoter, with multiple TSSs all within a 
single CpG island, CpG_174. Below is the expression peak. The height of the peak is proportional to 
the CAGE tags mapped to that region. The figure is further explained in Section 6.3.1. The image 
was obtained from http://fantom.gsc.riken.jp/zenbu/. 
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The region of this promoter contained several additional robust peaks of transcription 
initiation (p2@FBN1, p3@FBN1, p6@FBN1, p9@FBN1 and p11@FBN1), defining an 
extensive composite promoter (Forrest et al., 2014)(Figure 6.2B). As previously reported 
(Summers et al., 2009, Guo et al., 2008, Singh et al., 2008) this FBN1 promoter region 
was GC rich and contained a characteristic pyrimidine stretch, about 70 nucleotides 
upstream of the TSS associated with p1@FBN1.  Four additional TSS regions were 
identified by CAGE analysis. Initiation from any of these promoter regions would result 
in alternative 5’ UTR sequences spliced to the same first coding exon (Figure 6.2B). 
p11@FBN1 is probably associated with the rarely used Exon B of previous reports (Guo 
et al., 2008, Corson et al., 1993), while p7@FBN1/p25@FBN1  may be associated with 
the previously described Exon C (Corson et al., 1993)(Figure 6.2B). p8@FBN1 and 
p13@FBN1 were singleton low expressing broad promoters. p13@FBN1 was located 
within the first coding exon, immediately downstream of the start codon. All identified 
robust promoter regions were located within the CpG island, CpG_174 and all, excluding 
p13@FBN1, were located upstream the first start codon of NM_000138 (Figure 6.2A).  
Chapter 6. Identification and expression of promoters of the fibrillin gene family 
 159 
6.3.2 FBN2 has two promoter regions  
As shown in Figure 6.3, a total of 10 significant TSS clusters were detected in human 
FBN2, eight located in or upstream of the 5’ noncoding region of the gene and two 
appearing within intron 25 of the gene (Figure 6.3A).  
 
Figure 6.3. Identification of the major FBN2 promoters in human. (A) The full fibrillin-2 transcript, 
CpG island location and a set of robust promoters at the 5’ end (outlined in thick black line), and two 
additional TSS, p14@FBN2 and p18@FBN2 within intron 25 (outlined in thin black line). (B) 
Detailed view of the outlined region of p14@FBN2 and p18@FBN2, showing the architecture of the 
promoters, with multiple TSSs. Below is the CAGE expression peak. (C) Detailed view of the major 
TSS region consisting of  8 robust promoters. This figure is further explained in Section 6.3.2. The 
image was obtained from http://fantom.gsc.riken.jp/zenbu/. 
The two main TSS clusters (p1@FBN2 and p2@FBN2) were approximately 40 base 
pairs apart and formed a composite promoter (Figure 6.3C). The highest expressed 
promoter, p1@FBN2, showed initiation on two guanines separated by a CC dinucleotide. 
The region of these TSSs was within a CpG island (Figure 6.3A) but showed no 
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sequence homology with the FBN1 promoter region. This promoter region was 
characterized by a stretch of four adenines followed by a very cytosine-rich sequence. A 
number of other TSS regions were detected for FBN2. p17@FBN2, p3@FBN2, 
p6@FBN2 and p12@FBN2 were located within the first exon, downstream of p1@FBN2 
(Figure 6.3C).  p4@FBN2 and p5@FBN2 made up a composite promoter that lies 
upstream of p1@FBN2 and probably splice to the same first coding exon (Figure 6.3C). 
p14@FBN2 and p18@FBN2 were found in intron 25 and were associated with the short 
transcript ENST00000507835.1 (Figure 6.3A). Initiation of this transcript occurs over 
approximately 70 nucleotides (characteristic of a broad promoter), followed by an AT 
rich sequence.  CAGE tags did not support some published transcripts. For example, 
there was no support at the robust level for a promoter for the long FBN2 transcript 
ENST00000508053.1 which has an additional six 5′ non-coding exons (available at 
http://fantom.gsc.riken.jp/zenbu/). 
6.3.3 FBN3 has a single robust promoter   
Fibrillin-3 expression is restricted to foetal and embryonic tissue types (Corson et al., 
2004; confirmed in Chapter 3 and Chapter 4).  FANTOM5 had extensive 
representation of human cells and tissues from early developmental stages allowing for 
the identification of the promoter region and the most common starting nucleotide for 
human FBN3. There is a single broad promoter, p2@FBN3 and the major TSS is 2126 
nucleotides upstream from the ATG start codon of transcript NM_032447 (Figure 6.4A).  




Figure 6.4. Identification of the major FBN3 promoters in human. (A)The full fibrillin-3 transcript, 
CpG island location and the single robust promoter at the 5’ end (outlined in black). (B) Detailed 
view of the outlined region showing the architecture of the single promoter, with multiple CAGE tag 
peaks  all within a single CpG island, CpG_46. Below is the CAGE expression peak. There are 
several peaks associated with the single TSS. This figure is further explained in Section 6.3.3. The 
image was obtained from http://fantom.gsc.riken.jp/zenbu/. 
This region is pyrimidine rich and associated with CpG_46.  Expression from this 
promoter was very low after RLE normalisation (Table 6.3). There was no homology 
with any of the FBN1 or FBN2 promoter regions (Chapter 7). A second, sharp promoter 
region (p1@FBN3) was located further away from the start codon and was associated 
with a TATA box 30 nucleotides upstream. This promoter was annotated only at the 
permissive level (http://fantom.gsc.riken.jp/zenbu/). In addition, CAGE tags did not 
support previously published transcripts (AY203940 and AK022050), for two long 
transcripts which overlap FBN3 (Corson et al., 2004). Due to the low expression of 
FBN3, the promoter definition will require confirmation.  
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6.3.4 FANTOM5 determined expression of the fibrillin family 
The analysis of promoter sequences using CAGE technology provided quantitative as 
well as qualitative information about gene expression from the different promoters.  
RLE-normalised tag counts (Robinson et al., 2009, Forest et al., 2014) were used to 
determine the level of expression of the three fibrillin genes in the 975 tissues and cell 
lines. 
Both FBN1 and FBN2 showed a high level of expression in cells of mesenchymal origin 
in human, as previously reported for mouse (Summers et al., 2010). However, the highest 
expression was seen in different cell types for the two genes (Table 6.1 & 6.2). 
For FBN1, the 10 robust promoter regions (Figure 6.2), in general displayed the highest 
expression levels in the samples of mesenchymal origin including smooth muscle cells, 
fibroblasts, preadipocytes and adipocytes, chondrocytes, mesenchymal stem cells and 
cardiac myocytes (Table 6.1)(http://fantom.gsc.riken.jp/zenbu/).  Outside the main 
compound promoter, p11@FBN1 was expressed in multiple different fibroblast tissue 
samples, but displayed the highest expression levels in chorionic and amniotic membrane 
cells. p7@FBN1 showed peak levels of expression in neural tissue (Table 6.1). 
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FANTOM5 promoter ID Highest expression 
tissue/cell types 






  p1@FBN1 Smooth muscle cells 
(Aorta) 
714 2563 
 Fibroblast (Aorta)   
 Fibroblast (Skin)   
p2@FBN1 Smooth muscle cells 
(aortic) 
573 376 
 Fibroblasts (aortic)   
 Sertoli cells   
p3@FBN1 Smooth muscle cells 386 31 
 Fibroblasts (aortic)   
 Fibroblast (skin)   
p6@FBN1 Smooth muscle cells 
(pulmonary artery) 
419 13 
 Fibroblast (aortic)   
 Fibroblast (skin)   
p9@FBN1 Smooth muscle cells 
(pulmonary artery) 
299 12 
 Fibroblast (aortic)   
 Fibroblast (skin)   
p11@FBN1 Amniotic membrane 
cells  
314 10 
 Chorionic membrane 
cells  
  
 Fibroblast (skin)   
p8@FBN1 Fibroblast (aorta) 326 9 
 Chorionic membrane 
cells 
  




carcinoma cell line – 
HuH-28 
345 7 
 Corpus callosum   
 Fibroblast (aorta)   
p13@FBN1 Fibroblasts (aortic)  236 5 
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 Chorionic membrane 
cells 
  
 Basal cell carcinoma 
cell line TE354 
  
p25@FBN1 Diencephalon (adult) 135 4 
 Corpus callosum   
 Smooth muscle cells 
(aorta) 
  
Table 6.1. FBN1 promoter expression determined from FANTOM5 analysis. The table displays all 
the promoters identified for FBN1 and highlights the tissue/cell types where the promoters showed 
highest expressed, the total number of samples that expressed the promoter and the highest TPM 
associated with the promoter. Order of the promoters is presented based on the highest expression 
value (TPM). 
For FBN2, more embryonic and foetal tissues showed high expression than for FBN1, 
with the maximum normalised tag count seen in a range of cells from foetal tissues, 
fibroblasts, osteoblasts, placenta, hair follicle and lens epithelial cells 
(http://fantom.gsc.riken.jp/zenbu/).   
FANTOM5 promoter ID Highest expression 
tissue/cell type 






p1@FBN2 Normal embryonic 
palatal mesenchyme 
stem cell lines HEPM 
682 1548 
 Fibroblast (skin)   
 Sacrococcigeal 
teratoma cell line 
HTST 
  
p2@FBN2 Fibroblasts (skin) 586 82 
 Extraskeletal myxoid 
chondrosarcoma cell 
line HEMC SS 
  
 Normal embryonic 
palatal mesenchyme 
stem cell lines HEPM 
  
p3@FBN2 Placenta (adult) 579 37 
 Pancreatic carcinoma 
cell line NORP1 
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 Adipocyte   
p6@FBN2 Prostate Stromal Cells 234 15 
 Osteoblast   
 Extraskeletal myxoid 
chondrosarcoma cell 
line HEMC SS 
  
p14@FBN2 Testis (adult) 4 8 
p4@FBN2 Lens epithelial cells  358 7 
 Testicular germ cells 
embryonal carcinoma 
cell line NEC-15 
  
p18@FBN2 Testis (adult) 3 6 
p5@FBN2 Extraskeletal myxoid 
chondrosarcoma cell 
line HEMC SS 
267 5 
 Placenta (adult)   
 Teratocarcinoma cells   
p17@FBN2 Extraskeletal myxoid 
chondrosarcoma cell 
line HEMC SS 
52  4.6 
 Hair follicle dermal 
papilla cells 
  
 Fibroblast    
p12@FBN2 Fibroblast (Skin) 3 
donors 
71 5 
Table 6.2. FBN2 promoter expression determined from FANTOM5 analysis. The table displays all 
the promoters identified for FBN2 and highlights the tissue/cell types where the promoters showed 
highest expresison, the total number of samples that expressed the promoter and the highest TPM 
associated with the promoter. Order of the promoters is presented based on the highest expression 
value (TPM). 
The major significant promoters p1@FBN2 and p2@FBN2 displayed similar expression 
values and peaked in the same cell types (Figure 6.3)(Table 6.2) while p3@FBN2 
peaked in hematopoietic cell types. p14@FBN2 and p18@FBN2, located in intron 25, 
displayed highest expression in testis. The transcript deriving from these promoters, 
ENST00000507835.1, covers coding exons 26 to 34 of the full length FBN2 and the 
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polypeptide would consist of eight cbEGF domains with short N- and C-terminal flanking 
sequences (http://www.ensembl.org). 
As expected, FBN3 was almost exclusively expressed in cells of foetal and embryonic 
origin in human (Table 6.3) (Corson et al., 2004) (Chapter 3).  
FANTOM5 promoter ID Highest expression 
tissue/cell type 




value (RLE normalised 
TPM) 
p2@FBN3 Occipital lobe (foetal) 66 6 
 H9 embryonic stem 
cell line  Rep 1 
  
 H9 embryonic stem 
cell line Rep2 
  
Table 6.3. FBN3 Promoter Expression determined from FANTOM5 analysis. The table displays the 
promoter identified for FBN3 and highlights the tissue/cell types where the promoter showed highest 
expression, the total number of samples that expressed the promoter and the highest TPM associated 
with the promoter.  
This expression pattern was further observed in the more limited BioGPS data 
(http://biogps.org) (Chapter 1, Figure 1.6). p2@FBN3, was expressed at the highest 
level in foetal brain and embryonic cells (Figure 6.3).  
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6.4.5 Transcriptional Regulation 
 A total of 21 robust promoters were identified for FBN1, FBN2 and FBN3. MARA 
analysis was able to infer possible TF regulation for 13 of the robust promoters (Table 
6.4). The promoters noted in Table 6.4 are given in order along the chromosome to 
highlight the relationship between promoters within one composite promoter region. 
Name Transcript ID CpG island Composite  Transcription factors 
Fibrillin 1 
(FBN1) 
    
p13@FBN1 NM_000138 CpG:_174 SINGLETON None 
p8@FBN1 NM_000138 CpG:_174 SINGLETON None 
p25@FBN1 NM_000138 CpG:_174 p7, p25 None 
p7@FBN1 NM_000138 CpG:_174 p7, p25 FOXD3, 
HOXA9_MEIS1, 
MAZ, PATZ1, TFAP4, 
TFDP1 


























    
p14@FBN2 ENST00000507835.1 None p14, p18 None 
p18@FBN2 ENST00000507835.1 None p14, p18 None 
p17@FBN2 NM_001999 CpG:_186 SINGLETON TOPORS 
p3@FBN2 NM_001999 CpG:_186 SINGLETON KLF4 
p6@FBN2 NM_001999 CpG:_186 p6, p12 HIC1, HIF1A, KLF4, 
PAX5, TFAP2B, 
TOPORS 
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p12@FBN2 NM_001999 CpG:_186 p6, p12 HIF1A, KLF4, TFDP1, 
TOPORS 
p2@FBN2 NM_001999 CpG:_186 p1, p2 GFI1, GTF2I, HIF1A, 
MZF1, SP1, TRAP2B, 
TFDP1 
p1@FBN2 NM_001999 CpG:_186 p1, p2 GFI1, GTF2I, HIF1A, 
MZF1, SP1, TRAP2B, 
TFDP1 
p5@FBN2 NM_001999 CpG:_186 p4, p5 None 
p4@FBN2 NM_001999 CpG:_186 p4, p5 None 
Fibrillin-3 
(FBN3) 
    
p2@FBN3 NM_032447 CpG:_46 SINGLETON None 
Table 6.4. TF motifs association with fibrillin gene promoters. The table displays the promoters 
identified for fibillin-1, fibrillin-2 and fibrillin-3. This table highlights the transcripts associated with 
the promoters, the presence of CpG islands, promoter architecture (composite vs. single) and the 
MARA-identified TF regulation.  Order of the promoters is presented in the table based on the 
promoter location. All three fibrillin genes are transcribed from the reverse strand.  
Seven of the 10 FBN1 promoters were associated with potentially regulating TFs. Motifs 
associated with GTF2I, NKX3-1, TBX4-5 and TFAP4 TFs were found to regulate five 
fibrillin-1 promoters (Table 6.4). PRMD1, associated with p9@FBN1, was also a 
putative regulator of p11@FBN1.  
Of the 10 robust FBN2 promoter regions, a total of six were associated with TFs. 
p1@FBN2 and p2@FBN2 were regulated by the same TF motifs GFIT1, MZF1, SP1, 
TRAP2B , TFDP1, HIF1A and GFIT21 (Table 6.4). In addition, motifs associated with 
HIF1A regulated p6@FBN2 and p12@FBN2. There was a high prevalence of motifs for 
TOPORS and KLF4 TFs associated with broad promoter region consisting of p3@FBN2, 
p6@FBN2, p12@FBN2 and p17@FBN2 (Table 6.4) although there were no TFs 
associated with p14@FBN2 or p18@FBN2.  
There were no MARA determined motifs associated with p2@FBN3, though TF binding 
motifs for MAZ, PATZ1, RREB1, SP1 and TFAP4 were detected in an analysis 
performed through the ECR Browser (http://ecrbrowser.dcode.org/)(Section 6.2.3). 
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6.4 Discussion  
This chapter presents a study of the TSS and predicted TFs associated with the fibrillin 
gene family using FANTOM5 deepCAGE data. A total of 10 novel TSSs for FBN1 were 
identified, expanding from previous promoter analysis of FBN1 (Summers et al., 2009). 
The broad promoter region consists of both composite and single promoter structures, all 
associated with a single CpG island (CpG_174). Expression of FBN1 was mainly in cell 
and tissue types of mesenchymal origin (Summers et al., 2010)(Chapter 4), with the 
exception that p7@FBN1 showed high neuronal expression and p11@FBN1 was 
expressed in extra-embryonic membranes. Seven of the ten robust promoters were 
associated with identified TF motif by MARA analysis. The major composite promoter 
region (Figure 6.2) shared similar TFs (Table 6.1), while p7@FBN1 had differing motifs 
assigned. p7@FBN1 was associated with FOXD3, consistent with expression peaks in 
neural tissue/ cell types. FOXD3 (OMIM: 611539) is a regulator in embryonic neural 
crest formation. In addition there were several other early development motifs, for 
example PATZ1, MEIS1 and HOXA9 (Table 6.4). Five promoters had motifs for limb 
development, including TF TBX4-5 (OMIM: 601719)(OMIM: 601620)(Takeuchi et al., 
1999, Minguillon et al., 2005), consistent with the abnormalities of limb development in 
the presence of FBN1 mutations (Chapter 1, Section 1.3.4). While there was not a single 
TF motif shown to regulate all promoters within the fibrillin family, general TF, GTF2I 
(Orphanides et al., 1996) was associated with the high expressing promoters in both 
FBN1 and FBN2 (Table 6.4).  
A total of 10 novel TSSs were identified for FBN2 (Figure 6.3). FBN2 was highly 
expressed in mesenchyme cell types and early development. Some of the promoters were 
regulated by epithelial and pluripotency associated motifs, KLF4, PAX5, TRAP2B, and 
early expression motif, SP1 (Table 6.4), consistent with expression patterns and the 
predicted role of FBN2 in mesoderm formation (Chapter 3). Furthermore, the HIF1A 
(OMIM: 603348) motif was coupled with four major fibrillin-2 promoters including, 
p1@FBN2, p2@FBN2, p6@FBN2 and p12@FBN2, and HIF1A has recently been 
implicated in osteoblast formation (Wang et al., 2007). FBN2 is highly expressed in cells 
of osteoblast lineage (Table 6.4)(Summers et al., 2009) and mutations in FBN2 
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phenotypically show disruption in bone and cartilage formation (Chapter 1, Section 
1.3.5). The relationship between FBN2 and HIF1A will need to be further validated as a 
potential target for therapy in CCA.  
 One TSS was identified in FBN3, associated with a single CpG island (CpG_46)(Figure 
6.4). While the MARA analysis did not reveal motifs regulating p2@FBN3, several TF 
binding motifs, SP1, TRAF4, PATZ1, MAZ, and RREB1, were identified through the 
ECR browser conserved TFBS function (http://ecrbrowser.dcode.org/)(Section 6.2.1).  
Conservation of a motif across species is considered to be an indication of  likely 
biological function (Ovcharenko et al., 2004). All these factors are involved in 
embryogenesis and development. For example, general TF, SP1 (OMIM: 189906), has 
been shown to be involved in blastocyst segmentation (Wimmer et al.,1993), TRAF4 
(OMIM: 602464) was shown to be a crucial factor in skeletal, tracheal and neural tube 
development in the embryo (Regnier et al., 2002), and PATZ1 is a general TF in 
embryogenesis (Valentino et al., 2012). These findings are consistent with FBN3 
expression patterns in early development and foetal neural cells (Chapter 3)(Section 
6.3.3).  
6.5 Conclusions  
In summary, this chapter presented evidence of the promoter and TSS region architecture 
for the fibrillin gene family as well as possible regulatory motifs associated with specific 
promoter expression. FBN1 and FBN2 shared similar promoter architecture, presenting 
with a large broad promoter containing many TSS within the region as well as singleton 
TSS regions appearing outside the major broad promoter. Though both FBN1 and FBN2 
were highly expressed in cells of mesenchyme origin, the level of expression and tissue 
specificity varied between the two genes. In addition, the low expressing singleton 
promoters identified indicated further specific expression differences between the genes. 
The promoter region of FBN3 showed one major TSS (singleton) with tissue specific 
expression, mainly in foetal and embryonic cell types. There were no consistent TF 
identified for all three fibrillin genes. The variation in the promoter architecture and 
regulatory elements of the fibrillin gene family supports the concept of differential roles 
for FBN1, FBN2 and FBN3. Since in humans there is no one central regulator of the 
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fibrillin family, and the TSS regions show varying expression patterns (tissue specific) 
between the fibrillin genes, it was important to examine if this phenomenon also occurred 
in other species. This will be explored in Chapter 7 by looking at the sequence 
conservation of the promoters and other key fibrillin gene family regions across 
vertebrates.  
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Chapter 7. Evolutionary conservation of the fibrillin gene family  
7.1 Introduction 
Fibrillin-1 -and -2 are expressed across many cell types, mainly mesenchyme derived, 
and fibrillin-3 is highly expressed in early and fetal tissues, as outlined in this thesis.  The 
genes have independent expression patterns, so each gene appears to have a specific and 
different function (Chapters 3-6) and they are controlled by different regulatory 
sequences (Chapter 6). The multiple deleterious phenotypes associated with mutations in 
FBN1 and FBN2 suggest that these genes are important and likely to be conserved across 
species. The inactivation of the FBN3 gene in mice and rats (Corson et al., 2004) leaves 
open the question of potential redundancy of this gene in other mammals. Gene 
conservation and major evolutionary events are thought to have led to the development of 
the three fibrillin genes in humans (Piha-Gossack et al., 2012, Robertson et al., 2010).  
Comparative sequence analysis is a powerful tool that can be used to understand the 
evolutionary significance of (for example) conserved promoter regions, protein domains 
and mutation regions, across species, within a gene family. Chapter 6 identified key TSS 
regions within the fibrillin gene family. Investigating the sequence conservation of 
promoter regions has been previously used to predict 5’ regulatory regions within a gene, 
across various cell types (Sato et al., 2001), and across species (Rostas et al., 1986, 
Bashyam et al., 1996). Furthermore, studying promoter conservation can identify key 
regions that could be used in gene therapy to target gene expression (Li and Zhang, 2014, 
Summers et al., 2009, De Mey et al., 2010). This chapter examines the sequence 
conservation of the previously identified TSS regions in the fibrillin gene family. This 
was done to understand the evolutionary trends in transcriptional regulation. 
Mutations in amino acids that are critical to the function of a protein are likely to have 
major phenotypic consequences and such amino acids tend to be conserved across species 
(Strachen T., 2004). This chapter reports sequence homology studies on the sites of 
severe mutations in MFS and CAA, to determine the likely significance of the regions for 
protein function across the fibrillin family. As introduced in Chapter 1, Section 1.3.4 
and 1.3.5, the majority of neonatal MFS and CCA cases present with mutations in a 
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region containing many cbEGF-like domains and a single TB (TGFβ binding protein 
like) domain in both fibrillin-1 and -2. The region stretches from exon 24 to exon 33, 
consisting of TB5 domain in exon 24, followed by several cbEGF-like domains (Chapter 
1, Section 1.3.2). The severity of the phenotypes caused by mutations in this region in 
both genes, suggests that it plays an important role in the function of the encoded 
proteins. There were no mutations reported in fibrillin-3 for that region. In addition, four 
mutations resulting in truncation of fibrillin-1 at exon 64 have been shown to cause 
severe lipid depletion in patients diagnosed with MFS, extensively discussed in Chapter 
3. A study of the conservation of the amino acid sequence in the regions covering the 
severe phenotypes and the lipodystrophy phenotype both within and among fibrillins 
across vertebrates will help to understand the importance of the protein domains where 
these severe mutations reside within the fibrillin gene family.    
 
7.1.1. Aims of the Chapter  
This chapter reports a wide scale bioinformatics search to identify conservation of gene 
sequence and structure across vertebrates containing transcripts and/or annotated genes 
for FBN1, FBN2 and FBN3. The study examined the conservation of the main promoter 
regions of fibrillin gene family identified by the FANTOM5 project (Chapter 6). In 
addition, the analysis explored the conservation of various protein domains and amino 
acid regions of interest across species and among the fibrillin gene family, specifically 
addressing exons 24 – 32 where mutations are associated with the most severe 
phenotypes and exon 64 where mutations present with a high incidence of MFS with 
lipodystrophy. The overall aim of the study was to understand the functional significance 
of the different regions of the fibrillin genes through the conservation of key amino acids. 
7.2 Materials and Methods 
7.2.1 Conservation across vertebrates  
The search terms FBN1, FBN2 and FBN3 were entered into the search facility of 
Ensembl (http://www.ensembl.org) and all genes retrieved were examined for 
chromosome/scaffold location, flanking genes, and number of annotated exons. Amino 
acid sequences were obtained for those species that had sequence homologous to the start 
Chapter 7. Evolutionary conservation of the fibrillin gene family 
 174 
sites annotated for the human genes (Chapter 9, Appendix C). Amino acid sequence 
alignments were conducted by ClustalW analysis (DNASTAR, Lasergene, Madison, WI, 
USA). Percent identity was determined based on sequence displacement values 
determined by the ClustalW alignment (DNASTAR, Lasergene). All analysis was 
performed on genome builds available in Ensembl in 2013 (Table 7.1). 
7.2.2. Promoter conservation 
The promoter sequences for human FBN1, FBN2 and FBN3 were obtained from 
FANTOM5 human dataset (http://fantom.gsc.riken.jp/zenbu/)(Chapter 6). The 
promoters with the highest expression across all cell types were considered to identify the 
major transcription start site for each gene (p1@FBN1, p1@FBN2 and p2@FBN3). 
Nucleotide sequences from approximately 200bp upstream and 100bp downstream of 
these transcription start sites were obtained (Table 7.1). 
Gene name Gene symbol Genome Location Number of nucleotides (nt) 
Fibrillin-1 FBN1 Chr.15: 48645593- 48645905 312 
Fibrillin-2 FBN2 Chr.5: 127873797-127874203 406 
Fibrillin-3 FBN3 Chr.19: 8214401-8214701 300 
Table 7.1. The human nucleotide regions used in the BLAT (BLAST-like alignment tool) searches for 
promoter conversation studies. 
The retrieved human sequences were then entered into the BLAT search engine within 
Ensembl and equivalent sequences were recovered for FBN1, FBN2 and FBN3 in the 
following species, Mus musculus (mouse), Sus scrofa (pig), Ovis aries (sheep), Mustela 
putorius furo (ferret), Otolemur garnettii (bushbaby), Ailuropoda melanoleuca (panda) 
and Dasypus novemcinctus (armadillo) (www.ensembl.org). These species were selected 
for the promoter conservation analysis because they had mostly adequate sequencing of 
the 5’regions for all three fibrillin genes, excluding Fbn3 in mouse.  
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7.2.3 Conservation of amino acids associated with MFS, CCA 
and lipodystrophy 
Amino acid sequences (Chapter9, Appendix C) of exon 24-33 and exon 64 (based on 
the human sequence) of fibrillin-1, -2 and -3 were extracted for the following species: 
human, mouse, pig, sheep, ferret, bushbaby, armadillo, Gallus gallus (chicken), Ficedula 
albicollis (flycatcher), Meleagris gallopavo (turkey), Latimeria chalumnae (coelacanth), 
and Pelodiscus sinensis (Chinese softshell turtle). The sequences were aligned and 
percent identity was determined as outlined in Section 7.2.1. Conserved amino acid 
residues were visually identified within the alignments.  
7.3 Results: Conservation of fibrillins across vertebrates  
7.3.1 Conservation of Fibrillin-1  
The FBN1 gene in humans contained 66 annotated coding exons and one 5’ non-coding 
exon, and was flanked by CEP152 and SHC4 at the 5’ end and DUT and SLC12A1 at the 
3’ end. It was located on chromosome 15 and transcribed from the minus strand. The 
human FBN1 gene covered more than 237,000bps and the longest transcript consisted of 
11,695bps. A total of 58 species had a gene annotated as FBN1 and where data was 
available the same flanking genes were detected, except for Petromyzon marinus 
(lamprey) where none of these genes were located in the same region (Table 7.2 and 
Table 7.3). 
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Common Name Chromosome/Scaffold Flanking genes Exons 
Human* Chr. 15 DUT, CEP152, SHC4, SLC12A1 66 
Alpaca Sc_1602 DUT, SLC12A1 76 
Armadillo* Sc_5300: DUT 71 
Bushbaby* GL: 873530 DUT,CEP152, SLC12A1 65 
Cat* ChrB3 DUT, SLC12A1 67 
Chimpanzee* Chr.15 DUT, CEP152, SHC4, SLC12A1 66 
Cow* Chr. 10 CEP152, SHC4, DUT, SLC12A1 65 
Dog* Chr. 30 DUT, CEP152, SHC4, SLC12A1 65 
Dolphin* Sc_275 DUT, SLC12A1 71 
Elephant* Sc_80 DUT, CEP152, SLC12A1 65 
Ferret* Gl: 896926 DUT, CEP152, SHC4, SLC12A1 69 
Gibbon* GL: 397306 DUT, CEP152 65 
Gorilla* Chr. 15 DUT, CEP152, SHC4, SLC12A1 66 
Guinea Pig* Sc_23 Dut, Slc12a1 65 
Hedgehog Sc_3407 DUT 69 
Horse Chr. 1 CEP152, DUT, SLC12A1 70 
Hyrax* Sc_5473 Data not available 72 
Kangaroo rat Sc_ 603 Dut, Cep152, Slc12a1 70 
Lesser hedgehog tenrec Sc_6197 Data not available 86 
Macaque* Chr. 7 DUT, SLC12A1 65 
Marmoset* Chr. 10 DUT, CEP152, SHC4, SLC12A1 67 
Megabat* Sc_2805 Data not available 66 
Microbat GL:42970 DUT, SLC12A1 91 
Mouse Chr. 2 Cep152, Shc4, Dut, Slc12a1 66 
Mouse Lemur Sc_401 DUT, SLC12A1 68 
Opussum* Chr. 1 CEP152, SHC4, DUT, SLC12A1 66 
Orangutan* Chr. 15 DUT, CEP152, SHC4 73 
Panda* GL: 192544 DUT, CEP152, SLC12A1 65 
Pig* Chr. 1 CEP152, SCL12A1, SHC4 71 
Pika Sc_2374 DUT, SLC12A1 69 
Platypus* UltracontigUltra 375 CEP152, SLC12A1 60 
Rabbit* Chr. 17 DUT, CEP152, SHE4 67 
Rat Chr. 3 Dut, Cep152, Shc4, Slc12a1 65 
Sheep* Chr. 7 CEP152, SLC12A1 65 
Shrew* Sc_5245 Data not available 80 
Sloth Sc_5856 Data not available 68 
Squirrel* JH; 393281 SLC12A1, DUT 71 
Tarsier Sc_6131 Data not available 67 
Tree Shrew Sc_4047 CEP152 75 
Wallaby Sc_7349 Data not available 70 
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Table 7.2 Fibrillin-1 genes in mammals. The mapped location and number of exons of the fibrillin-1 
gene among mammalian species is shown.  The * signifies that the mammal has annotated genes for 
fibrillin-1, -2 and -3. Information was obtained from http://www.ensembl.org (See Section 7.2.1). 
 
Common Name  Chromosome/Scaffold Flanking genes  Exons 
Birds    
Chicken* Chr. 10 DUT, CEP152, SLC12A1 69 
Duck* KB743097.1 DUT, CEP152, SHC4, SLC12A1 64 
Flycather* JH603201.1 DUT, CEP152, SHC4, SLC12A1 64 
Turkey* Chr. 12 DUT, CEP152, SHC4 64 
Fish    
Cod Sc_2886  dut, slc12a1 92 
Coelacanth* JH127003 cep152,slc12a1, shc4 66 
Fugu Sc_1 dut, slc12a1 67 
Lamprey GL:476354 yjefn3, mtfmt 67 
Medaka Chr.3 dut, slc12a1 66 
Platyfish JH55670 shc4 44 
" AGAJ01039647 dut, slc12a1 21 
Spotted gar* LG3 dut, slc12a1, shc4 67 
Stickleback GroupII dut, slc12a1, shc4 79 
Tetraodon Chr. 5 slc12a1, dut 67 
Tilapia GL831355 dut, slc12a1, shc4 85 
Zebrafish Chr. 18 dut, slc12a1 4 
Reptiles and amphibians      
Anole lizard Sc_GL343806 dut 52 
Chinese softshell turtle* JH212494 dut, cep152, slc12a1 65 
Xenopus GL172857 cep152, slc12a1, shc4 66 
Table 7.3 Fibrillin-1 genes in other vertebrates. The mapped location and number of exons of the 
fibrillin-1 gene in birds, fish, reptiles and amphibians is shown. The * signifies that the species has 
annotated genes for fibrillin-1, -2 and -3. The information was obtained from 
http://www.ensembl.org (See Section 7.2.1). 
Fibrillin-1 transcripts were well represented in the available mammal, bird, reptile and 
amphibian genomes (Table 7.2 and 7.3). The fibrillin-1 sequence for Procavia capensis 
(hyrax), Echinops telfairi (lesser hedgehog tenrec), Pteropus vampyrus (megabat), Sorex 
araneus (shrew), Choloepus hoffmanni (sloth), Tarsius syrichta (tarsier) and Macropus 
eugenii (wallaby) had been mapped to scaffolds that did not have the flanking genes 
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present (Table 7.2). The identified fbn1 in Xiphophorus maculates  (platyfish) was 
divided across two scaffolds, JH55670 and AGAJ01039647, though located near the 
flanking genes (Table 7.3). The lamprey sequence also mapped to two scaffolds, one 
showing flanking genes that map approximately 20 Mb distal to FBN1 on chromosome 
15 in humans.  
The first half of the gene, in humans, contained three very long introns and only seven of 
the exons, with the second half having the majority of the exons interspersed with short 
introns. Figure 7.1 highlights this architecture of human FBN1 compared with the 
intron/exon architecture for species where the amino acid sequence at the beginning of 
the gene shows high similarity to the human sequence (mouse, sheep, ferret and Chinese 
softshell turtle).  For many species, the first annotated exon did not contain the start 
codon or did not contain sequence matching the first human coding exon, suggesting that 
annotation of the 5’ end of many FBN1 genes is incomplete. For example in pig, the first 
long intron was present but the longest intron absent and many more exons were 
identified. The first exon after this long intron in pig was found by BLAT analysis to map 
to the middle of the human gene, and it is likely that the intervening exons are artefacts of 
sequence annotation or assembly.  
 
Figure 7.1. Fibrillin-1 gene architecture. FBN1 gene structure (Chapter 6) of species discussed in 
Section 7.3.1 is shown. The vertical lines depict exons, and the horizontal (v-shaped) lines represent 
introns. These images were obtained from http://www.ensembl.org.   
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Mouse, sheep, ferret and Chinese softshell turtle showed the 5’ long intron and sparse 
exon distribution characteristic of the first half of the gene (Figure 7.1). Alignments of 
the total amino acid sequence of the species indicated that the first coding exon was 
homologous across these species, indicating high levels of similarity in the architecture of 
the gene (Table 7.4).  
A total of 19 mammals, birds and fish were selected for additional sequence analysis 
(MegAlign, DNstar) (Table 7.4).  When compared with the complete human fibrillin-1 
amino acid sequence, bushbaby had the highest percent identity at 97.9%, but all the 
mammals were close to this value (Table 7.4). In birds, the fibrillin-1 sequence was more 
diverse at around 87% (Table 7.4). While the Chinese softshell turtle showed a high level 
of homology at 87.4%, the fish were the most divergent with the highest amino acid 
percent identity in coelacanth at 76.8% (Table 7.4).  
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Common Name  FBN1 FBN2 FBN3 
Mammals    
Mouse  96.3 96.6 X 
Pig 96.5 94.7 86.5 
Sheep 97.5 97.7 82.6 
Ferret  96.8 97.7 84 
Bushbaby 97.9 97.5 82 
Panda  97.4 X 85.4 
Armadillo  96.7 91 82.9 
Birds     
Chicken  86.9 91.4 71.1 
Flycatcher  87.3 87.8 67.9 
Fish    
Coelacanth 76.8 80.8 X 
Fugu 71.6 X 69.2 
Medaka 72.3 X 68.7 
Spotted gar 75 X 63.4 
Stickleback 70.7 X 68.9 
Tetraodon 71.3 X 68.8 
Tilapia 73.3 X 68.3 
Reptile     
Chinese softshell turtle 87.4 92 48.2 
Table 7.4.  Percent identity of amino acid sequences to the human fibrillin sequences across 
vertebrates. The percent identity was defined through a ClustalW alignment (DNASTAR) of the 
predicted amino acid sequences (Appendix C). Fibrillin-2 sequences for panda and spotted gar and 
fibrillin-3 sequence for coelacanth were omitted from the analysis due incomplete sequencing. The X 
depicts no mapped gene to the respective genome.  
 
7.3.2 Conservation of Fibrillin-2  
The FBN2 gene was located on chromosome 5 in humans, between flanking genes 
SLC12A2 (3’ end) and SLC27A6 (5’ end). There were 65 annotated exons. The FBN2 
gene covered over 250,000 bps and the longest transcript was 11,132 bps. A total of 51 
vertebrates with annotated FBN2 genes were identified (Table 7.5 and 7.6). A gene 
annotated as encoding FBN2 was present in most mammal and bird genomes available, 
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but it was missing from the majority of fish genomes, except coelacanth, spotted gar, 
Astyanax mexicanus (cavefish) and Danio rerio (zebrafish) (Table 7.6).  
Many species lacked complete annotation, as measured by variations in the number of 
exons annotated, lack of synteny and lack of a start codon in the first coding exon, with 
respect to human. For example fbn2 in zebrafish had only 17 exons annotated (Table 
7.6).  In addition, species including armadillo, coelacanth, lesser hedgehog tenrec, 
platypus, shrew, sloth, and Dipodomys ordii (kangaroo rat) were mapped to short contigs 
with no flanking genes (Table 7.5). 
Common Name  Chromosomal/Scaffold Flanking genes  
 
Exons 
Human Chr. 5 SLC12A2, SLC27A6 65 
Alpaca  Sc_3525 SLC12A2 70 
Armadillo Sc_3526 Data not available  84 
Bushbaby Sc_GL873522.1 SLC12A2 66 
Cat  Chr. A1 *SLC12A2, *SLC27A6 66 
Chimpanzee Chr. 5 SCL12A2, SLC27A6 64 
Cow Chr. 7 SLC12A2, SLC27A6 100 
Dog Chr. 11 SLC12A2 , SLC27A6 65 
Dolphin Sc_186 SLC12A2  76 
Elephant  Sc_1 SLC12A2, SLC27A6 65 
Ferret GL896898.1 SLC12A2 65 
Gibbon GL397277.1 SLC12A2 64 
Gorilla  Chr. 5 Slc12a2 63 
Guinea Pig  Sc_6 Slc12a2, Slc27a6  71 
Hedgehog Sc_4310 Data not available  71 
Horse  Chr. 14 SLC12A2, SLC27A6 68 
Hyrax Sc_3612 *SCL12A2, SLC27A6 79 
Kangaroo rat  Sc_3272 Data not available  73 
Lesser hedgehog tenrec Sc_4180 Data not available  77 
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Macaque Chr. 6 SLC12A2, SLC27A6 69 
Marmoset Chr. 2 SLC12A2, SLC27A6 65 
Megabat  Sc_253 SCL12A2, *SCL27A6 77 
Microbat  GL429767 SLC12A2, SLC27A6 67 
Mouse  Chr. 18 Slc12a2, Slc27a6 65 
Mouse Lemur  Sc_2153 *SLC12A2, *SLC27A6 74 
Opussum Chr. 3 *SLC12A2  44 
Orangutan Chr. 5 SCL12A2, SLC27A6 65 
Panda GL192553.1 SLC12A2 , SLC27A6 68 
Pig Chr. 2 SLC12A2, SLC27A6 56 
Pika  Sc_2449 *SLC12A2,* SLC27A6 75 
Platypus Contig 4457 Data not available    
Rabbit  Chr. 3 SCL12A2, SLC27A6 65 
Rat  Chr. 18 Slc12a2, Slc27a6 59 
Sheep Chr. 5 SLC12A2 65 
Shrew  Sc_3494 Data not available  99 
Sloth Sc_3915 Data not available  74 
Squirrel JH393314.1 SLC12A2 66 
Tarsier  Sc_4048 *SLC12A2,* SLC27A76 83 
Tree Shrew  Sc_2703 *SLC12A2 76 
Table 7.5. Fibrillin-2 genes in mammals. The mapped location and number of exons of the fibrillin-2 
gene among mammalian species is shown. Information was obtained from http://www.ensembl.org 
(See Section 7.2.1).The * indicates the gene name varies on Ensembl.  
Chapter 7. Evolutionary conservation of the fibrillin gene family 
 183 
 
Common Name  Chromosomal/Scaffold Flanking genes  Exons 
Birds    
Chicken Chr. Z SLC12A2 74 
Duck KB743087.1 SLC12A2 63 
Flycatcher JH603436.1 SLC12A2 66 
Turkey  Chr. Z SLC12A2 66 
Zebra finch Chr. Z SLC12A2 67 
Fish    
Cave fish  KB882157.1 slc12a2 , slc27a6 67 
Coelacanth JH128014.1 Data not available  62 
Spotted gar LG_2 slc27a6, slc12a2 65 
Zebrafish Chr. 10 slc12a2 17 
Reptiles & amphibians    
Anole Lizard Chr. 2 slc12a2, slc27a6 66 
Chinese softshell turtle  JH211314.1 scl12a2, slc27a6 97 
Xenopus GL172643.1 slc12a2 , slc27a6 67 
Table 7.6 Fibrillin-2 genes in other vertebrates. The mapped location and number of exons of the 
fibrillin-2 gene in birds, fish, reptiles and amphibians is shown. The information was obtained from 
http://www.Ensembl.org (See Section 7.2.1). 
 
Human FBN2 intron/exon architecture was compared with the structure of the FBN2 gene 
in other species with a homologous first coding exon (Figure 7.2). Human, mouse, sheep, 
ferret and Chinese softshell turtle showed similar FBN2 exon/intron boundaries with long 
introns in the 5’region, as also found for FBN1 (Figure 7.1). 
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Figure 7.2. Fibrillin-2 gene architecture. FBN2 gene structure (Chapter 6) of species discussed in 
Section 7.3.2 is shown. The vertical lines depict exons, and the horizontal (v-shaped) lines represent 
introns. These images were obtained from http://www.ensembl.org.     
 
Amino acid sequence alignments were performed on a subset of vertebrate species to 
determine overall sequence homology to human fibrillin-2. The number of vertebrates in 
the alignment was depleted for fibrillin-2 in comparison to fibrillin-1 (Table 7.4). This 
was due to the lack of annotated fibrillin-2 genes in the fish species as well as incomplete 
sequencing of spotted gar and panda FBN2 genes. The mammals showed the highest 
sequence homology, as high as 97.7% (sheep and ferret)(Table 7.4). Similar to fibrillin-1 
(Table 7.3), the Chinese softshell turtle had higher amino acid sequence conservation 
than the birds, showing a percent identity of 92%, though chicken FBN2 had a percent 
identity of 91.4%.  Of the fish with an identified fibrillin-2 gene, coelacanth had a 
complete amino acid sequence and had 80.8% sequence homology with human (Table 




Chinese softshell turtle fbn2 
Ferret FBN2 
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7.3.3 Conservation of Fibrillin-3 
Fibrillin-3 mapped to chromosome 19 in humans, and contained 64 exons. The gene was 
located between flanking genes CERS4 (also known as LASS4) (upstream) and CTXN1, 
TIMM44 and CCL25 (downstream). The gene mapped within the annotated ELAVL1 
gene. Annotation and assembly of the FBN3 genes for many species was incomplete, as 
seen for FBN1 and FBN2. For example, FBN3 in the hyrax, platypus, shrew, wallaby, 
lamprey and anole lizard genomes was mapped to short contigs with no information on 
flanking genes (Table 7.7 and 7.8).  
Common Name Chromosome/Scaffold Flanking genes  Exons 
Mammals       
Human  Chr. 19 LASS4, (ELAVL1), CCL25, TIMM44 64 
Armadillo JH583495.1 CTNX1, ELAVL1 23 
Bushbaby GL873590.1 CCL25, ELAVL1, TIMM44 68 
Cat  Chr. A2 ELAVL1, TIMM44 72 
Chimpanzee Chr. 19 CCL25, ELAVL1, TIMM44, LASS4 62 
Cow Chr. 7 LASS4, TIMM44 66 
Dog Chr. 20 LASS4, TIMM44, ELAVL1 63 
Dolphin Sc_1255 CCL25 80 
Elephant  Sc_114 ELAVL1, TIMM44, LASS4, CCL25 72 
Ferret GL897062.1 CCL25, ELAVL1, TIMM44, LASS4 71 
Gibbon GL397524.1 CCL25, ELAVL1, TIMM44 59 
Gorilla  Chr. 19 LASS4, TIMM44, ELAVL1 68 
Guinea Pig  Sc_195 Lass4, Timm44, Elavl1 67 
Hyrax Sc_3824 Data not available  86 
Macaque Chr. 19 ELAVL1, TIMM44 67 
Marmoset Chr. 22 CCL25 56 
Megabat  Sc_1458 CCL25, LASS4 67 
Opossum Chr. 3 ELAVL1, TIMM44 64 
Orangutan Chr. 19 CCL25, ELAVL1, TIMM44, LASS4 66 
Panda GL192871.1 CCL25, ELAVL1 76 
Pig Chr. 2 CCL25, ELAVL1, TIMM44, LASS4 24 
Platypus Contig_4457 Data not available  60 
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Rabbit  GL018767 LASS4, TIMM44, CCL25 68 
Sheep  Chr. 5 CCL25, ELAVL1,  73 
Shrew  Sc_3690 Data not available  53 
Squirrel JH393398.1 CCL25, ELAVL1 63 
Tasmanian devil GL841426.1 TIMM44, ELAVL1 68 
Wallaby Sc_5231 Data not available  72 
Table 7.7. Fibrillin-3 genes in mammals. The mapped location and number of exons of the fibrillin-3 
gene among mammalian species is shown. Information was obtained from http://www.ensembl.org 
(See Section 7.2.1). 
 
Common Name  Chromosome/Scaffold Flanking genes  Exons 
Birds    
Chicken  Chr. 28 TIMM44, LASS4 65 
Duck KB743016.1 CTNX1, TIMM44 59 
Flycatcher JH603387.1 CTNX1, TIMM44 71 
Turkey Chr. 30 TIMM44, ELAVL1 10 
Zebra finch Chr. 28 TIMM44 68 
Fish       
Cave fish KB882097.1 ctnx1, timm44 65 
Cod Sc_1986 timm44 68 
Coelacanth JH126613.1 timm44 72 
Fugu Sc_122 timm44 62 
Lamprey GL476354 Data not available  67 
Medaka Chr. 4 timm44 81 
Platyfish JH556710.1 timm44 68 
Spotted gar Chr. LG19 ctnx1, timm44 64 
Stickleback groupVIII ctnx1 64 
Tetraodon Chr. 1 timm44 68 
Tilapia  GL831140.1 timm44 65 
Chapter 7. Evolutionary conservation of the fibrillin gene family 
 187 
Reptiles/amphibians    
Anole Lizard GL344437.1  Data not available 56 
Chinese softshell turtle JH209348.1 timm44 56 
Xenopus GL173191.1 timm44 63 
Table 7.8. Fibrillin-3 genes in birds, fish, reptiles and amphibians. The mapped location and number 
of exons of the fibrillin-3 gene in birds, fish, reptiles and amphibians is shown. Information was 
obtained from http://www.ensembl.org (See Section 7.2.1). 
In addition, FBN3 transcripts more often mapped to contigs and scaffolds rather than 
fully assembled chromosomes. FBN3 was less represented in the mammals analysed, but 
it was identified in the ferret, Cavia porcellus (guinea pig), and Ictidomys 
tridecemlineatus (squirrel) genomes (Table 7.7) though not in mouse or Rattus 
norvegicus (rat). This is consistent with previous findings that the Fbn3 gene is 
degenerate in mouse and rat (Corson et al., 2004).   
As seen in Figure 7.3, human FBN3 lacked the long 5’ intron regions found in FBN1 and 
FBN2 (Figure 7.1 & 7.2), with exons and introns relatively evenly dispersed throughout. 
This was also seen in FBN3 genes of squirrel and ferret (Figure 7.3). 
 
 
Figure 7.3 Fibrillin-3 gene architecture. FBN3 gene structure (Chapter 6) of species discussed in 
Section 7.3.3 is shown. The vertical lines depict exons, and the horizontal (v-shaped) lines represent 
introns. These images were obtained from http://www.ensembl.org.   
The predicted amino acid sequence was analysed to determine homology against several 
vertebrate species (Table 7.4).  There was overall less homology than that seen for the 
other fibrillin family members. Fbn3 in pig had the highest percent identity with human, 
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mammals at 82% (Table 7.4). Interestingly, squirrel Fbn3 had 85.1% homology with 
human. Chicken Fbn3 had the highest homology with human of the birds at 71.1%. 
Chinese softshell turtle had the lowest sequence homology at 48.2% and coelacanth had 
the highest of the fish at 69.2% (Table 7.4).  
 
7.3.4 Conservation of highest expressing promoter regions for 
fibrillin-1,-2 and -3 
The major promoter regions for FBN1, FBN2 and FBN3 were identified using the 
FANTOM5 data for human and mouse (Chapter 6)(Table 7.9). 
Gene  Promoter 
Name  
Location Sequence of TSS region (5’-3’) 
Human 
FBN1 
p9@FBN1 chr15: 48,937,983- 
48,937,988 
AAAAGT 
 p6@FBN1 chr15: 48,937,954- 
48,937,964 
CGCTGCGGGC 




 p2@FBN1 chr15: 48,937,854- 
48,937,881 
CAGGAGCCACAGCTGGCACAGCTGCGAG 













p1@FBN2 chr5: 127,873,926- 
127,873,945 
CTCCACCGCCGCATCTTCTC 











p2@FBN3 chr19: 8,214,471- 
8,214,486 
AGAGCTGCCACTCGGG 
Table 7.9. Human and mouse high expressing transcription start sites (TSS; determined from 
FANTOM5 database). Conservation of the sequence from 200 bases upstream to 100 bases 
downstream of these TSSs, which contained the promoter and regulatory elements, was determined 
across available vertebrates. See Figures 7.4 and 7.5.  
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An analysis of the region flanking the major transcription start sites was performed to 
determine if the sequence of these promoter regions was conserved across species.  
 
Figure 7.4. Sequence alignment of the promoter region of FBN1. The sequences are presented in 5’-
3’ direction showing the coding strand.  Human promoters detected in the FANTOM5 data are 
boxed and labelled within the human sequence. p1@Fbn1 and p2@Fbn2 are outlined in the mouse 
sequence. Nucleotides that are different from the human sequence are marked with black shading, 
except in the 3’ region of the panda where the sequence is not available (depicted with “N”). 
The alignment of the fibrillin-1 promoter region revealed a high level of conservation 
across the selected species. p1@FBN1, p2@FBN1 and p3@FBN1 showed sequence 
discrepancies in the ferret. p1@FBN1 was highly conserved, although a single nucleotide 
change was seen in all the non-human species, showing a pyrimidine switch (T→C) 
(Figure 7.4). p2@FBN1 also showed minor differences, with an insertion of  C and a 
transition from an A to a G nucleotide in all species other than humans (Figure 7.4). 
Chapter 7. Evolutionary conservation of the fibrillin gene family 
 190 
Sequence homology was high for p6@FBN1 and p9@FBN1, but concrete observations 
were unable to be made for p3@FBN1 due to incomplete sequencing. Directly upstream 
of the p9@FBN1 promoter region, the C/T rich region identified in (Guo et al., 2008, 
Summers et al., 2009) was found for all mammals examined (Figure 7.4).  
Of the five promoters for fibrillin-1 of mouse (http://fantom.gsc.riken.jp/zenbu/), 
p1@Fbn1 and p2@Fbn2 had the highest overall expression, and aligned with p1@FBN1 
and p2@FBN1 of human, respectively. p1@Fbn1 showed many sequence variations with 
the other species, while p2@Fbn2 was showed high sequence similarity (Figure 7.4). 
Overall, the transcription start site region of FBN1 was highly conserved across species 
(Figure 7.4).  
 
Figure 7.5. Sequence alignment of the promoter region of FBN2. The sequences are presented in 5’-
3’ direction showing the coding strand.  Human promoters detected in the FANTOM5 data are 
boxed and labelled within the human sequence. Nucleotides that are different from the human 
sequence are marked with black shading. 
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The alignment of the human sequence containing p1@FBN2 and p2@FBN2 with other 
species showed high sequence similarity across the transcription start site region (Figure 
7.5). p2@FBN2 showed two distinct sequence substitutions from T, in humans, to C in 
other species (Figure 7.5). There was a highly conserved G/C rich repeat region followed 
by a poly-A tail just upstream of p1@FBN2 (Figure 7.5). There was one robust promoter 
identified for Fbn2 in mouse, p1@Fbn2, but it was located further upstream of the region 
analysed (http://fantom.gsc.riken.jp/zenbu/).  
The alignment of the promoter region for FBN3 was less obvious (data not provided). 
Because it is only expressed in a limited number of foetal tissues, and is not found in 
mouse, only the human sequence was detected in the FANTOM5 data. The 5’ sequence 
was poorly annotated across the species examined; therefore concrete conservation of the 
region could not be determined. Further studies would be needed to determine the 
conservation of the FBN3 promoter, including sequencing the 5’ upstream region of 
FBN3 in species with an annotated FBN3 gene, then performing comparative studies.  
7.3.5 Conservation of the region of severe mutations 
Predicted amino acid sequences of exon 24-33 (www.ensembl.org) for human fibrillin-1, 
fibrillin-2 and fibrillin-3 were aligned (ClustalW), showing 75.1% homology between 
fibrillin-1/ fibrillin-2, 69.3% for fibrillin-2/ fibrillin-3 and 64.5% for fibrillin-1/fibrillin-3 
(Figure 7.6). This was greater than the sequence similarity over the whole amino acid 
sequence (fibrillin-1/fibrillin-2 = 68.3%; fibrillin-2/fibrillin-3 = 67.4%; fibrillin-
1/fibrillin-3 = 60.1%). 
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Figure 7.6. Predicted amino acid sequence of exons 24 to 33 in the three FBN genes. The conserved 
TB domain (TB5) is outlined. The * symbolises the beginning of the exons. Black shading shows 
sequence variation when compared to the majority sequence. 
The sequence similarity of the region was higher than the overall amino acid 
conservation (Table 7.10). In addition, the eight cysteine residues associated with the 
TB5 (in exon 24), were conserved across all three fibrillins (Figure 7.6) consistent with 
earlier TB domain analysis (Piha-Gossack et al., 2012). The region of severe FBN1 
mutations corresponding to the region of most FBN2 mutations was highly conserved 
across several vertebrate species for both FBN1 and FBN2 (Table 7.10).  
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Common Name Human FBN1  % identity with 
other FBN1 vertebrates 
Human FBN2 % identity with 
other FBN2 vertebrates  
Mouse 96.9 98.1 
Pig 98 99.2 
Sheep 98.3 98.7 
Ferret 97.8 98.7 
Bushbaby 98 95 
Panda 98 X* 
Armadillo 96.7 85.1 
Chicken 86.7 92.9 
Flycatcher 88.5 85.7 
Turkey 87.1 43.2 
Coelacanth 83.2 88.9 
Fugu 73.2 X 
Medaka 74.3 X 
Spotted gar 80 X 
Tetraodon 73.6 X 
Turtle 86.7 94.1 
Table 7.10. Percent Identity of predicted amino acid sequence for exons 24 to 33 of fibrillin-1 and 
fibrillin-2. The % identity was calculated from the Clustal W alignment (DNAStar, Lasergene, 
Madison, WI, USA) of the sequences against the human sequence. The X* signifies unannotated 
sequence in the region, while the X signifies that a transcript was not identified for that species. 
This region showed extremely high similarity in mammalian fibrillin-1 and fibrillin-2, 
highest in pig at 98.3% and 99.2%, respectively. Chicken showed the highest percent 
identity of the birds (86.7% for fibrillin-1 and 92.9% for fibrillin-2), and coelacanth the 
highest for the fish species (83.2% for fibrillin-1 and 88.9% for fibrillin-2). Sequence 
homology was also high in the Chinese softshell turtle at 86.7% and 94.1% for fibrillin-1 
and fibillin-2 respectively.  Thus the region showed considerable sequence homology 
across the group of vertebrates that could be assessed (Table 7.10)  
Chapter 7. Evolutionary conservation of the fibrillin gene family 
 194 
The high degree of conservation of this region is consistent with the severe nature of the 
phenotype caused by mutations in the region. The conservation of amino acids affected 
by a number of mutations with phenotypes ranging from severe neonatal to mild adult 
MFS and CCA (Table 7.11) was examined across species.  
 
Mutation  Exon 
Location 
Domain Region Mutation 
Type 
Disease Reference  
Fibrillin-1      
p.Ile953_Asp1113d
el 




Neonatal MFS Apitz et al., 
2010 
p.Gly1013Arg 24 TB5/cbEGF Tv Neonatal MFS Nijbroek et al., 
1995 
p.Ile1048Thr 25 cbEGF Tv  Neonatal MFS Lonnqvist et al., 
1996 
p.Arg1137Pro 27 cbEGF Missense  MFS Dietz et al., 1991 
p.Cys1265Arg 30 cbEGF Ts MFS Montgomery et 
al., 1998 




33 cbEGF In frame 
deletion 
Neonatal MFS Blyth et al., 
2008 









Jacquinet et al., 
2014 








et al., 2010 







Goldblatt et al., 
2011 









      
Fibrillin-2      
p.Gly1056Asp 24 TB5/cbEGF Tv CCA Park et al., 1998 
p.Asp1115His 26 cbEGF Tv CCA Babcock et al., 
1998 
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p.Cys1198Tyr 28 cbEGF Ts CCA Gupta et al., 
2002 
p.Cys1323Arg 31 cbEGF Ts CCA www.umd.be/FB
N2/ 
p.Cys1425Gly 33 cbEGF Tv CCA Callewaert et al., 
2009 
Table 7.11 Mutations affecting amino acids examined for conservation. The mutations analysed were 
within the severe MFS region (exon 24-33) and those with a lipid depletion phenotype (Exon 64) 
(Section 7.1 and 7.3.5). Transitions (purine to purine or pyrimidine to pyrimidine) are depicted with 
Ts and transversions (switch from a purine to a pyrimidine or vice versa) with Tv. 
Mutation p.Ile953_Asp1113del was discovered in fibrillin-1 of a patient presenting with 
severe neonatal MFS, ultimately leading to premature death (Apitz et al., 2010)(Table 
7.11). The mutation results in an in frame deletion of exon 24 to 26. The deletion begins 
at Ile953, which is located upstream of TB5 of fibrillin-1 and amino acid Ile 953 is 
conserved in fibrillin-1 and fibrillin-2 (Figure 7.6), highly conserved across vertebrates, 
along with exons 24-26 (Figure 7.7). p.Leu1364_Asp1404del of fibrillin-1, was also 
identified in a patient with severe neonatal MFS, resulting in an in frame deletion of exon 
33 (Blyth et al., 2008)(Table 7.11). Exon 33 contains a cbEGF binding domain and N-
glycosylation site (NGT) and is highly conserved across the vertebrates, with slight 
sequence differences in the fish species (Figure 7.8). Leu1364 is homologous across the 
three fibrillin proteins (Figure 7.6). Amino acids associated with mild forms and 
phenotypes of human MFS (Ile1048, Arg1137, Cys1265, and Gly1301 (Lonnqvist et al., 
1996, Dietz et al., 1991, Blyth et al., 2008, Montgomery et al., 1998))(Table 7.11) are 
also highly conserved across vertebrate species (Figure 7.8) and conserved across the 
fibrillin protein family (Figure 7.6).  
The recurrent mutation p.Gly1013Arg in fibrillin-1 has been associated with severe adult 
MFS, including cardiovascular complications (Nijbroek et al., 1995)(Table 7.11). The 
glycine residue at that position in fibrillin-1 is highly conserved across the vertebrates 
(Figure 7.7). Interestingly, a mutation at the glycine residue residing in the same location 
on fibrillin-2, Gly1056, has been implicated in a mild form of CCA (Table 7.11) and is 
fully conserved across the selected vertebrates (Figure 7.8). Both mutations are located 
within highly conserved cbEGF-like binding domains of fibrillin-1 and fibrillin-2 (Figure 
7.7 & 7.8). Furthermore, the glycine amino acid residue at that position is conserved in 
fibrillin-3 (Figure 7.6). Amino acid substitution mutation p.Asp1115His in fibrillin-2 
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was identified in a patient presenting phenotypically with CCA, located in exon 26 and 
Asp1115 was found to be fully conserved across the selected vertebrates (Figure 7.8). 
Fibrillin-2 amino acid residues, Cys1198, Cys1323 and Cys1425 (Gupta et al., 2002, 
Callewaert et al., 2009) (http://www.umd.be/FBN2/) have been associated with CCA, 
and were also highly conserved amino acid residues across the selected vertebrates 




Chapter 7. Evolutionary conservation of the fibrillin gene family 
 197 
 
Figure 7.7 The region of fibrilin-1 where mutations causing severe phenotypes occur.  Clustal W 
alignment (DNAStar, Lasergene, Madison, WI, USA) of exon 24-33 across vertebrates. The amino 
acids analysed are outlined and sequence differences from the human sequence are shaded in black. 
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Figure 7.8. The region of fibrilin-2 where mutations causing CCA occur.  Clustal W alignment 
(DNAStar, Lasergene, Madison, WI, USA) of exon 24-33 across vertebrates. The amino acids 
analysed are outlined and sequence differences from the human sequence are shaded in black.  
 
7.3.6 Fibrillin-1 mutations associated with lipid depletion 
As discussed in Chapter 3, Section 3.1.4, severe generalised lipodystrophy was recently 
identified in four patients diagnosed with MFS or marfanoid habitus (Jacquinet et al., 
2014, Graul-Neumann et al., 2010, Goldblatt et al., 2011, Takenouchi et al., 2013). All 
four cases had mutations affecting exon 64, at the C terminus of fibrillin-1 (Table 
7.11)(Figure 7.9). All the mutations coded for premature stop codons resulting in a 
truncated protein. The mutations universally removed the amino acid sequence 
N’RGRKRRSTNETDASNIE C’ (which will be referred to as the exon 64 lipid region) 
within exon 64, highlighted in Figure 7.9. Furthermore, the mutations subsequently 
deleted exon 65.  
Exon 64 is not highly conserved among fibrillin-1, -2 and -3 in humans and there are no 
known mutations in the aligning regions of exon 64 in fibrillin-2 or fibrillin-3. In 
addition, the exon 64 lipid region of fibrillin-1 was not conserved across the fibrillin gene 
family (Figure 7.10). The conservation of exon 64 in fibrillin-1 was analysed across the 
selected vertebrates (Figure 7.11). It was well conserved across mammals with sequence 
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discrepancies in bird, reptile and fish species, not only within the N’ terminus of the exon 
but also in the last five amino acids of the lipid region (Figure 7.11). Furthermore the 15 
amino acid residues upstream of the exon 64 lipid region were highly conserved across 
all the vertebrates analysed (Figure 7.11).  
 
 
Figure 7.9. Identifying the amino acid sequence of the exon 64 lipid region of fibrillin-1. This figure 
outlines the four fibrillin-1 mutations associated with a lipodytrophy phenotype (Table 7.11). (A) 
Shows the reference sequence for exon 64 in an unaffected phenotype, (B) shows the sequence of a 
patient with a c.8155_8156del mutation, (C) shows the sequence of a patient with a c.8156_8175del 
mutation, (D) shows the sequence of a patient with a c.8175_8182del and (E) shows the sequence of a 
patient with a c.8226+1G-T mutation, resulting in the deletion of exon 64. (B-E) result in a truncated 
protein. The amino acid sequences highlighted in pink share homology with the reference sequence. 
The blue line represents where the mutation occurs. The amino acids depicted after the blue line are 
those that are incorporated in the protein as a result of the frame shift. The X represents the stop 
codon. The exon 64 lipid region is shown in bold in the reference sequence (A). This figure was 
adapted from (Jacquinet et al., 2014). 
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Figure 7.10 Exon 64 alignment of fibrillin-1, -2 and -3, in human. A ClustalW alignment (DNAStar, 
Lasergene, Madison, WI, USA), shows the exon 64 lipid region (boxed in amino acids black; Section 
7.3.6), and sequence differences from the fibrillin-1 sequence are shaded in black.  
 
Figure 7.11 Conservation of exon 64 of fibrillin-1 across vertebrates. A ClustalW alignment 
(DNAStar, Lasergene, Madison, WI, USA), shows exon 64 lipid region (boxed in amino acids black; 
Section 7.3.6), and sequence differences from the human sequence are shaded in black.  
7.4 Discussion  
7.4.1 Fibrillin conservation  
This chapter presented evidence that the fibrillin gene family is well conserved across 
vertebrate species. This was based on the presence of annotated fibrillin genes/transcripts, 
chromosomal synteny, gene architecture and amino acid sequence homology seen across 
a wide range of vertebrates. FBN1, FBN2 and FBN3 genes were present in the majority 
of annotated genomes in the Ensembl database, including high representation across 
mammals, fish, birds and reptile species. Interestingly, there was a noticeable absence of 
annotated fbn2 genes in fish species, while the fbn3 identified in fish species had the 
intron/exon architecture expected for fbn2 genes (Table 7.6)(Figure 7.3). This could 
indicate the degeneration of fbn2 in some fish species (similar to Fbn3 in mouse and rat), 
although this seems unlikely since four fish species did have a fbn2 gene (Table 7.6). The 
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annotated fbn3 gene could represent an ancestral fbn2/3 gene. Alternatively, this result 
could reflect incomplete sequencing and annotation of these genomes. 
During the course of this research, two studies emerged proposing the evolutionary 
history of the fibrillin family based on the unique protein domain architecture (Piha-
Gossack et al., 2012, Robertson et al., 2010).  Roberston et al. (2010) concluded that a 
single fibrillin gene emerged first based on the unique protein domain organisation 
(Chapter 1, Section 1.3.2) and the presence of a single fibrillin gene in early Cnidarians 
(Jelly fish) (Reber-Muller et al., 1995). Piha-Gossack et al. (2012) proposed that the 
ancestral fibrillin gene underwent a gene duplication event at the point when jawed 
vertebrate species emerged, yielding fbn1 and fbn2/3. Through the evolution of tetrapods, 
the fbn2/3 gene split into separate and functionally relevant genes, known as fbn2 and 
fbn3. This is most likely the reason for the lack of identified fbn2 genes in fish, and the 
fbn3 genes identified may be the merged fbn2/3.  
Though the emerging evolutionary research supported the findings of this study, the loss 
of a functional Fbn3 gene in mice and rats is still not understood. Since the duplication 
event occurred prior to mammal and bird evolution, FBN3 should be present in all 
mammals, including mice and rats (Corson et al., 2003). Corson et al. (2003) 
demonstrated that a functional Fbn3 was not present in mice or rats though Fbn1 and 
Fbn2 are present. They speculate that the Fbn3 gene may have been disrupted during 
mouse evolution because remnants of the gene are still present between the flanking 
genes.  This present study was able to identify a total of 47 vertebrates with annotated 
FBN3 genes, including members of the rodent family, guinea pig and squirrel, which also 
contained annotated genes for Fbn1 and Fbn2. The evidence that Fbn3 is present and 
associated with transcripts in other rodent family members could help to provide further 
information about the role of Fbn3. Future work could be done to knock down or 
knockout the Fbn3 gene in the other rodent family members to examine whether the gene 
is redundant in rodents.  
Extensive work on the FBN1 promoter region had been previously done (Summers et al., 
2009). The 5’ UTR region of FBN1 was shown to be highly conserved in primates (Singh 
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et al., 2008) and in multiple vertebrate species including mouse and pig (Summers, et al., 
2009, Singh et al., 2006). The present study provides evidence that the specific 
transcription start sites in FBN1 might be shared across species (Figure 7.4). This study 
included an analysis of conservation of the promoter regions of FBN2 and FBN3. The 
FBN2 promoter region was highly conserved across the selected species, and it was 
inferred that TSS determined by FANTOM5 CAGE analysis (Table 7.9), identified high 
expressing promoters in sequence that was conserved across the species analysed (Figure 
7.5). Furthermore, this study identified a conserved G/C region upstream of the major 
transcription start site of FBN2 (Figure 7.5). There was very poor sequence homology 
for FBN3 across the selected species, including the promoter region defined by 
p2@FBN3, and hence it seems likely that this region is not strongly conserved.  
This study also demonstrated high homology across regions of the FBN1 and FBN2 
genes associated with severe mutations, indicating the importance of specific amino 
acids, in the fibrillin family. The regions contained exon 24-33 in FBN1 and FBN2. The 
conservation analysis showed overall amino acid sequence homology across these 
regions, that was higher than for the total protein, even in fibrillin-3 (Figure 7.6). In 
addition, there was high conservation of reported single amino acid residues across 
vertebrates (Figure 7.7 and 7.8) and the fibrillin protein family (Section 7.3.5). A study 
done on the factor IX gene, involved in the development of hemophilia B, recognised that 
the more conserved the amino acid, the more likely mutation of that amino acid would 
lead to disease (Popat et al., 1991), a widely accepted theory in the scientific community 
(Strachen T., 2004). While the mutations examined were all already implicated in 
disease, the conservation and consensus sequences indicate regions of fibrillin-3 that may 
harbour mutations with phenotypic effect.   
In contrast, the proposed exon 64 lipid region was not highly conserved across the 
fibrillin family, though it was conserved across FBN1 genes in mammals (Figure 7.10 
and 7.11). Exon 64 is located downstream the final cbEGF binding domain in fibrillin-1. 
The exon 64 lipid region amino acid sequence that was removed as a result of the 
mutations (Figure 7.9)(Table 7.11) consisted of 50% polar and acidic amino acids, and 
was replaced (Figure 7.9B,C and D) in three cases with a highly charged amino acid 
sequence  ETEKHKRN  (Jacquinet et al., 2014). Since mutation c.8226+G-T does not 
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add the highly charged amino acid sequence, it may not be the only factor in the 
development of adipose depletion in with exon 64 fibrillin-1 mutations. Classic MFS 
caused by mutations in other exons generally presents with fat depletion along with 
symptoms that are recognised by the Ghent criteria (Summers et al., 2012), for example 
an exon 25 missense mutation (Summers et al., 2006). It is likely that mutations found in 
exon 64 and 65 that result in classic MFS will also involve a lipodystrophy-like 
phenotype (Collod-Beroud et al., 2003), possibly due to protein missfolding (Jensen et 
al., 2014). Therefore the exon 64 lipid region and the whole of the unaffected exon 65 
sequence may be important in adipose maintenance.  
7.4.2 Conclusions 
This chapter has shown results consistent with available literature supporting the 
evolutionary trends and conservation of the fibrillin gene family. The long 5’ introns of 
FBN1 and FBN2 are consistent with slower production of mature mRNA than FBN3 
which lacks these long introns (Singh and Padgett, 2009) and may reflect the different 
functions of the genes. In addition, preliminary results showed that the TSS regions of 
FBN1 and FBN2 are conserved across vertebrates, although very different from each 
other. This suggests that other species would also show differential expression of the two 
genes (Chapters 3 and 4), mediated through the different transcription factor binding 
motifs associated with the conserved promoter region (Chapter 6). Future studies 
(suggested in Section 7.3.5) will need to be conducted to examine the conservation of the 
TSS region in FBN3. Finally, the chapter has proposed a highly conserved amino acid 
sequence within exon 64 of FBN1 that may be important in adipose development. 
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Chapter 8. General Discussion and Future Studies 
8.1 Summary of Results  
The underlying hypothesis to be tested by the research reported in this thesis was that 
fibrillin-1 is a central regulator of mesenchymal cell differentiation (Summers et al., 
2010). The results showed that the three fibrillin genes are expressed at different 
developmental stages and in different mature cell types (Chapters 3 and 4), in spite of 
the high level of conservation of the protein three sequences across a wide evolutionary 
spectrum (Chapter 7). The different roles were reflected in both the genes with which 
each fibrillin gene was co-expressed (Chapters 3 - 5) and the sequences of their 
regulatory regions (promoters) (Chapters 6 and 7). However, when FBN1 was knocked 
down in fibroblasts (Chapter 5), only a small number of genes were up and 
downregulated, suggesting that fibrillin-1 may be an endpoint rather than key regulator of 
mesenchymal cells.  
 
8.1.1 Fibrillins are differentially expressed.  
The first aim of this study (Chapter 1, Section 1.5) was to analyse the expression of the 
three fibrillin genes at different stages of development and differentiation. Previous 
studies using animal models and human tissues had shown that each fibrillin was present 
at different developmental stages. Zhang et al., (1995) performed in situ hybridization 
assays on mouse embryos at several stages and first proposed that fibrillin-1 was 
expressed in late embryogensis and involved in structural support of developing tissues. 
Also, fibrillin-2 was a possible regulator of early elastic fibre formation and highly 
present in early morphogenesis (Zhang et al., 1995). Quondamatteo et al., (2002) showed 
that fibrillin-1 and fibrillin-2 have different developmental roles based on variability in 
levels of the proteins in different human foetal tissues and organs (weeks 5-12 of 
gestation). Fibrillin-3 was later characterised by (Corson et al., 2004) and proposed to 
have specific functions in human development (Sabatier et al., 2010). Corson et al. 
(2004) demonstrated that fibrillin-3 was not present within rodents, though expressed in 
human foetal tissues such as fibroblasts, brain, and lung (gestation weeks 6-12).  
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In the present study, the expression of fibrillins in various human cell lines was 
examined. The results presented in Chapters 3 and 4 showed that FBN3 was the earliest 
fibrillin to be expressed during ES cell differentiation to mesoderm, followed by FBN2 
and then FBN1. FBN3 was associated with the pluripotent state and its unique role was 
highlighted by the fact that it was not expressed in any of the other cell lines examined, 
which represent more mature mesenchymal states. FBN2 was expressed at the stage of 
mesoderm formation, suggesting FBN2 maybe a mesoderm marker. FBN1 was expressed 
later than either FBN2 or FBN3, in cells already predetermined to go to mesenchymal 
lineages, but it was minimal at the highest level of differentiation suggesting that it may 
be a marker for relatively plastic mesenchymal cells prior to commitment to a specific 
lineage. Surprisingly, given the lipodystrophic phenotype associated with Marfan 
syndrome and other FBN1 mutations, fibrillin-1 was apparently required only at the early 
stages of adipogenic differentiation, and degraded once the process was established.  The 
presence of fibrillin-1 in early adipose differentiation (Chapter 3, Section 3.3.3) may be 
evidence that it assists in preadipocyte scaffold formation. The mRNA was also 
expressed in adult adipocytes (Chapter 6) so may be involved in the constant turnover of 
adipose ECM. In addition, fibrillin-1 was not required to sustain the ECM of cells in 
culture, since one chondrocyte lineage and one osteosarcoma line could proliferate in the 
absence of extracellular fibrillin-1 protein. Consistent with the hypothesis that fibrillin-1 
is a marker for early mesenchymal stages, the osteosarcoma line MG63, with a relatively 
immature osteoblast phenotype, had a high level of FBN1 mRNA and fibrillin-1 protein 
while the more mature osteosarcoma SAOS2 had very low levels. 
 
8.1.2 Fibrillins are co-expressed with genes characteristic of 
different roles  
As shown in Chapter 3, expression of FBN3 was highly correlated with genes involved 
in early embryogenesis, ECM formation, neuronal development and importantly with 
markers of pluripotency. FBN3 mRNA has been detected in meiosis stage II oocytes 
(Kocabas et al., 2006) suggesting that it may be one of the maternal mRNAs that 
populate the oocyte to support the early development of the zygote. Co-expressed genes 
in later foetal stages (Sabatier et al., 2010) were not assessed here but would likely be a 
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different set of genes, possibly associated with development of the foetal mesenchyme. 
Alternatively this later expression of FBN3 might reflect maintenance of a small 
population of pluripotent cells within foetal tissues. These hypotheses could be tested 
using the co-expression analysis outlined here on RNA from foetal tissues. The origin 
(maternal or embryonic) of the FBN3 mRNA in very early embryos could be tested using 
genetic variation in the FBN3 gene. 
FBN2 was co-expressed with genes involved in mesoderm formation (notably EOMES) 
and limb development, suggesting FBN2 maybe a mesoderm marker. In fact, there were 
no genes that co-expressed with FBN2 in the later differentiated samples and the mRNA 
levels remained at a low level in all the cell types (Chapter 4). This is consistent with 
observations that FBN2 may have a role in guiding the formation of the elastin associated 
microfibrils during development (Quondamatteo et al., 2002). Similarly, FBN2 mRNA 
levels remained unaltered despite the depletion of FBN1 in siRNA experiments discussed 
in Chapter 5, supporting differential roles for the fibrillin gene family.    
The co-expression analyses presented in Chapters 3, 4 and 5 provided further evidence 
of the distinct role of FBN1. Its expression was highly correlated with ECM specific 
genes and genes associated with connective tissue diseases. One association that was 
strongly supported by the co-expression studies was the link between the ECM and the 
cytoskeleton. Recent studies suggest changes within the ECM, whether through collagen 
reorganisation or mechanosensing, can alter cellular mobility by causing disruptions in 
cytoplasmic actin fibres (Starke et al., 2014, Provenzano and Keely, 2011). Therefore, it 
is suggested that ECM shape can dictate the plasticity and adaptive response of the 
cytoskeleton (Chapter 5, Figure 5.17). This is important since fibrillin-1 microfibrils are 
valuable structural components of the ECM and this was highlighted by the frequent 
appearance of cytoskeleton genes in the ECM clusters containing FBN1 probesets in 
unaltered adult mesenchyme cells (Chapter 4) and upregulation of actin / actin related 
genes in siRNA treated fibroblasts (Chapter 5).  Since the studies presented in the thesis 
were performed in cell culture systems, whether cancer, transformed or primary cells 
types, the need for communication between the cytoskeletal actin and ECM fibrillin 
microfibrils was limited and further studies should be conducted using tissues or mixed 
cell type models. Future work within in vivo animal model systems that have all three 
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fibrillin genes, for example pig, would greatly improve the study across tissue types 
(Lunney, 2007). For instance, creating a FBN1 knockdown pig would allow for further 
studies on actin response in many mesenchyme tissue types.  
 
8.1.3 Fibrillin genes use alternative promoters in different cell 
types 
In Chapter 6 it was shown that the fibrillin gene family has differentially regulated 
transcription start sites, different promoter structures and no identifiable consistent 
transcription factors (Chapter 6). This was determined using deepCAGE data obtained 
from FANTOM5. Both FBN1 and FBN2 shared similar broad promoter structures, with 
transcription initiation occurring at different nucleotides depending on the cell/ tissue 
type. Promoters for both genes were highly active in cells of mesenchyme origin, for 
example fibroblasts.  The major FBN1 promoters maintained high expression in adult 
mesenchyme cells, consistent with the presence of motifs for transcription factors TBX4 
and TBX5, which are involved in later limb development (Chapter 6, Section 6.5). 
Alternate promoter usage was evident with p7@FBN1, showing high levels of expression 
in neuronal tissues and regulation by neuronal transcription factor, FOXD3. Conversely, 
FBN2 promoters were shown to be regulated by transcription factors highly correlated 
with mesoderm formation, for example KLF4, PAX5 and TRAP2B (Chapter 6, Section 
6.4.5). Furthermore, several FBN2 promoters showed high expression in osteoblast cell 
types, which was consistent with predicted regulation by osteoblast formation 
transcription factor HIF1A (Chapter 6, Section 6.5).  In contrast, the promoter structure 
of FBN3 showed a single major TSS with tissue expression mainly within foetal and 
embryonic cell types. The promoter was predicted to be regulated by key embryogenesis 
transcription factors, SP1, TRAF4 and PATZ1 (Chapter 6, Section 6.4.5). 
 
8.1.4 Fibrillins are highly conserved across vertebrates 
There are significant phenotypes associated with mutations of FBN1 and FBN2 (Chapter 
1). Mutation of FBN3 has not been described and the study of its role is hampered by the 
lack of a functional Fbn3 gene in mouse and rat (Corson et al., 2004). However, the 
present study identified Fbn3 transcripts in other rodents, for example squirrel (Chapter 
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7), though the functional nature of the gene will need to be addressed in the future. The 
different times of expression and varying sets of co-expressed genes suggested that the 
fibrillins have different roles in the multicellular eukaryote. Therefore a study of the 
evolutionary conservation of the fibrillins, focussing on promoters because of their role in 
gene regulation and two regions of significant mutations, was performed (Chapter 7). 
The promoter regions for FBN1 and FBN2 were well conserved across vertebrates. 
Conservation in the promoter region of FBN3 was unable to be determined due to poor 
annotation of the 5’UTR region of the gene across vertebrates. In addition, high levels of 
conservation of the “neonatal region” (where severe FBN1 mutations and almost all 
FBN2 mutations map) were shown across vertebrates. This represents a key candidate for 
inactivating mutations of FBN3. Finally, conservation of the lipodystrophy region at the 
3’ end of the genes was observed. It is likely that this region of FBN1 is critical for 
adipose development and a strong candidate for disease-causing mutations in FBN2 and 
FBN3. Future work to determine the importance of the region in the fibrillin family could 
include upregulation of the truncated region in fibrillin-1 to determine if adipose cells can 
recover. This could be achieved by creating a FBN1 mutant pig as proposed in Section 
8.1.2. In addition, truncating the 3’ lipodystrophy region in both FBN2 and FBN3 in early 
development could determine if development is altered or unaffected in an in vivo model 
system or in appropriate primary cell types. Therefore the conservation of fibrillin 
sequence across vertebrates shows the importance of this gene family. It contrasts with 
the differing expression patterns and roles of the fibrilllins and shows that relatively 
subtle changes in amino acid sequence can make major differences to protein function. 
8.2 Fibrillins as cellular regulators 
Summers et al (2010) showed the high correlation of Fbn1 expression in mouse 
mesenchymal cells advanced the hypothesis that fibrillin-1 might be a central regulator of 
mesenchymal state, suggesting that fibrillin-1 levels might control the expression of a 
suite of mesenchymal genes during development of connective tissue types. Given their 
structural similarity, fibrillin-2 and fibrillin-3 could also be major regulators of different 
stages of differentiation. 
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8.2.1 Is fibrillin-1 a master regulator of mesenchymal state?  
In this thesis several lines of evidence indicate that fibrillin-1 is unlikely to be a key 
regulator of mesenchymal function. 
Firstly, cultures of cells from two mesenchymal lineages grew satisfactorily in the 
absence of a fibrillin-1 microfibril matrix (Chapter 4). If fibrillin-1 is a key regulatory 
protein in mesenchymal cells, it would be expected that these cells might show 
phenotypic abnormalities or fail to grow. It could be explained by the fact that these lines 
represent more mature differentiation (where fibrillin-1 may be less important) and this is 
validated for the osteosarcoma SAOS2 (Section 8.1.1). Alternatively, since these are both 
immortal cell lines adapted for culture they may not need the full repertoire of 
mesenchymal genes that are necessary for a solid tissue in a multicellular organism. 
Secondly, knocking down FBN1 mRNA to about 20% of its normal level in primary 
fibroblasts (Chapter 5) did not result in failure of the culture or in major phenotypic 
abnormalities of the cells, even though slight cytoskeleton actin fibre alterations were 
visible. In addition, knocking down FBN1 mRNA in the chondrocyte and osteosarcoma 
lines which showed high levels of fibrillin-1 protein had no impact on cell function and 
showed no concomitant up or down regulation of any genes. 
Thirdly, in the NHDF cell line, knockdown of FBN1 only affected a small number of 
genes. Although some of these were in FBN1 co-expression clusters, many other co-
expressed genes were unaffected by FBN1KD, suggesting that it only interacts with a 
minimal set of ECM related genes. 
However, the severe connective tissue phenotype that results from FBN1 mutations 
(Chapter 1) and the high level of FBN1 conservation across vertebrates (Chapter 7) is 
consistent with a key role in mesenchymal tissues, manifested through both the structural 
function and the role in TFGβ regulation. In this thesis the role of fibrillin-1 in early 
embryogenesis, adipogenesis and mature cell types was examined. Due to the low levels 
of expression of FBN1 in early development, high levels of fibrillin-1 protein in early 
adipogenesis and consistent FBN1 expression levels in more mature cells types, FBN1 
may have broad regulatory properties in early mesenchyme lineage differentiation. The 
role of fibrillin-1 in later differentiation and mature cells types could be limited to 
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sequestering and inactivation of TGFB (single pathway regulation) and structural support 
of the ECM. Future work such as permanent knockdown of FBN1 early in differentiation 
could provide evidence as to whether fibrillin-1 is required in early development, 
therefore indicating possible key regulatory characteristics. If FBN1 were knocked down 
early in lineage progression (for example during embryoid body formation from H1 ES 
cells or at Day 1 of adipose differentiation in ADMSCs), would the MSCs continue to 
differentiate to the predetermined cell type, or would differentiation be negatively 
affected, or stunted? In addition, would any of the co-expressed genes determined in 
Chapter 3 become up or downregulated, possibly indicating further targets for gene 
therapy treatment.  
8.2.2 Are fibrillin-2 and fibrillin-3 regulatory genes?   
The proposed early regulatory action by fibrillin-1 could be similar to what is seen in 
both fibrillin-2 and fibrillin-3. Fibrillin-2 failed to co-express with any genes in adipose 
differentiation or in more mature cells types, and had low levels of mRNA expression. 
However, FBN2 was highly expressed prior to FBN1 expression in early ES cell 
differentiation to mesoderm, and co-expressed with many key mesoderm specific 
markers. Therefore, FBN2 could have regulatory properties in mesoderm formation but is 
likely an endpoint in mesenchyme lineage progression and adult cell types. FBN3 mRNA 
appeared very early in ES cells, co-expressing with several key ES and pluirpotency 
markers, and is also expressed in foetal tissues during human development. Therefore, 
fibrillin-3 could be a key regulator of early differentiation, and an endpoint important for 
early connective tissue development in foetal tissues. Future knockdown studies during 
early ES cell differentiation and mesoderm development, either in vitro (human ES cells) 
or in vivo (pig) would be useful in determining whether depletion of FBN3 would block 
development to embryoid body formation, or if depleted levels of FBN2 in mesoderm 
differentiation would affect mesenchymal stem cell formation and progression. The 
knockdown of FBN3 could also determine whether the gene is redundant as the 
functional transcript has been lost in certain rodents, or if the gene is embryonic lethal, 
therefore implying the role of fibrillin-3 must have been assumed by fibrillin-2 or another 
protein in mice and rats. In addition to permanent knockdown or knockout experiments, 
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conditional knockouts at specific points in ES development, for example mesoderm and 
embryonic body formation for FBN2 and FBN3, respectively, could further determine the 
role of the fibrillin genes at specific developmental stages. As was shown in Chapter 3, 
there were multiple genes that co-expressed with FBN2 and FBN3 providing insight into 
the function of the genes. The proposed future knockdown/knockout studies (either 
permanent or conditional), along with performing widescale co-expression studies as 
described in this thesis, could determine whether any of the co-expressed genes are 
altered. This would then provide further evidence to the regulatory role of FBN2 and 
FBN3 in early development as well as propose genes targets that could assist in treating 
diseases with FBN2 and possible FBN3 mutations.  
8.3 Role of fibrillin family members in differentiation and 
development 
In Section 8.2, it is proposed the fibrillin-1, fibrillin-2 and fibrillin-3 have the potential to 
be key regulators at different points within early development, though their role in mature 
mesenchyme cell types could be classified as an endpoint. These studies have provided 
evidence for two waves of expression for each of these genes, one during the initial 
stages of embryo formation (exemplified by the pattern of expression in ES cells) and a 
second in maturing or mature connective tissues. A model is proposed where the early, 
precisely timed expression of the different fibrillins is essential to trigger appropriate 
signalling leading to the development of mesoderm and further differentiation into 
mesenchyme.  The later wave of expression in foetal and adult tissues is involved in 
regulating local TGFß family member levels as well as providing structure to the 
connective tissues, but may not have the central regulatory role at these developmental 
stages. The proposed experiments in early embryogenesis and lineage progression 
described above would be important in uncovering the exact timing and importance of 
the regulatory roles.  
Although extensive studies have been performed on FBN1 and FBN2 null or mutant 
mice, the lack of FBN3 and the anatomical and physiological differences between mice 
and humans limit their relevance to human conditions. Large animals (for example pigs 
and sheep) have been used extensively to develop surgical techniques for use in humans 
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and to understand human physiology and pathology (Lunney, 2007, Hasenfuss, 1998, 
Dixon and Spinale, 2009, Meeusen EN, 2009). Recent developments in large animal 
genome modification and genome editing (Bruce et al., 2013, Lillico et al., 
2013)(Chapter 5, Section 5.4.3) open the possibility of developing relevant models to 
investigate the fibrillin gene family. This will be particularly relevant in understanding 
the role and function of FBN3. In addition to large animal models, to further understand 
the evolutionary loss of Fbn3 in rodents, introducing cDNA containing functional Fbn3 
(from other species, for example, squirrel) into mouse and/or rat ES cells could reveal the 
functional relevance of the gene in rodents.   
This thesis has provided a better understanding of the fibrillin gene family (Sections 8.1 
and 8.2) and dicusses their role in not only diseases with known mutations but also many 
other associated diseases such as thoracic aneurysm and dissections, obesity, 
lipodystrophy, and ovarian syndromes. The work presented in this thesis has contributed 
to the field of fibrillin research by proposing mechanisms by which the gene family 
participates in the development, differentiation and maintenance of mesenchyme cell 
types.  
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9.1 Appendix A 
ARK_ID Sample identifier 260/280 nm RINe  
2195M0001 MG63 D-1 1.85 9.2 
2195M0002 MG63 D0 1.73 9.6 
2195M0003 MG63 D1 CONTROL 1.84 9.5 
2195M0004 MG63 D1 NT 1.82 9.6 
2195M0005 MG63 D1 FBN1KD 1.83 9.7 
2195M0006 MG63 D2 CONTROL 1.76 9.6 
2195M0007 MG63 D2 NT 1.83 9.8 
2195M0008 MG63 D2 FBN1KD 1.74 9.7 
2195M0009 MG63 D3 CONTROL 1.79 9.6 
2195M0010 MG63 D3 NT 1.82 9.6 
2195M0011 MG63 D3 FBN1KD 1.82 9.6 
2195M0012 MG63 D4 CONTROL 1.9 9.5 
2195M0013 MG63 D4 NT 1.84 9.6 
2195M0014 MG63 D4 FBN1KD 1.85 9.7 
2195M0015 MG63 D7 CONTROL 1.77 9.5 
2195M0016 MG63 D7 NT 1.75 9.6 
2195M0017 MG63 D7 FBN1KD 1.8 9.5 
2195M0018 C20A4 D-1 1.93 7.7 
2195M0019 C20A4 D0  1.47 9.1 
2195M0020 C20A4 D1 CONTROL 1.83 9.6 
2195M0021 C20A4 D1 NT 1.67 9.6 
2195M0022 C20A4 D1 FBN1KD 1.83 9.8 
2195M0023 C20A4 D2 CONTROL 1.76 9.7 
2195M0024 C20A4 D2 NT 1.86 9 
2195M0025 C20A4 D2 FBN1KD 1.83 9.7 
2195M0026 C20A4 D3 CONTROL 1.7 8.9 
2195M0027 C20A4 D3 NT 1.52 8.8 
2195M0028 C20A4 D3 FBN1KD 1.32 8 
2195M0029 C20A4 D4 CONTROL 1.76 9 
2195M0030 C20A4 D4 NT 1.98 9 
2195M0031 C20A4 D4 FBN1KD 1.75 9.5 
2195M0032 C20A4 D7 CONTROL 1.71 9.4 
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2195M0033 C20A4 D7 NT 1.71 9.5 
ARK_ID Sample identifier 260/280 nm RINe  
2195M0034 C20A4 D7 FBN1KD 1.71 9.6 
2195M0035 NHDF D-1 2.07 9.4 
2195M0036 NHDF D0 2.03 9.4 
2195M0037 NHDFD1 control 2.06 9.4 
2195M0038 NHDF D1 NT 2.08 9.54 
2195M0039 NHDF D1 FBN1KD 2.07 9.1 
2195M0040 NHDFD2 control 2.16 9.5 
2195M0041 NHDF D2 NT 1.72 9.7 
2195M0042 NHDF D2 FBN1KD 2.06 9.5 
2195M0043 NHDF D3 CONTROL 1.82 9.6 
2195M0044 NHDF D3 NT 1.89 9.2 
2195M0045 NHDF D3 FBN1KD 1.85 9.2 
2195M0046 NHDF D4 control 1.99 9.5 
2195M0047 NHDF D4 NT 2.05 9.6 
2195M0048 NHDF D4 FBN1KD 2 9.3 
2195M0049 NHDF D7 control 2.06 9.4 
2195M0050 NHDF D7 NT 2.05 9.5 
2195M0051 NHDF D7 FBN1KD 2.06 9.4 
2195M0052 NHDF D0 2.17 9.6 
2195M0053 NHDFD1 control 2.15 9.5 
2195M0054 NHDF D1 NT 2.13 9.5 
2195M0055 NHDF D1 FBN1KD 2.18 9.5 
2195M0056 NHDFD2 control 2.16 9.5 
2195M0057 NHDF D2 NT 1.81 9.6 
2195M0058 NHDF D2 FBN1KD 2.08 9.7 
2195M0059 NHDF D3 CONTROL 1.86 9.4 
2195M0060 NHDF D3 NT 1.81 8.7 
2195M0061 NHDF D3 FBN1KD 1.84 9.3 
2195M0062 NHDF D4 control 2.11 9.5 
2195M0063 NHDF D4 NT 2.14 9.4 
2195M0064 NHDF D4 FBN1KD 2.36 8.9 
2195M0065 NHDF D7 control 2.12 9.4 
2195M0066 NHDF D7 NT 2.18 9.5 
2195M0067 NHDF D7 FBN1KD 2.1 9.5 
2195M0068 ADMSC +1 1.93 9.3 
2195M0069 ADMSC +2 1.87 6 
2195M0070 ADMSC +18 1.95 8.8 
2195M0071 ADMSC -1 1.85 9.1 
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2195M0072 ADMSC-2 1.92 9.2 
2195M0073 ADMSC -18 1.99 9.5 
ARK_ID Sample identifier 260/280 nm RINe  
2195M0074 hESMP +3 1.98 9.2 
2195M0075 hESMP+6 1.89 9.1 
2195M0076 hESMP+18 1.95 9.2 
2195M0077 hESMP-3 1.95 9.5 
2195M0078 hESMP-6 1.92 8.8 
2195M0079 hESMP-18 2.01 9.3 
2195M0080 H1 D0 2.02 8.7 
2195M0081 H1 D3 2.06 9.6 
2195M0082 H1 D5 2.04 9.6 
2195M0083 SAOS2D7  1.85 9.2 
2195M0084 SAOS2 D7 2.12 9.5 
2195M0085 MG63 D7 1.91 9.2 
2195M0086 MG63D7 2.13 9.5 
2195M0087 C20A4 D7 1.81 9 
2195M0088 C20A7 D7 2.13 8.8 
2195M0089 TC28A2 D7 1.88 9.6 
2195M0090 TC28A2D7 2.14 9.3 
2195M0091 C28I2 2.13 9.2 
2195M0092 RH1 (24hours) 1.99 9.5 
2195M0093 THP1 1.76 6.8 
2195M0094 HEK293 2.13 9.6 
2195M0095 MG63 T16 (C3) 2.02 9.6 
2195M0096 SAOS2 T16 (Ex9) 2.06 9.6 
 
Chapter 9. Appendences 
 217 
9.2 Appendix B  
Files contained in C.D on the inside back cover of this thesis.  
9.2.1 BioLayout Express 3D Files for Chapter 3 
9.2.2 BioLayout Express 3D Files for Chapter 4 
9.2.3 BioLayout Express 3D Files for Chapter 5 
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9.3 Appendix C 
Common Name Fibrillin-1 Fibrillin-2 Fibrillin-3 
Human  ENSP00000325527 ENSP00000424571 ENSP00000470498 
Mouse  ENSMUSP00000099524 ENSMUSP00000025497 X 
Pig  ENSSSCP00000005017 ENSSSCP00000015165 ENSSSCP00000014445 
Sheep  ENSOARP00000022590 ENSOARP00000018461 ENSOARP00000003672 
Ferret  ENSMPUP00000011768 ENSMPUP00000011697 ENSMPUP00000007296 
Bushbaby  ENSOGAP00000008576 ENSOGAP00000007715 ENSOGAP00000011557 
Panda ENSAMEP00000001943 ENSAMEP00000005373 ENSAMEP00000009357 
Armadillo ENSDNOP00000005602 ENSDNOP00000012246 ENSDNOP00000026528 
Chicken  ENSGALP00000007941 ENSGALP00000023620 ENSGALP00000000432 
Flycatcher  ENSFALP00000012028 ENSFALP00000012882 ENSFALP00000001070 
Turkey  ENSMGAP00000007192 ENSMGAP00000008154 ENSMGAP00000018726 
Coelacanth  ENSLACP00000010136 ENSLACP00000002844 ENSLACP00000018340 
Fugu ENSTRUP00000043351 X ENSTRUP00000032967 
Medaka  ENSORLP00000003276 X ENSORLP00000006743 
Spotted gar  ENSLOCP00000005288 ENSLOCP00000010204 ENSLOCP00000016276 
Stickleback ENSGACP00000022153 X ENSGACP00000013669 
Tetraodon ENSTNIP00000003762 X ENSTNIP00000001525 
Tilapia  ENSONIP00000016782 X ENSONIP00000002223 
Chinese softshell 
turtle 
ENSPSIP00000014935 ENSPSIP00000017170 ENSPSIP00000016490 
Table C1. Table of protein ID from http://ensembl.org.   
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